PROMOTION OR INHIBITION OF ANGIOGENESIS AND CARDIOVASCULARIZATION BY TUMOR NECROSIS FACTOR LIGAND/RECEPTOR HOMOLOGS

Abstract: Compositions and methods are disclosed for stimulating or inhibiting angiogenesis and/or cardiovascularization in mammals, including humans. Pharmaceutical compositions are based on polypeptides or antagonists thereto that have been identified for one or more of these uses. Disorders that can be diagnosed, prevented, or treated by the compositions herein include trauma such as wounds, various cancers, and disorders of the vessels including atherosclerosis and cardiac hypertrophy.

Description: PROMOTION OR INHIBITION OF ANGIOGENESIS AND CARDIOVASCULARIZATION BY TUMOR NECROSIS FACTOR LIGAND RECEPTOR HOMOLOGS Background of the Invention Field of the Invention The present invention relates to compositions and methods for promotmg or inhibiting angiogenesis and or cardiovasculanzation in mammals in need of such biological effect This includes the diagnosis and treatment of cardiovascular disorders as well as oncological disorders Descπption of Background Cardiac Disorders and Factors Heart failure affects approximately five million Americans, and new cases of heart failure number about 400,000 each year It is the single most frequent cause of hospitahzation for people age 65 and older in the US Recent advances m the management of acute cardiac diseases, including acute myocardial infarction, are resultmg in an expanding patient population that will eventually develop chronic heart failure From 1979 to 1995 hospitahzations for congestive heart failure (CHF) rose from 377,000 to 872,000 (a 130 percent mcrease) and CHF deaths mcreased 116 percent CHF is a syndrome characterized by left ventricular dysfunction, reduced exercise tolerance, impaired quality of life, and markedly shortened life expectancy The sine qua non of heart failure is an inability of the heart to pump blood at a rate sufficient to meet the metabolic needs of the body's tissues (in other words, there is insufficient cardiac output) At least four major compensatory mechanisms are activated m the settmg of heart failure to boost cardiac output, including peπpheral vasoconstπction, mcreased heart rate, mcreased cardiac contractility, and mcreased plasma volume These effects are mediated primarily by the sympathetic nervous system and the renin-angiotensin system See Eichhorn, American Journal of Medicme, 104 163-169 (1998) Increased output from the sympathetic nervous system increases vascular tone, heart rate, and contractility Angiotensm II elevates blood pressure by 1) directly stimulating vascular smooth muscle contraction, 2) promotmg plasma volume expansion by stimulating aldosterone and antidiuretic hormone secretion, 3) stimulating sympathetic- mediated vascular tone, and 4) catalyzing the degradation of bradyki n, which has vasodilatory and natπuretic activity See review by Brown and Vaughan. Circulation, 97 1411-1420 (1998) As noted below, angiotensm II may also have directly deleteπous effects on the heart by promotmg myocyte necrosis (impairing systolic function) and lntracardiac fibrosis (impaiπng diasto c and m some cases systolic function) See Weber, Circulation. 96 4065-4082 (1998) A consistent feature of congestive heart failure (CHF) is cardiac hypertrophy, an enlargement of the heart that is activated by both mechanical and hormonal stimuli and enables the heart to adapt to demands for mcreased cardiac output Morgan and Baker, Circulation 83 13-25 (1991) This hypertrophic response is frequently associated with a vaπety of distinct pathological conditions such as hypertension, aortic stenosis, myocardial infarction, cardiomyopathy, valvular regurgitation, and intracardiac shunt, all of which result m chronic hemodynamic overload Hypertrophy is generally defined as an increase m size of an organ or structure independent of natural growth that does not involve tumor formation Hypertrophy of the heart is due either to an mcrease in the mass of the individual cells (myocytes), or to an mcrease in the number of cells making up the tissue (hyperplasia), or both While the enlargement of an embryonic heart is largely dependent on an mcrease m myocyte number (which continues until shortly after birth) post-natal cardiac mvocvtes lose their pro terative capacity Further growth occurs through hypertrophy ot the individual cells Adult mvocyte hypertrophy is initially beneficial as a short term response to impaired cardiac function by permitting a decrease in the load on individual muscle fibers With severe long-standing overload, however the hypertrophied cells begin to deteriorate and die Katz, "Heart Failure", m Katz A M ed . Physiology ot the Heart (New York Raven Press, 1992) pp 638-668 Cardiac hypertrophy is a significant risk factor for both mortality and morbidity in the clinical course of heart failure Katz Trends Cardiovasc Med , 5 37-44 (1995) For further details of the causes and pathology of cardiac hypertrophy see, e g , Heart Disease A Textbook of Cardiovascular Medicine. Braunwald, E ed (W B Saunders Co , 1988), Chapter 14, "Pathophysiology of Heart Failure " On a cellular level, the heart is composed of myocytes and surrounding support cells, genencally called non-myocytes While non-myocytes are pnmaπly fibroblast/mesenchymal cells, they also include endothelial and smooth muscle cells Indeed, although myocytes make up most of the adult myocardial mass, they represent only about 30% of the total cell numbers present m heart In response to hormonal, physiological, hemodynamic, and pathological stimuli, adult ventπcular muscle cells can adapt to increased workloads through the activation of a hypertrophic process This response is characteπzed by an increase m myocyte cell size and contractile protem content of individual cardiac muscle cells, without concomitant cell division and activation of embryonic genes, including the gene for atπal natπuretic peptide (AMP) Chien et al , FASEB J , 5 3037-3046 (1991), Chien et al , Annu Rev Phvsiol . 55 77-95 (1993) An increment m myocardial mass as a result of an increase m myocyte size that is associated with an accumulation of interstitial collagen within the extracellular matrix and around lntramyocardial coronary arteπes has been descπbed m left ventπcular hypertrophy secondary to pressure overload in humans Caspaπ et al , Cardiovasc Res . 11 554-558 (1977), Schwarz et al , Am J Cardiol , 42 895-903 (1978), Hess et al , Circulation, 63 360-371 (1981), Pearlman et al , Lab Invest , 46 158-164 (1982) It has also been suggested that paracπne factors produced by non-mvocyte supporting cells may additionally be involved in the development of cardiac hypertrophy, and vanous non-myocyte deπved hypertrophic factors, such as, leukocyte inhibitory factor (LIF) and endothelm, have been identified Metcalf, Growth Factors, 7 169-173 (1992), Kurzrock et al . Endocnne Reviews, 12 208-217 (1991), Inoue et al , Proc . Natl Acad Sci USA, 86 2863-2867 (1989), Yanagisawa and Masaki. Trends Pharm Sci , 10 374-378 (1989), U S Patent No 5,573,762 (issued November 12, 1996) Further exemplary factors that have been identified as potential mediators of cardiac hypertrophy include cardιotrophιn-1 (CT-1) (Pennica et al , Proc Nat Acad Sci USA, 92 1142-1146 (1995)), catecholamines, adrenocorticosteroids, angiotensm, and prostaglandms At present, the treatment of cardiac hypertrophy vanes depending on the underlying cardiac disease Catecholamines, adrenocorticosteroids, angiotensm, prostaglandms, LIF, endothehn (including endothelm- 1, -2, and -3 and big endothelm), and CT-1 are among the factors identified as potential mediators of hypertrophy For example, beta-adrenergic receptor blocking drugs (beta-blockers, e g , propranolol, timolol, tertalolol, carteolol, nadolol, betaxolol, penbutolol, acetobutolol, atenolol, metoprolol, carvedilol, etc ) and verapamil have been used extensively m the treatment of hypertrophic cardiomyopathy The beneficial effects of beta-blockers on symptoms (e g , chest pam) and exercise tolerance are largely due to a decrease in the heart rate with a consequent prolongation of diastole and mcreased passive ventπcular filling Thompson et al , Br Heart J , 44 488-98 (1980), Harrison et al , Circulation, 29 84-98 (1964) Verapamil has been descπbed to improve ventπcular filling and probably reducing myocardial ischemia Bonow et al , Circulation, 72 853-64 (1985) Nifedipine and diltiazem have also been used occasionally in the treatment ol hypertrophic cardiomyopathy Lorell et al Circulation, 65 499-507 (1982) Betocchi et al Am J Cardiol 78 451-457 (1996) However because of its potent vasodilating properties nifedipine may be harmful especially in patients with outflow obstruction Disopyramide has been used to re ev e symptoms bv virtue of its negative inotropic properties Pollick N Engl J Med 307 997-999 (1982) In many patients however the initial benefits decrease with time Wigle et al , Circulation, 92 1680-1692 (1995) Antihypertensive drug therapy has been reported to have beneficial effects on cardiac hypertrophy associated with elevated blood pressure Examples of drugs used in antihypertensive therapy, alone or m combination are calcium antagonists, e g , mtrendipine, -adrenergic receptor blocking agents, e g , those listed above, angiotensm converting enzyme (ACE) inhibitors such as quinapnl, captopnl enalapπl, ramipπl, benazepπl, fosinopnl, and hsmopπl, diuretics, e g , chorothiazide, hydrochlorothiazide hydroflumethazide, methylchlothiazide, benzthiazide, dichlorphenamide, acetazolamide, and mdapamide, and calcium channel blockers, e g , diltiazem, nifedipine, verapamil, and mcardipine For example, treatment of hypertension with diltiazem and captopnl showed a decrease m left ventπcular muscle mass, but the Doppler indices of diastohc function did not normalize Szlachcic et al , Am J Cardiol , 63 198-201 (1989), Shahi et al Lancet, 336 458-461 (1990) These findings were interpreted to indicate that excessive amounts of interstitial collagen may remain after regression of left ventπcular hypertrophy Rossi et al , Am Heart J , 124 700-709 (1992) Rossi et al , supra, investigated the effect of captopnl on the prevention and regression of myocardial cell hypertrophy and interstitial fibrosis in pressure overload cardiac hypertrophy, m expenmental rats Agents that mcrease cardiac contractility directly (lontropic agents) were initially thought to benefit patients with heart failure because they improved cardiac output in the short term However, all positive inotropic agents except digoxigenin have been found to result in mcreased long-term mortality, in spite of short-term improvements in cardiac performance Massie, Cuπ Op in Cardiology, 12 209-217 (1997), Reddy et al . Cuπ Opin Cardiol , 12 233-241 (1997) Beta-adrenergic receptor blockers have recently been advocated for use in heart failure Evidence from clinical tπals suggests that improvements in cardiac function can be achieved without increased mortahtv though documented improvements patient survival have not yet been demonstrated See also U S Pat Nos 5,624,806, 5,661,122, and 5,610,134 and WO 95/28173 regardmg the use of cardιotropm-1 or antagonists thereof, or growth hormone and/or insulin-like growth factor-I in the treatment of CHF Another treatment modality is heart transplantation, but this is limited by the availability of donor hearts Endothelm is a vasoconstπcting peptide compnsmg 21 ammo acids, isolated from swme artenal endothelial culture supernatant and structurally determined Yanagisawa et al , Nature, 332 411-415 (1988) Endothelm was later found to exhibit vanous actions, and endothelm antibodies as endothelm antagonists have proven effective in the treatment of mvocardial infarction, renal failure, and other diseases Smce endothelm is present in live bodies and exhibits vasoconstπctmg action, it is expected to be an endogenous factor mvolved m the regulation of the circulatory system and may be associated with hypertension, cardiovascular diseases such as myocardial infarction, and renal diseases such as acute renal failure Endothelm antagonists are descnbed. for example, m U S Pat No 5,773,414, JP Pat Publ 3130299/1991 EP 457,195, EP 460,679, and EP 552,489 A new endothelm B receptor for identifying endothelm receptor antagonists is descπbed in U S Pat No 5,773,223 Cuπent therapy for heart failure is pnmaπly directed to using angiotensin-converting enzyme (ACE) inhibitors, such as captopnl, and diuretics These drugs improve hemodynamic profile and exercise tolerance and reduce the incidence of morbidity and mortality in patients with CHF Kramer et al Circulation, 67(4) 807-816 ( 1983) Captopnl Multicenter Research Group J A C C 2(4) 755-763 ( 1983) The CONSENSUS Trial Study Group N Engl J Med , 316(23) 1429 1435 (1987) The SOLVD Investigators N Engl J Med 325(5) 293-302 (1991) Further thev are useful m treating hypertension left ventricular dysfunction atherosclerotic vascular disease, and diabetic nephropathv Brown and Vaughan, supia However despite proven efficacy, response to ACE inhibitors has been limited For example, while prolonging survival in the setting of heart failure ACE inhibitors appear to slow the progression towards end-stage heart failure and substantial numbers of patients on ACE inhibitors have functional class III heart failure Moreover, improvement of functional capacity and exercise time is only small and mortality, although reduced continues to be high The CONSENSUS Tnal Study Group, N Engl J Med , 3±6(23) 1429-1453 (1987), The SOLVD Investigators, N Engl J Med , 325(5) 293-302 (1991), Cohn et al . N Engl J Med , 325(5) 303-310 (1991), The Captopπl-Digoxin Multicenter Research Group, JAMA, 259(4) 539-544 (1988) Hence ACE inhibitors consistently appear unable to relieve symptoms m more than 60% of heart failure patients and reduce mortality of heart failure only by approximately 15-20% For further adverse effects, see Brown and Vaughan, supra An alternative to ACE inhibitors is represented by specific ATI receptor antagonists Clinical studies are planned to compare the efficacy of these two modalities m the treatment of cardiovascular and renal disease However, animal model data suggests that the ACE/Ang II pathway, while clearly involved in cardiac hypertrophy, is not the only, or even the primary pathway active m this role Mouse genetic "knockout" models have been made to test individual components of the pathway In one such model, the pπmarv cardiac receptor for Ang II, AT sub 1 A, has been genetically deleted, these mice do not develop hypertrophy when Ang II is given expenmentally (confirming the basic success of the model m eliminating hypertrophy secondary to Ang II) However, when the aorta is constπcted m these animals (a model of hypertensive cardiac stress), the hearts still become hypertrophic This suggests that alternative signaling pathways, not dependmg on this receptor (AT sub 1 A), are activated in hypertension ACE inhibitors would presumably not be able to inhibit these pathways See Harada et al , Circulation, 97 1952-1959 (1998) See also Homey, Circulation, 97 1890-1892 (1998) regarding the enigma associated with the process and mechanism of cardiac hypertrophy About 750,000 patients suffer from acute myocardial infarction (AMI) annually, and approximately one-fourth of all deaths in the United States are due to AMI In recent years, thrombolvtic agents e g streptokinase, urokinase, and in particular tissue plasmmogen activator (t-PA) have significantly increased the survival of patients who suffered myocardial infarction When administered as a continuous intravenous infusion over 1 5 to 4 hours, t-PA produces coronary patency at 90 minutes in 69% to 90% of the treated patients Topol et al , Am J Cardiol . 61, 723-728 (1988), Neuhaus et al , J Am Coll Cardiol . J2 581-587 (1988), Neuhaus et al , J Am Coll Cardiol . 14 1566-1569 (1989) The highest patency rates have been reported with high dose or accelerated dosing regimens Topol, J Am Coll Cardiol , 15 922-924 (1990) t-PA may also be administered as a single bolus, although due to its relatively short half-life, it is better suited for infusion therapy Tebbe et al , Am J Cardiol , 64 448-453 (1989) A t-PA vaπant, specifically designed to have longer half-life and very high fibπn specificity, TNK t-PA (a T103N, N117Q, KHRR(296-299)AAAA t-PA vaπant, Keyt et al , Proc Natl Acad Sci USA, 91 3670-3674 (1994)) is particularly suitable for bolus administration However, despite all these advances, the long-term prognosis of patient survival depends greatly on the post-infarction momtoπng and treatment of the patients, which should include monitoring and treatment of cardiac hypertrophy Growth Factors Vanous naturally occumng polypeptides reportedly induce the proliferation of endothelial cells Among those polypeptides are the basic and acidic fibroblast growth factors (FGF) (Burgess and Maciag Annual Rev Biochem . 58 575 (1989)), platelet-derived endothelial cell growth factor (PD-ECGF) (Ishikawa et al , Nature 338 557 (1989)), and vascular endothelial growth factor (VEGF) Leung et al Science, 246 1306 (1989), Feπara and Henzel. Biochem Biophvs Res Commun . 161 851 (1989), Tischer et al , Biochem Biophys Res Commun , 165 1198 (1989), EP 471 754B granted July 31 1996 Media conditioned by cells transfected with the human VEGF (hVEGF) cDNA promoted the proliferation of capillary endothelial cells, whereas control cells did not Leung et al , Science, 246 1306 (1989) Several additional cDNAs were identified in human cDNA libraries that encode 121-, 189-, and 206-amιno acid lsoforms of hVEGF (also collectively refeπed to as hVEGF-related protems) The 121-amιno acid protein differs from hVEGF by virtue of the deletion of the 44 amino acids between residues 116 and 159 in hVEGF The 189- amino acid protein differs from hVEGF by virtue of the insertion of 24 ammo acids at residue 116 m hVEGF, and apparently is identical to human vascular permeability factor (hVPF) The 206-amιno acid protem differs from hVEGF by virtue of an insertion of 41 ammo acids at residue 116 in hVEGF Houck et al , Mol Endocπn . 5 1806 (1991), Feπara et al . J Cell Biochem , 47 211 (1991). Feπara et al . Endocnne Reviews L3 18 (1992), Keck et al , Science. 246 1309 (1989), Connolly et al , J Biol Chem . 264 20017 (1989), EP 370 989 published May 30, 1990 It is now well established that angiogenesis, which mvolves the formation of new blood vessels from preexistmg endothelium, is implicated m the pathogenesis of a vaπety of disorders These include solid tumors and metastasis, atherosclerosis, retrolental fibroplasia, hemangiomas, chronic inflammation intraocular neovascular syndromes such as prohferative retinopafhies, e g , diabetic retmopathy, age-related macular degeneration (AMD), neovascular glaucoma, immune rejection of transplanted corneal tissue and other tissues, rheumatoid arthritis, and psoπasis Folkman et al J Biol Chem , 267 10931-10934 (1992), Klagsbrun et al , Annu Rev Physiol . 53 217-239 (1991), and Garner A, "Vascular diseases" In Pathobiology of Ocular Disease A Dynamic Approach. Garner A, Khntworth GK, Eds , 2nd Edition (Marcel Dekker, NY, 1994), pp 1625-1710 In the case of tumor growth, angiogenesis appears to be crucial for the transition from hvperplasia to neoplasm, and for providing nounshment to the growing solid tumor Folkman et al , Nature 339 58 (1989) The neovasculaπzation allows the tumor cells to acquire a growth advantage and prohferative autonomy compared to the normal cells Accordingly, a coπelation has been observed between density of micro vessels m tumor sections and patient survival in breast cancer as well as in several other tumors Weidner et al , N Engl J Med, 324 1-6 (1991), Horak et al Lancet, 340 1120-1124 (1992), Macchiaπni et al , Lancet 340 145-146 (1992) The search for positive regulators of angiogenesis has yielded many candidates, including aFGF, bFGF, TGF-α, TGF-β, HGF, TNF-α, angiogenm IL-8 etc Folkman et al , J B C , supra and Klagsbrun et al , supra The negative regulators so far identified include thrombospondin (Good et αl , Proc Natl Acad Sci USA , 87 6624-6628 (1990)), the 16-kιlodalton N-terminal fragment of prolactm (Clapp et αl Endocrinology 133 1292- 1299 (1993)), angiostatin (O'Reilly et αl Cell, 79 315-328 (1994)), and endostatin O'Reilly et αl Cell, 88 277-285 (1996) Work done over the last several years has established the kev role of VEGF not only in stimulating vascular endothelial cell proliferation, but also m inducing vascular permeability and angiogenesis Ferrara et αl , Endocr Rev , 18 4-25 (1997) The findmg that the loss of even a single VEGF allele results in embryonic lethality pomts to an meplaceable role played bv this factor in the development and differentiation of the vascular system Furthermore VEGF has been shown to be a kev mediator ol neovasculaπzation associated with tumors and intraocular disorders Feπara et al Endocr Rev supra The VEGF mRNA is overexpressed bv the majority of human tumors examined Berkman et al J Clin Invest. 91 153-159 (1993), Brown et al Human Pathol , 26 86-91 (1995), Brown et al Cancer Res 53 4727-4735 (1993) Mattern et al Brit J Cancer 73 931-934 (1996), Dvorak et al Am J Pathol , 146 1029-1039 (1995) Also the concentration levels of VEGF in eye fluids are highly coπelated to the presence of active proliferation of blood vessels in patients with diabetic and other ischemia-related retinopathies Aiello et al N_ Engl J Med , 331 1480-1487 (1994) Furthermore, recent studies have demonstrated the localization of VEGF in choroidal neovascular membranes in patients affected by AMD Lopez et al Invest Ophthalmol Vis Sci , 37 855-868 (1996) Anti- VEGF neutralizing antibodies suppress the growth of a vaπety of human tumor cell lmes in nude mice (Kim rt fl/ Nature. 362 841-844 (1993), Waπen et al J Clin Invest , 95 1789-1797 (1995), Borgstrom et al Cancer Res . 56 4032-4039 (1996), Melnvk et al Cancer Res , 56 921-924 (1996)) and also inhibit intraocular angiogenesis in models of lschemic retinal disorders Adamis et al Arch Ophthalmol . 114 66-71 (1996) Therefore, anti-VEGF monoclonal antibodies or other inhibitors of VEGF action are promising candidates for the treatment of solid tumors and vanous intraocular neovascular disorders Such antibodies are descnbed, for example, m EP 817,648 published January 14, 1998 and m PCT/US 98/06724 filed Apπl 3, 1998 There exist several other growth factors and mitogens, mcludmg transformmg oncogenes, that are capable of rapidly mducmg a complex set of genes to be expressed by certam cells Lau and Nathans, Molecular Aspects of Cellular Regulation. 6 165-202 (1991) These genes, which have been named immediate-early- or early- response genes, are transcnptionally activated withm mmutes after contact with a growth factor or mitogen, independent of de novo protem synthesis A group of these intermediate-early genes encodes secreted, extracellular protems that are needed for coordination of complex biological processes such as differentiation and proliferation regeneration, and wound healmg Ryseck et al . Cell Growth Differ , 2 235-233 (1991) Highlv-related proteins that belong to this group include cef 10 (Simmons et al , Proc Natl Acad Sci USA, 86 1178-1182 (1989)), cyr 61, which is rapidly activated by serum- or platelet-deπved growth factor (PDGF) (O'Bπen et al , Mol Cell Biol , JO 3569-3577 (1990), human connective tissue growth factor (CTGF) (Bradham et al , J Cell Biol , 114 1285-1294 (1991)), which is secreted by human vascular endothelial cells m high levels after activation with transformmg growth factor beta (TGF-β), exhibits PDGF-hke biological and immunological activities, and competes with PDGF for a particular cell surface receptor, fisp-12 (Ryseck et al , Cell Growth Differ , 2 235-233 (1991)), human vascular IBP- ke growth factor (VIGF) (WO 96/17931), and nov, normally aπested m adult kidney cells, which was found to be overexpressed in myeloblastosis-associated- virus-type- 1 -induced nephroblastomas Joloit et al , Mol Cell Biol . 12 10-21 ( 1992) The expression of these immediate-early genes acts as "third messengers" in the cascade of events tπggered by growth factors It is also thought that they are needed to mtegrate and coordmate complex biological processes, such as differentiation and wound healmg in which cell proliferation is a common event As additional mitogens, msulin-like growth factor bindmg proteins (IGFBPs) have been shown, m complex with insulin-like growth factor (IGF), to stimulate increased bmdmg of IGF to fibroblast and smooth muscle cell surface receptors Clemmons er α/ J Clin Invest . 77 1548 (1986) Inhibitory effects of IGFBP on various IGF actions in vitro include stimulation of glucose transport by adipocytes, sulfate incorporation by chondrocytes, and thymidine inco oration in fibroblast Zapf et al . J Clin Invest . 63 1077 (1979) In addition, inhibitory effects of IGFBPs on growth factor-mediated mitogen activity in normal cells have been shown Tumor Necrosis Factor Receptors and Ligands Various molecules, such as tumor necrosis factor-α ("TNF- α"), tumor necrosis factor-β ("TNF- β" or "lymphotoxin- α"), lymphotoxin- β ("LT- β"), CD30 gand, CD27 gand, CD40 ligand, OX-40 gand, 4-1BB gand, Apo-1 ligand (also refeπed to as Fas ligand or CD95 ligand), and Apo-2 ligand (also refeπed to as TRAIL) have been identified as members of the tumor necrosis factor ("TNF") family of cytokines [See, e.g , Grass and Dower, Blood, 85'3378-3404 (1995), Pitti et al., J. Biol. Chem.. 271 :12687-12690 (1996); Wiley et al., Immunity. 3 673-682 (1995), Browning et al., Cell, 72.847-856 (1993), Armitage et al. Nature, 357:80-82 (1992), WO 97/01633 published January 16, 1997, WO 97/25428 published July 17, 1997]. Induction of vanous cellular responses mediated by such TNF family cytokines is believed to be initiated by their bmdmg to specific cell receptors. Two distinct TNF receptors of approximately 55-kDa (TNFR1) and 75-kDa (TNFR2) have been identified [Hohman et al., J. Biol. Chem.. 264: 14927-14934 (1989); Brockhaus et al., Proc. Nail. Acad. Sci., 87 3127-3131 (1990); EP 417,563. published March 20, 1991] and human and mouse cDNAs coπespondmg to both receptor types have been isolated and charactenzed [Loetscher et al., Cell, 61.351 (1990); Schall et al, Cell. 61:361 (1990); Smith et al., Science, 248: 1019-1023 (1990); Lewis et al., Proc Natl. Acad. Sci . 88:2830-2834 (1991), Goodwm et al., Mol. Cell. Biol., JJ:3020-3026 (1991)]. Extensive polymorphisms have been associated with both TNF receptor genes [see, e.g., Takao et al., Immunogenetics. 37:199-203 (1993)] Both TNFRs share the typical structure of cell surface receptors including extracellular, transmembrane and mtracellular regions. The extracellular portions of both receptors are found naturally also as soluble TNF-binding protems [Nophar, Y. et al., EMBO J., 9:3269 (1990); and Kohno, T. et al., Proc. Natl. Acad. Sci. U.S.A.. 87:8331 (1990)]. More recently, the cloning of recombinant soluble TNF receptors was reported by Hale et al. [J Cell Biochem. Supplement 15F. 1991, p. 113 (P424)]. The extracellular portion of type 1 and type 2 TNFRs (TNFR1 and TNFR2) contains a repetitive ammo acid sequence pattern of four cysteme-πch domains (CRDs) designated 1 through 4, starting from the NH 2 - terminus. Each CRD is about 40 amino acids long and contains 4 to 6 cysteme residues at positions which are well conserved [Schall et al., supra; Loetscher et al., supra; Smith et al., supra; Nophar et al., supra; Kohno et al., supra] . In TNFR1, the approximate boundaπes of the four CRDs are as follows: CRD1- amino acids 14 to about 53; CRD2- ammo acids from about 54 to about 97; CRD3- ammo acids from about 98 to about 138; CRD4- ammo acids from about 139 to about 167. In TNFR2, CRDl includes ammo acids 17 to about 54; CRD2- ammo acids from about 55 to about 97; CRD3- ammo acids from about 98 to about 140; and CRD4- ammo acids from about 141 to about 179 [Banner et al., Cell, 73 431-435 (1993)]. The potential role of the CRDs in ligand binding is also descπbed by Banner et al., supra A similar repetitive pattern of CRDs exists m several other cell-surface protems, including the p75 nerve growth factor receptor (NGFR) [Johnson et al., Cell. 47:545 (1986), Radeke et al.. Nature, 325:593 (1987)], the B cell antigen CD40 [Stamenkovic et al, EMBO J . 8: 1403 (1989)], the T cell antigen OX40 [Mallet et al., EMBO 1. 9: 1063 (1990)] and the Fas antigen [Yonehara et al, supra and Itoh et al., Cell. 66.233-243 (1991)] CRDs are also found m the soluble TNFR (sTNFR)-lιke T2 protems of the Shope and myxoma poxviruses [Upton et al., Virology J60 20-29 ( 1987) Smith et al Biochem Biophvs Res Commun J76 335 ( 1991 ) Upton et al . Virology. 184 370 (1991)] Optimal alignment of these sequences indicates that the positions ot the cvsteine residues are well conserved These receptors are sometimes collectively refeπed to as members of the TNF/NGF receptor superfamily Recent studies on p75NGFR showed that the deletion of CRDl [Welcher, A A et al . Proc Natl Acad Sci USA 88 159-163 (1991)] or a 5-ammo acid insertion in this domain [Yan H and Chao, M V , J_ Biol Chem , 266 12099-12104 (1991)] had little or no effect on NGF binding [Yan, H and Chao M V supra] p75 NGFR contams a proline-πch stretch of about 60 amino acids, between its CRD4 and transmembrane region, which is not involved in NGF binding [Peetre, C et al , Eur J Hematol , 41 414-419 (1988), Seckinger, P et al , J Biol Chem , 264 11966-11973 (1989), Yan, H and Chao, M V , supra] A similar proline-πch region is found The TNF family hgands identified to date, with the exception of lymphotoxin-α. are type II transmembrane protems, whose C-terminus is extracellular In contrast, most receptors in the TNF receptor (TNFR) family identified to date are type I transmembrane proteins In both the TNF ligand and receptor families, however, homology identified between family members has been found mamly in the extracellular domam ("ECD") Several of the TNF family cytokines. mcludmg TNF-α, Apo-1 ligand and CD40 ligand, are cleaved proteolytically at the cell surface, the resultmg protem in each case typically forms a homotπmenc molecule that functions as a soluble cytokme TNF receptor family proteins are also usually cleaved proteolytically to release soluble receptor ECDs that can function as inhibitors of the cognate cytokines Recently, other members of the TNFR family have been identified Such newly identified members of the TNFR family include CARl, HVEM and osteoprotegenn (OPG) [Brojatsch et al , Cel], 87 845-855 (1996), Montgomery et al , Cell, 87 427-436 (1996), Marsters et al . J Biol Chem , 272 14029-14032 (1997), Simonet et al , Cell, 89 309-319 (1997)] Unlike other known TNFR-like molecules, Simonet et al , supra, report that OPG contains no hydrophobic transmembrane-spanmng sequence Moreover, a new member of the TNF/NGF receptor family has been identified m mouse a receptor refeπed to as "GITR" for "glucocorticoid-induced tumor necrosis factor receptor family-related gene" [Nocentmi et al , Proc Natl Acad Sci USA 94 6216-6221 (1997)] The mouse GITR receptor is a 228 ammo acid type I transmembrane protein that is expressed in normal mouse T lymphocytes from thymus, spleen and lymph nodes Expression of the mouse GITR receptor was induced in T lymphocytes upon activation with antι-CD3 antibodies, Con A or phorbol 12-myπstate 13-acetate It was speculated by the authors that the mouse GITR receptor was involved m the regulation of T cell receptor-mediated cell death In Marsters et al , Cuπ Biol , 6 750 (1996), investigators descπbe a full length native sequence human polypeptide, called Apo-3, which exhibits similanty to the TNFR family in its extracellular cysteme-πch repeats and resembles TNFR1 and CD95 in that it contams a cytoplasmic death domain sequence [see also Marsters et al , Cuπ Biol , 6 1669 (1996)] Apo-3 has also been refeπed to by other investigators as DR3, wsl-1 and TRAMP [Chinnaiyan et al , Science, 274 990 (1996), Kitson et al , Nature, 384 372 (1996) Bodmer et al , Immunity, 6 79 (1997)1 Pan et al have disclosed another TNF receptor familv member refeπed to as "DR4" [Pan et al , Science, 276 111-113 (1997)] The DR4 was reported to contain a cytoplasmic death domam capable of engaging the cell suicide apparatus Pan et al disclose that DR4 is believed to be a receptor tor the hgand known as Apo-2 ligand or TRAIL In Shendan et al , Science. 277 818-821 (1997) and Pan et al , Science, 277 815-818 (1997), another molecule believed to be a receptor for the Apo-2 ligand (TRAIL) is described That molecule is refeπed to as DR5 (it has also been alternatively refeπed to as Apo-2) Like DR4, DR5 is reported to contain a cytoplasmic death domain and be capable of signaling apoptosis In Shendan et al , supra a receptor called DcRl (or alternatively, Apo-2DcR) is disclosed as being a potential decoy receptor for Apo-2 ligand (TRAIL) Shendan et al report that DcRl can inhibit Apo-2 ligand function in vitro See also, Pan et al , supra, for disclosure on the decoy receptor refeπed to as TRID For a review of the TNF family of cytokines and their receptors, see Grass and Dower, supra Need for Further Treatments In view of the role of vascular endothelial cell growth and angiogenesis in many diseases and disorders, it is desirable to have a means of reducing or inhibiting one or more of the biological effects causing these processes It is also desirable to have a means of assaying for the presence of pathogenic polypeptides in normal and diseased conditions, and especially cancer Further, m a specific aspect, as there is no generally applicable therapy for the treatment of cardiac hypertrophy, the identification of factors that can prevent or reduce cardiac myocyte hypertrophy is of pπmary importance in the development of new therapeutic strategies to inhibit pathophysiological cardiac growth While there are several treatment modalities for vanous cardiovascular and oncologic disorders, there is still a need for additional therapeutic approaches Summary of the Invention Accordmgly, the present invention concerns compositions and methods for promotmg or inhibiting angiogenesis and or cardiovasculaπzation m mammals Applicants have identified cDNA clones that encode novel polypeptides, wherein the polypeptides are designated in the present application as "PR0364" and "PRO 175" These novel protems tested positive in vanous cardiovascular assays that test promotion or inhibition of certam biological activities Accordmgly, the proteins are believed to be useful drags for the diagnosis and/or treatment (including prevention) of disorders where such effects are desired, such as the promotion or inhibition of angiogenesis, inhibition of growth or proliferation of vascular endothelial cells, inhibition of tumor growth and inhibition of angiogenesis-dependent tissue growth In one embodiment, the present invention concerns a composition compnsmg a PR0364 (hGITR) polypeptide in admixture with a pharmaceutically acceptable earner In another embodiment, the present mvention provides a composition compnsmg a PRO 175 (hGITRL or GLITTER) polypeptide in admixture with a pharmaceutically acceptable earner In one aspect, the composition compnses a therapeutically effective amount of either or both polypeptides In another aspect, the composition compnses a further active mgredient, namely, a cardiovascular, endothelial, or angiogemc agent or an angiostatic agent, preferably an angiogenic or angiostatic agent Preferably, the composition is stenle PR0364 or PROl 75 polypeptide may be administered in the form of a liquid pharmaceutical formulation, which may be preserved to achieve extended storage stability Preserved liquid pharmaceutical formulations might contain multiple doses of PR0364 or PROl 75 polypeptide. and might, therefore, be suitable for repeated use In a further embodiment, the mvention supplies a method for preparing such composition for the treatment of a cardiovascular, endothelial, and angiogenic disorder compnsmg admixing a therapeutically effective amount of PR0364 or PRO 175 polypeptide with the earner In a still further aspect the invention provides a pharmaceutical product comprising (a) such composition comprising a therapeutically effective dosage PR0364 or PRO 175 polypeptide, (b) a container containing said composition, and (c) a label affixed to said container, or a package insert included in said pharmaceutical product refernng to the use ot said PR0364 or PRO 175 polypeptide in the treatment of a cardiovascular, endothelial, and angiogenic disorder In a still further aspect, the invention provides a process for diagnosing a disease or a susceptibility to a disease related to a mutation in PR0364 or PROl 75 polypeptide nucleic acid sequence compnsmg (a) isolating a nucleic acid sequence encodmg PR0364 or PRO 175 polypeptide from a sample deπved from a host, and (b) determining a mutation in the PR0364 or PRO 175 polypeptide nucleic acid sequence In a still further aspect, the invention provides a diagnostic process compnsmg analyzing for the presence of PR0364 or PROl 75 polypeptide in a sample deπved from a host In yet another embodiment, the present invention concerns a method of diagnosmg cardiovascular, endothelial. and angiogenic disorders in a mammal compnsmg detecting the level of expression of a gene encoding a PR0364 or PROl 75 polypeptide (a) m a test sample of tissue cells obtamed from the mammal, and (b) in a control sample of known normal tissue cells of the same cell type, wherein a higher or lower expression level m the test sample indicates the presence of a cardiovascular, endothelial, and angiogenic dysfunction m the mammal from which the test tissue cells were obtamed In yet another embodiment, the invention concerns a method for treatmg a cardiovascular, endothelial, and angiogenic disorder m a mammal compnsmg administering to the mammal an effective amount of a PR0364 or PRO 175 polypeptide Preferably, the disorder is cardiac hypertrophy, trauma such as wounds or burns, or a type of cancer In a further aspect, the mammal is further exposed to angioplasty or a drug that treats cardiovascular, endothelial, and angiogenic disorders such as ACE inhibitors or chemotherapeutic agents if the cardiovascular, endothelial. and angiogenic disorder is a type of cancer Preferably, the mammal is human, preferably one who is at πsk of developmg cardiac hypertrophy and more preferably has suffered myocardial mfarction In another prefeπed aspect, the cardiac hypertrophy is charactenzed by the presence of an elevated level of PGF 2α Alternatively, the cardiac hypertrophy may be induced by myocardial mfarction, wherein preferably the administration of PR0364 or PRO 175 polypeptide is initiated within 48 hours, more preferably within 24 hours, following myocardial infarction In another prefeπed embodiment, the cardiovascular, endothelial, and angiogenic disorder is cardiac hypertrophy and said PR0364 or PR0175 polypeptide is administered together with a cardiovascular, endothelial. or angiogenic agent The prefeπed cardiovascular, endothelial, or angiogenic agent for this purpose is selected from the group consisting of an antihypertensive drug, an ACE inhibitor, an endothelm receptor antagonist, and a thrombolytic agent If a thrombolytic agent is administered, preferably the PR0364 or PRO 175 polypeptide is admmistered following administration of such agent More preferably, the thrombolytic agent is recombinant human tissue plasminogen activator In another prefeπed aspect, the cardiovascular, endothelial. and angiogenic disorder is cardiac hypertrophy and the PR0364 or PR0175 polypeptide is admmistered following primary angioplasty for the treatment of acute myocardial mfarction, preferably wherem the mammal is further exposed to angioplasty or a cardiovascular, endothelial, or angiogenic agent In another prefeπed embodiment the cardio ascular endothelial and angiogenic disorder is a cancer and the PR0364 or PRO 175 polypeptide is administered m combination with a chemotherapeutic agent, a growth inhibitory agent or a cytotoxic agent In another embodiment, the invention furnishes a process for identifying agonists to a PR0364 or PRO 175 polypeptide compnsmg (a) contacting cells and a compound to be screened under conditions suitable for the stimulation of cell proliferation by PR0364 or PROl 75. and (b) measuπng the proliferation of the cells to determine if the compound is an effective agonist (c) The invention further supplies an agonist to a PR0364 or PRO 175 polypeptide that is identified by the above process In another embodiment, the invention provides a method for identifying a compound that inhibits the expression or activity of a PR0364 or PRO 175 polypeptide compnsmg contactmg a candidate compound with a PR0364 or PRO 175 polypeptide under conditions and for a time sufficient to allow the compound and polypeptide to mteract In a specific prefeπed aspect, either the candidate compound or the PR0364 or PRO 175 polypeptide is immobilized on a solid support In another prefeπed aspect, the non- immobilized component caines a detectable label Preferably, this process comprises the steps of (a) contacting cells and a compound to be screened m the presence of PR0364 or PR0175 polypeptide under conditions suitable for the stimulation of cell proliferation by PR0364 or PR0175 polypeptide, and (b) measuring the proliferation of the cells to determine if the compound is an effective antagonist In a still further embodiment, the mvention furnishes a compound that inhibits the expression or activity of a PR0364 or PRO 175 polypeptide, such as a compound that is identified by the process set forth above In a further embodiment, the mvention concerns a method for treatmg a cardiovascular, endothelial, and angiogenic disorder in a mammal compnsmg administering to the mammal an effective amount of an antagonist to a PR0364 or PRO 175 polypeptide Preferably, the cardiovascular, endothelial, and angiogenic disorder is cardiac hypertrophy, trauma, a cancer or age-related macular degeneration Also prefeπed is where the mammal is human, and where an effective amount of an angiogenic or angiostatic agent is admmistered m conjunction with the antagonist One type of antagonist of a PR0364 or PRO 175 polypeptide that inhibits one or more of the functions or activities of the PR0364 or PRO 175 polypeptide is an antibody Hence, m another aspect, the invention provides an isolated antibody that bmds a PR0364 or PRO 175 polypeptide Additionally, the invention provides an isolated antibody that binds a PR0364 or PRO 175 polypeptide In a prefeπed aspect, the antibody is a monoclonal antibody, which preferably has non-human complementanty-determining-region (CDR) residues and human framework-region (FR) residues The antibody may be labeled and may be immobilized on a solid support In a further aspect, the antibody is an antibody fragment, a single-chain antibody, or an anti-idiotypic antibody In another embodiment, the invention provides a method for determining the presence of a PR0364 or PR0175 polypeptide compnsmg exposing a cell suspected of containing the PR0364 or PR0175 polypeptide to an anti- PR0364 or -PRO 175 antibody and determining bmdmg of said antibody to said cell In a still further embodiment, the invention provides a method of diagnosmg cardiovascular, endothelial, and angiogenic disorders in a mammal compnsmg (a) contactmg an antι-PR0364 or -PRO 175 antibody with a test sample of tissue cells obtained from the mammal, and (b) detecting the formation of a complex between the antι-PR0364 or PRO 175 antibody and the PR0364 or PRO 175 polypeptide in the test sample The detection mav be qualitative or quantitative, and may be performed in comparison with monitoπng the complex formation in a control sample of known normal tissue cells of the same cell type A larger or smaller quantity of complexes formed in the test sample indicates the presence of a cardiovascular, endothelial. and angiogenic dysfunction in the mammal from which the test tissue cells were obtained The antibody preferably caπies a detectable label Complex formation can be monitored, for example, by light microscopy, flow cytometry, fluorimetry, or other techniques known in the art The test sample is usually obtained from an individual suspected to have a cardiovascular, endothelial, and angiogenic disorder In further aspects, the invention provides a cancer diagnostic kit compnsmg an antι-PR0364 or -PROl 75 antibody and a earner in suitable packagmg Preferably, such kit further compnses instructions for using said antibody to detect the PR0364 or PRO 175 polypeptide Preferably, the earner is a buffer, for example In a further embodiment, the invention provides an article of manufacture, compnsmg a contamer; a label on the contamer; and a composition compnsmg an anti- PR0364 or -PR0175 antibody contained within the contamer, wherem the label on the container indicates that the composition can be used for treating cardiovascular, endothelial, and angiogenic disorders In yet another embodiment, the invention provides a method for inhibiting angiogenesis mduced by a PR0364 or PRO 175 polypeptide in a mammal compnsmg administering a therapeutically effective amount of the antι-PR0364 or -PRO 175 antibody to the mammal Preferably, the mammal is a human, and more preferably the mammal has a tumor or a retmal disorder In a still further embodiment, the mvention provides a method for treating a cardiovascular, endothelial, and angiogenic disorder m a mammal that suffers therefrom compnsmg administering to the mammal a gene that codes for a PR0364 or PROl 75 polypeptide . In a prefeπed embodiment, the mammal is human In another prefeπed embodiment, the gene is admmistered via ex vivo gene therapy In a further prefeπed embodiment, the gene is compnsed withm a vector, more preferably an adenoviral. adeno-associated viral, lentiviral, or retroviral vector In yet another aspect, the mvention supplies a recombinant retroviral particle compnsmg a retroviral vector consisting essentially of a promoter, nucleic acid encodmg a PR0364 or PROl 75 polypeptide, and a signal sequence for cellular secretion of the polypeptide. wherein the retroviral vector is in association with retroviral structural protems Preferably, the signal sequence is from a mammal, such as from a native a PR0364 or PRO 175 polypeptide. In a still further embodiment, the invention supplies an ex vivo producer cell compnsmg a nucleic acid construct that expresses retroviral structural protems and also compnses a retroviral vector consisting essentially of a promoter, nucleic acid encoding a PR0364 or PRO 175 polypeptide, and a signal sequence for cellular secretion of the polypeptide, wherem said producer cell packages the retroviral vector in association with the structural protems to produce recombmant retroviral particles BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 shows a nucleotide sequence (SEQ ID NO 1) containing the nucleotide sequence (SEQ ID NO.2) of a native sequence PR0364 cDNA (nucleotides 121-843), wherem the nucleotide sequence (SEQ ID NO. l) is a clone designated herem as "UNQ319" and/or "DNA47365-1206" Also presented is the position of the initiator methionine residue as well as the position of three oligonucleotide pπmers designated "47365. tm.f ', 47365 tm p and "47365 tm r as underlined The putative transmembrane domain of the protein is encoded by nucleotides 604-660 in the figure Figure 2 shows the PRO 364 amino acid sequence (SEQ ID NO 3) deri ed from nucleotides 121-843 of the nucleotide sequence shown in Figure 1 (SEQ ID NO 2) A potential transmembrane domain exists between and including ammo acids 162 to 180 m the figure Figures 3A-C show a consensus nucleotide sequence (SEQ ID NO 4) designated "<consen01>" Figure 4 shows the "<consen01>" consensus nucleotide sequence shown in Figures 3A-C designated in the present application as DNA44825 (SEQ ID NO 4) Also presented is the position of the oligonucleotide pπmers designated "44825 GITR f (SEQ ID NO 5), "44825 fl" (SEQ ID NO 6), "44825 GITR p (SEQ ID NO 7), "44825 r2" (SEQ ID NO 8), "44825 pi" (SEQ ID NO 9), "44825 GITR r" (SEQ ID NO 10) "44825 £2" (SEQ ID NO 11), and "44825 rl" (SEQ ID NO 12) as underlmed Figures 5A-B show the encoding nucleotide sequence (SEQ ID NO 13) and deduced amino acid sequence (SEQ ID NO 14) of a cDNA clone designated herem as PRO 175-1150 Figure 6 illustrates the relative mRNA expression of PR0364 in vanous human cells and tissues, as determined by quantitative reverse-transcπptase PCR Figure 7 illustrates the relative mRNA expression of PR0364 in primary human T cells and monocytes (treated with antι-CD3 antibody, PHA or LPS), as determined by quantitative reverse-transcnptase PCR Figure 8 shows a Northern blot analysis of PRO 175 mRNA expression m human tissues (identified adult and fetal tissues) and tumor cell lmes (HL60 promyelocytic leukemia, HeLa S3 cervical carcinoma, K562 chronic myelogenous leukemima, MOLT4 lymphoblastic leukemia, Raji Burkitt's lymphoma, SW480 colorectal adenocarcmoma, A549 lung carcmoma and G361 melanoma) Figure 9 shows an analysis of soluble PRO 175 polypeptide by SDS-PAGE Figure 10 shows the results of a co-precipitation assay descnbed in Example 6 below The autoradiograph of the SDS-PAGE gel revealed the PR0364-IgG molecule bound to the radioiodinated PRO 175 polypeptide Bindmg was not observed for the other lmmunoadhesin constructs identified Figure 11A shows the results of FACS analysis of transfected 293 cells assayed for bindmg to the identified receptors or ligand lmmunoadhesin constructs Figure 11B shows the results of FACS analysis of HUVEC cells assayed for bindmg to the identified lmmunoadhesin constructs Figure 12 is a histogram showing the effect of PR0175 ligand on c-fos expression in human peπcytes Detailed Descπption of the Invention I Definitions The phrases "cardiovascular, endothelial. and angiogenic disorder" and "cardiovascular endothelial, and angiogenic dysfunction" are used interchangeably and refer to systemic disorders that affect vessels, such as diabetes mel tus. as well as diseases of the vessels themselves, such as of the arteπes capillaπes. veins, and/or lymphatics This would include indications that stimulate angiogenesis and/or cardiovasculaπzation and those that inhibit angiogenesis and or cardiovasculanzation Such disorders include, for example, arteπal disease, such as atherosclerosis, hypertension, inflammatory vascu tides, Revnaud's disease and Reynaud's phenomenon, aneurysms, and artenal restenosis, venous and lymphatic disorders such as thrombophlebitis, lymphangitis, and Ivmphedema and other vascular disorders such as peπpheral vascular disease, cancer such as vascular tumors. e g , hemangioma (capillary and cavernous), glomus tumors, telangiectasia bacillary angiomatosis hemangioendothelioma. angiosarcoma haemangiopencvtoma. Kaposi's sarcoma lymphangioma. and Ivmphangiosarcoma, tumor angiogenesis trauma such as wounds, burns, and other injured tissue, implant fixation scamng, ischemia reperfiision injury, rheumatoid arthπtis. cerebrovascular disease, renal diseases such as acute renal failure, and osteoporosis This would also include angma. myocardial infarctions such as acute myocardial infarctions, cardiac hypertrophy, and heart failure such as CHF "Hypertrophy", as used herein, is defined as an increase m mass of an organ or structure independent of natural growth that does not involve tumor formation Hypertrophy of an organ or tissue is due either to an increase in the mass of the individual cells (true hypertrophy), or to an increase in the number of cells making up the tissue (hyperplasia), or both Certain organs, such as the heart, lose the ability to divide shortly after birth Accordingly, "cardiac hypertrophy" is defined as an mcrease in mass of the heart, which, in adults, is charactenzed by an increase in myocyte cell size and contractile protem content without concomitant cell division The character of the stress responsible for mcitmg the hypertrophy, (e g , increased preload, increased afterload, loss of myocytes, as in myocardial infarction, or pnmary depression of contractility), appears to play a cπtical role in determining the nature of the response The early stage of cardiac hypertrophy is usually charactenzed morphologically by increases in the size of mycrofibπls and mitochondπa, as well as by enlargement of mitochondπa and nuclei At this stage, while muscle cells are larger than normal, cellular organization is largely preserved At a more advanced stage of cardiac hypertrophy, there are preferential increases in the size or number of specific organelles, such as mitochondπa, and new contractile elements are added m localized areas of the cells, m an lπegular manner Cells subjected to long-standing hypertrophy show more obvious disruptions m cellular organization, mcludmg markedly enlarged nuclei with highly lobulated membranes, which displace adjacent myofibnls and cause breakdown of normal Z-band registration The phrase "cardiac hypertrophy" is used to include all stages of the progression of this condition, charactenzed by vanous degrees of structural damage of the heart muscle, regardless of the underlymg cardiac disorder Hence, the term also includes physiological conditions instrumental in the development of cardiac hypertrophy, such as elevated blood pressure, aortic stenosis, or myocardial infarction "Heart failure" refers to an abnormality of cardiac function where the heart does not pump blood at the rate needed for the requirements of metabolizing tissues The heart failure can be caused by a number of factors, mcludmg lschemic, congenital, rheumatic, or ldiopathic forms "Congestive heart failure" (CHF) is a progressive pathologic state where the heart is mcreasmgly unable to supply adequate cardiac output (the volume of blood pumped by the heart over time) to deliver the oxygenated blood to peπpheral tissues As CHF progresses, structural and hemodynamic damages occur While these damages have a vaπety of manifestations, one characteπstic symptom is ventπcular hypertrophy CHF is a common end result of a number of vanous cardiac disorders "Myocardial mfarction" generally results from atherosclerosis of the coronary arteπes, often with supeπmposed coronary thrombosis It may be divided into two major types transmural infarcts, in which myocardial necrosis involves the full thickness of the ventncular wall, and subendocardial (nontransmural) infarcts, m which the necrosis involves the subendocardium, the intramural myocardium, or both, without extending all the way through the ventπcular wall to the epicardium Myocardial infarction is known to cause both a change in hemodynamic effects and an alteration in structure in the damaged and healthy zones of the heart Thus, for example, myocardial mfarction reduces the maximum cardiac output and the stroke volume of the heart Also associated with mvocardial infarction is a stimulation of the DNA synthesis occurnng in the interstice as well as an increase in the formation of collagen in the areas of the heart not affected As a result of the increased stress or strain placed on the heart m prolonged hypertension due, for example, to the increased total peπpheral resistance, cardiac hvpertrophv has long been associated w ith "hypertension" A characteristic of the ventπcle that becomes hypertrophic as a result ot chronic pressure overload is an impaired diastohc performance Fouad et al J Am Coll Cardiol . 4 1500-1506 (1984), Smith et al J Am Coll Cardiol , 5 869-874 (1985) A prolonged left ventπcular relaxation has been detected in earlv essential hypertension in spite of normal or supranormal systolic function Hartford et al Hypertension, 6 329-338 (1984) However, there is no close parallelism between blood pressure levels and cardiac hypertrophy Although improvement in left ventπcular function in response to antihypertensive therapy has been reported in humans, patients vaπously treated with a diuretic (hydrochlorothiazide), a β-blocker (propranolol), or a calcium channel blocker (diltiazem), have shown reversal of left ventπcular hypertrophy, without improvement m diastohc function Inouye et al , Am J Cardiol , 53 1583-7 (1984) Another complex cardiac disease associated with cardiac hypertrophy is "hypertrophic cardiomyopathy" This condition is charactenzed by a great diversity of morphologic, functional, and clinical features (Maron et al N Engl J Med , 316 780-789 (1987), Spinto et al N Engl J Med , 320 749-755 (1989), Louie and Edwards, Prog Cardiovasc Dis , 36 275-308 (1994), Wigle et al , Circulation, 92 1680-1692 (1995)), the heterogeneity of which is accentuated by the fact that it afflicts patients of all ages Spinto et al N Engl J Med . 336 775- 785 (1997) The causative factors of hypertrophic cardiomyopathy are also diverse and little understood In general, mutations m genes encoding sarcomenc protems are associated with hypertrophic cardiomyopathy Recent data suggest that β-myosin heavy chain mutations may account for approximately 30 to 40 percent of cases of familial hypertrophic cardiomyopathy Watkins et al N Engl J Med . 326 1108-1114 (1992), Schwartz et al. Circulation. 9J 532-540 (1995), Maπan and Roberts, Circulation, 92 1336-1347 (1995), Thierfelder et al , Cell, 77 701-712 (1994), Watkins et al , Nat Gen , JJ . 434-437 (1995) Besides β-myosm heavy chain, other locations of genetic mutations include cardiac tropomn T, alpha topomyosm, cardiac myosm bindmg protem C, essential myosin light chain, and regulatory mvosm light cham See Malik and Watkins, Cuπ Opin Cardiol . 12 295-302 (1997) Supravalvular "aortic stenosis" is an mheπted vascular disorder charactenzed bv narrowing of the ascendmg aorta, but other arteπes, mcludmg the pulmonary artenes. may also be affected Untreated aortic stenosis may lead to increased mtracardiac pressure resulting in myocardial hypertrophy and eventually heart failure and death The pathogenesis of this disorder is not fully understood, but hypertrophy and possibly hyperplasia of medial smooth muscle are prominent features of this disorder It has been reported that molecular vanants of the elastm gene are involved in the development and pathogenesis of aortic stenosis U S Patent No 5 650,282 issued July 22, 1997 "Valvular regurgitation" occurs as a result of heart diseases resultmg m disorders of the cardiac valves Vanous diseases, like rheumatic fever, can cause the shnnking or pulling apart of the valve oπfice, while other diseases may result m endocarditis, an inflammation of the endocardium or lining membrane of the atπoventπcular oπfices and operation of the heart Defects such as the naπowmg of the valve stenosis or the defective closing of the valve result in an accumulation of blood in the heart cavity or regurgitation of blood past the valve If uncoπected, prolonged valvular stenosis or insufficiency may result in cardiac hypertrophy and associated damage to the heart muscle, which may eventually necessitate valve replacement The treatment of all these, and other cardiovascular endothelial. and angiogenic disorders vv Inch mav or may not be accompanied by cardiac hvpertrophy. is encompassed by the present invention The terms "cancer" "cancerous", and "malignant" refer to or describe the physiological condition in mammals that is typically charactenzed by unregulated cell growth Examples of cancer include but are not limited to, carcinoma including adenocarcinoma, lymphoma, blastoma. melanoma, sarcoma, and leukemia More particular examples of such cancers include squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, gastrointestinal cancer, Hodgkm's and non-Hodgkin's lymphoma, pancreatic cancer, g oblastoma, cervical cancer, ovanan cancer, liver cancer such as hepatic carcinoma and hepatoma. bladder cancer, breast cancer, colon cancer, colorectal cancer, endometπal carcinoma, salivary gland carcinoma, kidney cancer such as renal cell carcinoma and Wilms' tumors, basal cell carcinoma, melanoma, prostate cancer, vulval cancer, thyroid cancer, testicular cancer, esophageal cancer, and various types of head and neck cancer The prefeπed cancers for treatment herem are breast, colon, lung, melanoma, ovarian, and others involving vascular tumors as noted above The term "cytotoxic agent" as used herein refers to a substance that inhibits or prevents the function of cells and or causes destruction of cells The term is intended to include radioactive isotopes (e g , I. I, Y, and 186 Re), chemotherapeutic agents, and toxins such as enzymatically active toxins of bacteπal, fungal, plant, or animal ongm, or fragments thereof A "chemotherapeutic agent" is a chemical compound useful in the treatment of cancer Examples of chemotherapeutic agents include alkylating agents, fohc acid antagonists, anti-metabolites of nucleic acid metabolism, antibiotics, pyπmidme analogs, 5-fluorouracιl, cisplatm, punne nucleosides, amines, ammo acids, tnazol nucleosides, or corticosteroids Specific examples include Adπamycin, Doxorabicin. 5-Fluorouracιl, Cytosine arabinoside ("Ara-C"), Cyclophosphamide, Thiotepa, Busulfan, Cytoxin, Taxol, Toxotere, Methotrexate, Cisplatm, Melphalan, Vinblastme, Bleomycin, Etoposide, Ifosfamide, Mitomycm C, Mitoxantrone, Vincreistine, Vinorelbine, Carboplatin, Teniposide, Daunomycin, Carminomycin. Ammopteπn, Dactinomycin. Mitomycins, Esperamicms (see U S Pat No 4,675,187), Melphalan, and other related nitrogen mustards Also included m this definition are hormonal agents that act to regulate or inhibit hormone action on tumors, such as tamoxifen and onapπstone A "growth-inhibitory agent" when used herein refers to a compound or composition that inhibits growth of a cell, such as an Wnt-overexpressmg cancer cell, either in vitro or in vivo Thus, the growth-inhibitory agent is one which significantly reduces the percentage of malignant cells m S phase Examples of growth- inhibitory agents include agents that block cell cycle progression (at a place other than S phase), such as agents that induce Gl aπest and M-phase aπest Classical M-phase blockers mclude the vincas (vincπstine and vinblastme), taxol, and topo II inhibitors such as doxorabicin, daunorubicin. etoposide, and bleomycin Those agents that aπest Gl also spill over mto S-phase aπest, for example, DNA alkylating agents such as tamoxifen, predmsone, dacarbazme, mechlorethamme, cisplatm, methotrexate, 5-fluorouracιl, and ara-C Further information can be found in The Molecular Basis of Cancer Mendelsohn and Israel, eds , Chapter 1 , entitled "Cell cycle regulation, oncogenes. and antineoplastic drags" by Murakami et al (WB Saunders Philadelphia, 1995), especially p 13 Additional examples include tumor necrosis factor (TNF), an antibody capable of inhibiting or neutralizing the angiogenic activity of acidic or basic FGF or hepatocyte growth factor (HGF), an antibody capable of inhibiting or neutralizing the coagulant activities of tissue factor, protein C, or protein S (see WO 91/01753. published 21 February 1991), or an antibody capable of binding to HER2 receptor (WO 89/06692), such as the 4D5 antibody (and functional equivalents thereof) (e g , WO 92/22653) "Treatment" is an intervention performed with the intention oi preventing the development or altering the pathology ol a cardiovascular, endothelial. and angiogenic disorder The concept ot treatment is used in the broadest sense, and specifically includes the prevention (prophylaxis), moderation, reduction, and cunng of cardiovascular, endothelial, and angiogenic disorders of any stage Accordingly, "treatment" refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) a cardiovascular, endothelial and angiogenic disorder such as hypertrophy Those in need of treatment include those already with the disorder as well as those prone to have the disorder or those in whom the disorder is to be prevented The disorder may result from any cause, including ldiopathic. cardiotrophic, or myotrophic causes, or ischemia or ischemic insults, such as myocardial infarction "Chronic" administration refers to administration of the agent(s) in a continuous mode as opposed to an acute mode, so as to maintam the initial effect, such as an anti-hypertrophic effect, for an extended peπod of time "Mammal" for purposes of treatment refers to any animal classified as a mammal, mcludmg humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, horses, cats, cows, sheep, pigs, etc. Preferably, the mammal is human Administration "in combination with" one or more further therapeutic agents includes simultaneous (concuπent) and consecutive administration m any order The phrase "cardiovascular, endothelial, or angiogenic agents" refers geneπcally to any drag that acts in treating cardiovascular, endothelial, and angiogenic disorders Examples or cardiovascular agents are those that promote vascular homeostasis by modulatmg blood pressure, heart rate, heart contractility, and endothelial and smooth muscle biology, all of which factors have a role m cardiovascular disease Specific examples of these mclude angιotensιn-II receptor antagonists, endothelm receptor antagonists such as, for example, BOSENTAN™ and MOXONODIN™, lnterferon-gamma (IFN-γ) ; des-aspartate-angiotensm I, thrombolytic agents, e g , streptokinase, urokinase, t-PA, and a t-PA vanant specifically designed to have longer half-life and very high fibrin specificity, TNK t-PA (a T103N, N117Q, KHRR(296-299)AAAA t-PA vaπant, Keyt et al , Proc Natl Acad Sci. USA 91, 3670-3674 (1994)), inotropic or hypertensive agents such as digoxigenm and β-adrenergic receptor blocking agents, e g , propranolol, timolol, tertalolol, carteolol, nadolol, betaxolol. penbutolol, acetobutolol, atenolol, metoprolol, and carvedilol, angiotensm converting enzyme (ACE) inhibitors, e g , qumapπl, captopnl. enalapπl. ramipnl, benazepπl, fosinopπl, and lisinopπl. diuretics, e g , chorothiazide, hydrochlorothiazide, hydroflumethazide, methylchlothiazide, benzthiazide, dichlorphenamide, acetazolamide, and mdapamide; and calcium channel blockers, e g , diltiazem. nifedipine, verapamil, mcardipme One prefeπed category of this type is a therapeutic agent used for the treatment of cardiac hypertrophy or of a physiological condition instrumental in the development of cardiac hypertrophy, such as elevated blood pressure, aortic stenosis, or myocardial infarction "Angiogenic agents" and "endothelial agents" are active agents that promote angiogenesis and or endothelial cell growth, or, if applicable, vasculogenesis This would mclude factors that accelerate wound healing, such as growth hormone, insulin-like growth factor-I (IGF-I), VEGF, VIGF, PDGF, epidermal growth factor (EGF), CTGF and members of its family, FGF, and TGF-α and TGF-β "Angiostatic agents" are active agents that inhibit angiogenesis or vasculogenesis or otherwise inhibit or prevent growth of cancer cells Examples include antibodies or other antagonists to angiogenic agents as defined above, such as antibodies to VEGF They additionally include cytotherapeutic agents such as cytotoxic agents, chemotherapeutic agents, growth-inhibitory agents, apoptotic agents, and other agents to treat cancer, such as antι-HER-2. antι-CD20, and other bioactive and organic chemical agents In a pharmacological sense in the context of the present invention, a "therapeutically effective amount" ot an active agent such as a PR0364 or PRO 175 polypeptide or antagonist thereto refers to an amount effective in the treatment of a cardiovascular, endothelial. and angiogenic disorder As used herein, a "PR0364 polypeptide" is used to refer to a native-sequence PR0364 polypeptide having the same amino acid sequence as a PR0364 (SEQ ID NO 3) polypeptide derived from nature Such native sequence PR0364 polypeptide can be isolated from nature or can be produced by recombinant or synthetic means The term specifically encompasses naturally-occuπmg truncated or secreted forms of a PR0364 (e g , soluble forms containing for instance, an extracellular domain sequence), naturally-occurring vanant forms (e g , alternatively spliced forms) and naturally-occuinng allehc vaπants of the PR0364 polypeptide The terms "PR0364 polypeptide" and "PR0364" when used herein refer to the same polypeptides refeπed to in the literature as "GITR" In one embodiment of the invention, the native sequence PR0364 polypeptide is a mature or full-length native sequence PR0364 polypeptide comprising amino acids 1 to 241 of Figure 1 (SEQ ID NO 3) Additional embodiments are directed to PR0364 polypeptide comprising amino acids 26-241 of Figure 2 (SEQ ID NO.3) In yet another embodiment of the invention, the native sequence PR0364 polypeptide is an extracellular domain sequence of the full-length PR0364 protein, wherem the putative transmembrane domam of the full-length PR0364 protem includes amino acids 162-180 of the sequence shown in Figure 2 (SEQ ID NO 3) Alternatively, the PR0364 polypeptide is obtained or obtainable by expressing the polypeptide encoded by the cDNA insert of the vector DNA47365-1206 deposited as ATCC 209436 Thus, additional embodiments of the present invention are directed to polypeptides compnsmg amino acids 1-161 or 26-161 of the amino acid sequence shown m Figure 2 (SEQ ID NO 3). The term " extracellular domain" when used in reference to a PR0364 polypeptide refers to a form of the PR0364 polypeptide which is essentially free of its transmembrane and cytoplasmic domains Ordinanly, an ECD will have less than 1 % of such transmembrane and or cytoplasmic domains and preferably, will have less than 0 5% of such domains Included are deletion vanants or fragments of the full length or ECD m which one or more ammo acids are deleted from the N- or C- terminus Preferably, such deletion vaπants or fragments possess a desired activity, such as described herem It will be understood that any transmembrane domam identified for the PR0364 polypeptide of the present invention is identified pursuant to cπteπa routmely employed in the art for identifying that type of hydrophobic domain The exact boundaries of a transmembrane domam may vary but most likely by no more than about 5 ammo acids at either end of the domain as initially identified Accordmgly, the PR0364 polypeptide ECD may optionally compnse ammo acids Y to X of Figure 2 (SEQ ID NO 3), wherem Y is any one of ammo acid residues 1 to 26 and X is any one of ammo acid residues 157 to 167 of Figure 2 (SEQ ID NO 3) The term "vaπant" when used m reference to a PR0364 polypeptide is defined below as having at least about 80% ammo acid sequence identity with the PR0364 polypeptide having the deduced ammo acid sequence shown in Figure 2 (SEQ ID NO 3) for a full-length native sequence PR0364 polypeptide or an extracellular domain sequence thereof Such PR0364 polypeptide vaπants include, for instance, PR0364 polypeptides wherein one or more ammo acid residues are added, or deleted, at the N- or C-termmus of the sequence of Figure 2 (SEQ ID NO 3) Ordinarily, a PR0364 polypeptide variant will have at least about 80% ammo acid sequence identity, preferably at least about 85% amino acid sequence identity, more preferably at least about 90% ammo acid sequence identity, even more preferably at least about 95% amino acid sequence identity and yet more preferably 98% ammo acid sequence identity with the amino acid sequence of Figure 2 (SEQ ID NO 3) As used herein, a "PROl 75 polypeptide" is used to refer to a native-sequence PRO 175 polypeptide having the same amino acid sequence as a PRO 175 (SEQ ID NO: 14) polypeptide derived from nature. Such native sequence PRO 175 polypeptide can be isolated from nature or can be produced by recombinant or synthetic means. The term specifically encompasses naturally-occuπing truncated or secreted forms of a PRO 175 polypeptide (e.g., soluble forms containing for instance, an extracellular domain sequence), naturally-occurring variant forms (e.g., alternatively spliced forms) and naturally-occurring allelic variants of the PRO 175 polypeptide. The terms "PR0175 polypeptide" and "PR0175" when used herein refer to the same polypeptides refeπed to in the literature as "GLITTER". In one embodiment of the invention, the native sequence polypeptide encoded by PRO 175 is a mature or full-length native-sequence polypeptide comprising amino acids 1 to 177 of Figure 5 (SEQ ID NO:14). In yet another embodiment of the invention, the PR0175 polypeptide comprises amino acids 52 to 177 of Figure 5 (SEQ ID NO:14). Optionally the PR0175 polypeptide is obtained or obtainable by expressing the polypeptide encoded by the cDNA insert of the vector deposited as ATCC 209466. Thus, additional embodiments of the present invention are directed to polypeptides comprising amino acids 1 to 177 or 52 to 177 of Figure 5 (SEQ ID NO: 14). The term " extracellular domain" when used in reference to a PRO 175 polypeptide refers to a form of the PRO 175 polypeptide which is essentially free of its transmembrane and cytoplasmic domains. Ordinarily, an ECD will have less than 1% of such transmembrane and/or cytoplasmic domains and preferably, will have less than 0.5% of such domains. Included are deletion variants or fragments of the full length or ECD in which one or more amino acids are deleted from the N- or C- terminus. Preferably, such deletion variants or fragments possess a desired activity, such as described herein. It will be understood that any transmembrane domain identified for the PRO 175 polypeptide of the present invention is identified pursuant to criteria routinely employed in the art for identifying that type of hydrophobic domain. The exact boundaries of a transmembrane domain may vary but most likely by no more than about 5 amino acids at either end of the domain as initially identified. Accordingly, the PRO 175 polypeptide ECD will comprise amino acid residues X to 177 of Figure 5 (SEQ ID NO: 14), wherein X is any one of amino acid residues 48 to 57 of Figure 5 (SEQ ID NO: 14). The term "variant" when used in reference to a PRO 175 polypeptide is defined below as having at least about 80%) amino acid sequence identity with the PRO 175 polypeptide having the deduced amino acid sequence shown in Figure 5 (SEQ ID NO: 14) for a full-length native sequence PRO 175 polypeptide or an extracellular domain sequence thereof. A PRO 175 polypeptide variant will include, for instance, a PRO 175 polypeptide wherein one or more amino acid residues are added, or deleted, at the N- or C-terminus of the sequence of Figure 5 (SEQ ID NO: 14). Ordinarily, a PROl 75 polypeptide variant will have at least about 80% amino acid sequence identity, preferably at least about 85% amino acid sequence identity, more preferably at least about 90%) amino acid sequence identity, even more preferably at least about 95% amino acid sequence identity and yet more preferably 98% amino acid sequence identity with the amino acid sequence of Figure 5 (SEQ ID NO: 14). "Percent (%) amino acid sequence identity" with respect to the sequences identified herein is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the PRO 364 polypeptide sequence or the PRO 175 polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art. One skilled in the art can determine appropriate parameters for measuring alignment, including assigning algorithms needed to achieve maximal alignment over the full-length sequences being compared. For purposes herein, percent amino acid identity values can be obtained using the sequence comparison computer program. ALIGN-2. which was authored by Genentech. Inc and the source code of which has been filed with user documentation in the US Copyright Office. Washington. DC, 20559, registered under the US Copyright Registration No TXU510087 The ALIGN-2 program is publicly available through Genentech. Inc , South San Francisco, CA All sequence comparison parameters are set by the ALIGN-2 program and do not vary Methods for performing sequence alignment and determining sequence identity are known to the skilled artisan, may be performed without undue experimentation, and calculations of % identity values may be obtained with defi teness "Isolated." when used to descnbe the vanous polypeptides disclosed herein, means polypeptide that has been identified and separated and/or recovered from a component of its natural environment Contaminant components of its natural environment are matenals that would typically interfere with diagnostic or therapeutic uses for the polypeptide. and may include enzymes, hormones, and other proteinaceous or non-protemaceous solutes In prefeπed embodiments, the polypeptide will be punfied ( 1 ) to a degree sufficient to obtam at least 15 residues of N-termmal or internal ammo acid sequence by use of a spinning cup sequenator, or (2) to homogeneity by SDS-PAGE under non-reducing or reducing conditions using Coomassie blue or, preferably, silver stam Isolated polypeptide includes polypeptide in situ within recombmant cells, since at least one component of the PR0364 or the PRO 175 ligand polypeptide natural environment will not be present Ordinanly, however, isolated polypeptide will be prepared by at least one purification step An "isolated" PR0364 or PRO 175 nucleic acid molecule is a nucleic acid molecule that is identified and separated from at least one contaminant nucleic acid molecule with which it is ordinarily associated m the natural source of the PR0364 or PR0175 nucleic acid An isolated PR0364 or PR0175 nucleic acid molecule is other than m the form or settmg m which it is found m nature Isolated PR0364 or PRO 175 nucleic acid molecules therefore are distinguished from the PR0364 or PRO 175 nucleic acid molecule as they exist m natural cells However, an isolated PR0364 or PR0175 nucleic acid molecule mcludes PR0364 or PR0175 nucleic acid molecules contained in cells that ordinanly express PR0364 or PRO 175 where, for example, the nucleic acid molecule is in a chromosomal location different from that of natural cells The term "control sequences" refers to DNA sequences necessary for the expression of an operably linked codmg sequence m a particular host organism The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a nbosome bindmg site Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence For example, DNA for a presequence or secretory leader is operably linked to DNA for a PR0364 or PR0175 polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a codmg sequence if it affects the transcπption of the sequence, or a nbosome binding site is operably linked to a codmg sequence if it is positioned so as to facilitate translation Generally, "operably linked" means that the DNA sequences bemg linked are contiguous, and, in the case of a secretory leader, contiguous and in readmg phase However, enhancers do not have to be contiguous Linking is accomplished by ligation at convenient restnction sites If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice "Stringency" of hybridization reactions is readily determinable by one of ordinary skill in the art, and generally is an empiπcal calculation dependent upon probe length, washing temperature, and salt concentration In general, longer probes require higher temperatures for proper annealing, while shorter probes need lower temperatures Hybπdization generally depends on the ability of denatured DNA to reanneal when complementary strands are present in an environment below their melting temperature The higher the degree ot desired homology between the probe and hvbπdizable sequence the higher the relative temperature that can be used s a result, it follows that higher relative temperatures would tend to make the reaction conditions more stringent, while lower temperatures less so For additional details and explanation of stringency of hybridization reactions, see Ausubel et al Cuπent Protocols in Molecular Biology (Wiley Interscience Publishers. 1995) "Stringent conditions" or "high-stπngency conditions" as defined herein, may be identified bv those that (1) employ low ionic strength and high temperature for washing, for example. 0 015 M sodium chloπde/0 0015 M sodium cιtrate/0 1% sodium dodecvl sulfate at 50°C, (2) employ dunng hybndization a denatuπng agent, such as formamide, for example, 50% (v/v) formamide with 0 1% bovine serum albumιn 0 1% Fιcoll/0 1% polyvιnylpyπohdone/50mM sodium phosphate buffer at pH 6 5 with 750 mM sodium chloride 75 mM sodium citrate at 42°C, or (3) employ 50% formamide, 5 x SSC (0 75 M NaCl, 0 075 M sodium citrate), 50 mM sodium phosphate (pH 6 8), 0 1% sodium pyrophosphate. 5 x Denhardt's solution, sonicated salmon sperm DNA (50 μg/ml), 0 1% SDS, and 10% dextran sulfate at 42°C, with washes at 42°C in 0 2 x SSC (sodium chlonde/sodium citrate) and 50% formamide at 55 °C. followed by a high-stringency wash consisting of 0 1 x SSC containing EDTA at 55°C "Moderately-stnngent conditions" may be identified as descπbed by Sambrook et al Molecular Cloning A Laboratory Manual (New York Cold Spring Harbor Press, 1989), and include the use of washing solution and hybπdization conditions (e g , temperature, ionic strength, and %SDS) less stringent than those descπbed above An example of moderately stringent conditions is overnight incubation at 37 °C in a solution compnsmg 20% formamide, 5 x SSC (150 mM NaCl, 15 mM tπsodium citrate), 50 mM sodium phosphate (pH 7 6), 5 x Denhardt's solution, 10% dextran sulfate, and 20 mg/mL denatured sheared salmon sperm DNA. followed by washmg the filters in 1 x SSC at about 37-50°C The skilled artisan will recognize how to adjust the temperature, ionic strength, etc as necessary to accommodate factors such as probe length and the like The modifier "epitope-tagged" when used herem refers to a chimeπc polypeptide compnsmg a PR0364 or PRO 175 polypeptide fused to a "tag polypeptide" The tag polypeptide has enough residues to provide an epitope agamst which an antibody can be made, yet is short enough such that it does not interfere with activity of the polypeptide to which it is fused The tag polypeptide preferably also is fairly unique so that the antibody does not substantially cross-react with other epitopes Suitable tag polypeptides generally have at least six ammo acid residues and usually between about 8 and 50 ammo acid residues (preferably, between about 10 and 20 ammo acid residues) "Active" or "activity" in the context of PR0364 or PRO 175 vanants refers to form(s) of PR0364 or PRO 175 protems that retain the biologic and/or lmmunologic activities of a native or naturally-occurnng PR0364 or PRO 175 polypeptide "Biological activity" in the context of a molecule that antagonizes PR0364 or PRO 175 polypeptide that can be identified by the screenmg assays disclosed herein (e g , an organic or inorganic small molecule, peptide. etc ) is used to refer to the ability of such molecules to bind or complex with the PR0364 or PRO 175 polypeptide identified herem, or otherwise interfere with the interaction of the PR0364 or PR0175 polypeptides with other cellular protems Particularly prefeπed biological activity includes cardiac hypertrophy, activity that acts on systemic disorders that affect vessels such as diabetes melhtus, as well as diseases of the arteπes, capillaπes, vems. and/or lymphatics, and cancer The term "antagonist" is used m the broadest sense, and mcludes any molecule that partially or fully blocks, inhibits, or neutralizes one or more of the biological activities of a native PR0364 or PRO 175 polypeptide disclosed herem. for example if applicable, its mitogemc or angiogenic activity Antagonists ot PR0364 or PR0175 polypeptide may act by interfering with the binding of PR0364 or PR0175 polypeptide to a cellular receptor, by incapacitating or killing cells that have been activated by PR0364 or PRO 175 polypeptide, or bv interfering with vascular endothelial cell activation after binding of PR0364 or PRO 175 polypeptide to a cellular receptor All such points of intervention by a PR0364 or PR0175 polypeptide antagonist shall be considered equivalent for purposes of this invention The antagonists inhibit the mitogemc, angiogenic, or other biological activity of PR0364 or PRO 175 polypeptides. and thus are useful for the treatment of diseases or disorders charactenzed by undesirable excessiv e neovasculaπzation, including by way of example tumors, and especially solid malignant tumors, rheumatoid arthπtis, psoπasis, atherosclerosis, diabetic and other retinopathies. retrolental fibroplasia, age-related macular degeneration, neovascular glaucoma, hemangiomas, thyroid hyperplasias (mcludmg Grave's disease), corneal and other tissue transplantation, and chronic inflammation The antagonists also are useful for the treatment of diseases or disorders characterized by undesirable excessive vascular permeability, such as edema associated with brain tumors, ascites associated with malignancies. Meigs' syndrome, lung inflammation, nephrotic syndrome, peπcardial effusion (such as that associated with pencarditis). and pleural effusion In a similar manner, the term "agonist" is used m the broadest sense and mcludes any molecule that mimics a biological activity of a native PR0364 or PRO 175 polypeptide disclosed herein Suitable agonist or antagonist molecules specifically include agonist or antagonist antibodies or antibody fragments, fragments, or ammo acid sequence vanants of native PR0364 or PR0175 polypeptides "Antibodies" (Abs) and "immunoglobuhns" (Igs) are glycoproteins having the same structural charactenstics While antibodies exhibit binding specificity to a specific antigen, immunoglobulms mclude both antibodies and other antibody-like molecules that lack antigen specificity Polypeptides of the latter kind are, for example, produced at low levels by the lymph system and at mcreased levels by myelomas The term "antibody" is used m the broadest sense and specifically covers, without limitation, mtact monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e g , bispecific antibodies) formed from at least two intact antibodies, and antibody fragments, so long as they exhibit the desired biological activity "Native antibodies" and "native immunoglobulms" are usually heterotetrameπc glycoproteins of about 150,000 daltons. composed of two identical light (L) chams and two identical heavy (H) chains Each light chain is linked to a heavy chain by one covalent disulfide bond, while the number of disulfide linkages v aπes among the heavy chams of different lmmunoglobu n lsotypes Each heavy and light chain also has regularly spaced mtrachain disulfide bπdges Each heavy chain has at one end a vaπable domam (V H ) followed bv a number of constant domams Each light chain has a vanable domain at one end (V L ) and a constant domain at its other end. the constant domam of the light chain is aligned with the first constant domam of the heavy cham. and the light- chain vaπable domam is aligned with the vaπable domain of the heavy cham Particular amino acid residues are believed to form an interface between the light- and heavy-chain vaπable domams The term "vaπable" refers to the fact that certam portions of the vaπable domams differ extensively m sequence among antibodies and are used m the binding and specificity of each particular antibodv to and for its particular antigen However, the vanability is not evenly distπbuted throughout the vaπable domains of antibodies It is concentrated m three segments called complementanty-determmmg regions (CDRs) or hypervaπable regions both in the light-chain and the heavy-chain vanable domains The more highly conserved portions of vaπable domains are called the framework regions (FR) The vaπable domains of native heavy and light chains each compnse four FR regions, largely adopting a β-sheet configuration, connected by three CDRs, which form loops connecting, and in some cases forming part of, the β-sheet structure The CDRs m each cham are held together in close proximity bv the FR regions and. with the CDRs from the other chain, contribute to the formation of the antigen-bmding site of antibodies See Kabat et al . NIH Publ No 91-3242. Vol I. pages 647- 669 (1991) The constant domams are not involved directly m binding an antibody to an antigen, but exhibit vanous effector functions, such as participation of the antibodv m antibody-dependent cellular toxicity "Antibody fragments" comprise a portion of an intact antibody, preferably the antigen-binding or vaπable region of the intact antibody Examples of antibody fragments include Fab. Fab', F(ab') 2 , and Fv fragments, diabodies, linear antibodies (Zapata et al . Protein Eng . 8(10) 1057-1062 (1995)), single-chain antibody molecules, and multispecific antibodies formed from antibody fragments Papam digestion of antibodies produces two identical antigen-binding fragments, called "Fab" fragments, each with a single antigen-binding site, and a residual "Fc" fragment, whose name reflects its ability to crystallize readily Pepsin treatment yields an F(ab') 2 fragment that has two antigen-combming sites and is still capable of cross-linking antigen "Fv" is the minimum antibody fragment that contams a complete antigen-recognition and -b ding site This region consists of a dimer of one heavy- and one light-chain vaπable domain m tight, non-covalent association It is m this configuration that the three CDRs of each vaπable domam interact to define an antigen- bmding site on the surface of the V H -V L dimer Collectively, the six CDRs confer antigen-bmding specificity to the antibody However, even a single vanable domam (or half of an Fv compnsmg only three CDRs specific for an antigen) has the ability to recognize and bmd antigen, although at a lower affinity than the entire binding site. The Fab fragment also contams the constant domam of the light cham and the first constant domam (CHI) of the heavy cham Fab' fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain CHI domain mcludmg one or more cystemes from the antibody hinge region Fab'- SH is the designation herem for Fab' in which the cysteine resιdue(s) of the constant domams bear a free thiol group F(ab') 2 antibody fragments originally were produced as parrs of Fab' fragments that have hmge cystemes between them Other chemical couplings of antibody fragments are also known The "light chams" of antibodies (immunoglobulms) from any vertebrate species can be assigned to one of two clearly distinct types, called kappa (K) and lambda (λ), based on the ammo acid sequences of their constant domams Dependmg on the ammo acid sequence of the constant domain of their heavy chams, immunoglobulms can be assigned to different classes There are five major classes of lmmunoglobu ns IgA, IgD, IgE, IgG, and IgM; and several of these may be further divided into subclasses (isotypes), e g , IgGl, IgG2, IgG3, IgG4, IgA, and IgA2. The heavy-chain constant domams that coπespond to the different classes of immunoglobulins are called α, δ, e, γ, and μ, respectively The subumt structures and three-dimensional configurations of different classes of immunoglobulms are well known The term "monoclonal antibody" as used herein refers to an antibody obtamed from a population of substantially homogeneous antibodies, l e , the individual antibodies compnsmg the population are identical except for possible naturally-occurnng mutations that may be present in minor amounts Monoclonal antibodies are highly specific, bemg directed agamst a single antigemc site Furthermore, in contrast to conventional (polyclonal) antibody preparations that typically include different antibodies directed agamst different determinants (epitopes), each monoclonal antibody is directed agamst a single determinant on the antigen In addition to their specificity, the monoclonal antibodies are advantageous in that they are synthesized by the hybndoma culture, uncontammated by other immunoglobulms The modifier "monoclonal" indicates the character ol the antibodv as being obtained from a substantially homogeneous population ot antibodies and is not to be construed as requiring production ot the antibodv bv any particular method For example, the monoclonal antibodies to be used m accordance ith the present invention may be made by the hvbndoma method first descπbed bv Kohler et al Nature. 256 495 ( 1975) or may be made by recombinant DNA methods (see, e g , U S Patent No 4 816,567) The "monoclonal antibodies" may also be isolated from phage antibodv hbraπes using the techniques described in Clackson et al Nature. 352 624-628 (1991) and Marks et al J Mol Biol , 222 581-597 (1991), for example The monoclonal antibodies herem specifically include "chimenc" antibodies (immunoglobulms) in which a portion of the heavy and/or light cham is identical with or homologous to coπesponding sequences m antibodies denved from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chaιn(s) is identical with or homologous to coπespondmg sequences in antibodies deπved from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity U S Patent No 4,816,567, Momson et al Proc Natl Acad Sci USA, 81 6851-6855 (1984) "Humanized" forms of non-human (e g , murine) antibodies are chimenc immunoglobulms, immunoglobulin chams, or fragments thereof (such as Fv, Fab, Fab'. F(ab') 2 or other antigen-bmdmg subsequences of antibodies) that contain minimal sequence derived from non-human immunoglobulin For the most part, humanized antibodies are human immunoglobulms (recipient antibody) in which residues from a CDR of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit havmg the desired specificity, affinity, and capacity In some instances, Fv FR residues of the human immunoglobulin are replaced by coπespondmg non-human residues Furthermore, humanized antibodies may compnse residues that are found neither in the recipient antibody nor in the imported CDR or framework sequences These modifications are made to further refine and maximize antibody performance In general, the humanized antibody will compnse substantially all of at least one, and typically two, vanable domains, m which all or substantially all of the CDR regions coπespond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin sequence The humanized antibody preferably also will compnse at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin For further details, see Jones et al Nature, 321 522-525 (1986), Reichmann et al , Nature, 332 323-329 (1988), and Presta. Cuπ Op Struct Biol . 2 593-596 (1992) The humanized antibody includes a PRIMATIZED™ antibody wherem the antigen-binding region of the antibody is deπved from an antibody produced by immunizing macaque monkeys with the antigen of interest "Single-chain Fv" or "sFv" antibody fragments compnse the V H and V L domains of an antibody, wherem these domams are present in a smgle polypeptide cham Preferably, the Fv polypeptide further compnses a polypeptide linker between the V H and V L domams that enables the sFv to form the desired structure for antigen bmdmg For a review of sFv see Pluckthun in The Pharmacology of Monoclonal Antibodies, vol 113, Rosenburg and Moore, eds (Springer- Verlag New York, 1994), pp 269-315 The term "diabodies" refers to small antibodv fragments with two antigen-binding sites, which fragments compnse a heavy-chain variable domain (V H ) connected to a light-chain vaπable domam (V L ) in the same polypeptide cham (V H - V L ) By using a linker that is too short to allow paiπng between the two domams on the same chain, the domams are forced to pair with the complementary domains of another cham and create two antigen-binding sites Diabodies are described more tullv in for example EP 404 097 WO 93 1 1 161 and Holhnger et al Proc Natl Acad Sci USA. 90 6444-6448 (1993) An "isolated" antibody is one that has been identified and separated and/or recovered from a component of its natural environment Contaminant components of its natural environment are materials that would interfere with diagnostic or therapeutic uses for the antibodv, and mav include enzymes hormones and other protemaceous or nonprotemaceous solutes In prefeπed embodiments, the antibody will be puπfied ( 1 ) to greater than 95% by weight of antibody as determined by the Lowry method and most preferably more than 99% by weight (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spu ing cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or nonreducing conditions usmg Coomassie blue or, preferably, silver stam Isolated antibodv includes the antibody in situ within recombinant cells smce at least one component of the antibody's natural environment will not be present Ordinanly, however, isolated antibody will be prepared by at least one puπfication step The word "label" when used herein refers to a detectable compound or composition that is conjugated directly or indirectly to the antibody so as to generate a "labeled" antibody The label may be detectable by itself (e g , radioisotope labels or fluorescent labels) or, m the case of an enzymatic label, mav catalyze chemical alteration of a substrate compound or composition that is detectable By "solid phase" is meant a non-aqueous matπx to which an antibodv of the present mvention can adhere Examples of solid phases encompassed herem include those formed partially or entirely of glass (e g , controlled pore glass), polysacchaπdes (e g , agarose), polyacrylamides, polystyrene, polyvmyl alcohol and sihcones In certam embodiments, dependmg on the context the solid phase can compnse the well of an assay plate, in others it is a punfication column (e g , an affinity chromatography column) This term also includes a discontmuous solid phase of discrete particles, such as those descnbed in U S Patent No 4,275,149 A "hposome" is a small vesicle composed of vanous types of hpids, phosphohpids and/or surfactant that is useful for delivery of a drag (such as the PR0364 or PRO 175 polypeptide or antibodies thereto disclosed herem) to a mammal The components of the hposome are commonly aπanged in a bilayer formation, similar to the hpid aπangement of biological membranes As used herem, the term "lmmunoadhesin" designates antibody-like molecules that combme the binding specificity of a heterologous protein (an "adhesin") with the effector functions of immunoglobulin constant domains Structurally, the immunoadhesins compnse a fusion of an ammo acid sequence with the desired bmdmg specificity that is other than the antigen recognition and binding site of an antibody (i e , is "heterologous"), and an immunoglobulin constant domam sequence The adhesin part of an lmmunoadhesin molecule typically is a contiguous ammo acid sequence compnsmg at least the binding site of a receptor or a ligand The immunoglobulin constant domam sequence m the lmmunoadhesin may be obtamed from any immunoglobulin, such as IgG-1, IgG-2, IgG-3, or IgG-4 subtypes, IgA (including IgA-1 and IgA-2) IgE, IgD, or IgM II Compositions and Methods of the Invention A Preparation of the PRQ364 or PRO 175 Polypeptides The present mvention provides newly identified and isolated nucleotide sequences encoding polypeptides refeπed to in the present application as PR0364 (also refeπed to as PR0687 or UNQ 319) and as PR0175 In particular, cDNAs encoding PR0364 and PRO 175 polypeptides have been identified and isolated as disclosed in further detail m the Examples below It is noted that protems produced in separate expression rounds may be given different PRO numbers but the UNQ number is unique for any given DNA and the encoded protein, and will not be changed. The description below relates primarily to production of PR0364 and PR0175 polypeptide by culturing cells transformed or transfected with a vector containing nucleic acid encoding PR0364 or PRO 175 polypeptide. It is. of course, contemplated that alternative methods that are well known in the art may be employed to prepare PR0364 or PR0175. For instance, the PR0364 or PR0175 polypeptide sequence, or portions thereof, may be produced by direct peptide synthesis using solid-phase techniques. See, e.g., Stewart et al., Solid-Phase Peptide Synthesis (W.H. Freeman Co.: San Francisco, CA, 1969); Meπifield. J. Am. Chem. Soc, 85: 2149-2154 (1963). In vitro protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be accomplished, for instance, with an Applied Biosystems Peptide Synthesizer (Foster City, CA) using manufacturer's instructions. Various portions PR0364 or PR0175 may be chemically synthesized separately and combined using chemical or enzymatic methods to produce the full-length PR0364 or PROl 75 polypeptide. Isolation of DNA Encoding PRQ364 or PRQ175 DNA encoding PR0364 or PR0175 polypeptide may be obtained from a cDNA library prepared from tissue believed to possess the mRNA encoding PR0364 or PRO 175 and to express it at a detectable level. Accordingly, DNAs encoding human PR0364 or human PRO 175 can be conveniently obtained from cDNA libraries prepared from human tissues, such as described in the Examples. The gene encoding PR0364 or PRO 175 polypeptide may also be obtained from a genomic library or by oligonucleotide synthesis. Libraries can be screened with probes (such as antibodies to the PR0364 or PR0175 polypeptide or oligonucleotides of at least about 20-80 bases) designed to identify the gene of interest or the protein encoded by it. Screening the cDNA or genomic library with the selected probe may be conducted using standard procedures, such as described in Sambrook et al., supra. An alternative means to isolate the gene encoding PR0364 or PR0175 is to use PCR methodology. Sambrook et al., supra; Dieffenbach et al., PCR Primer: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1995). The Examples below describe techniques for screening a cDNA library. The oligonucleotide sequences selected as probes should be of sufficient length and sufficiently unambiguous that false positives are minimized. The oligonucleotide is preferably labeled such that it can be detected upon hybridization to DNA in the library 32 being screened. Methods of labeling are well known in the art, and include the use of radiolabels like P-labeled ATP, biotinylation, or enzyme labeling. Hybridization conditions, including moderate stringency and high stringency, are provided in Sambrook et al. , supra. Sequences identified in such library screening methods can be compared and aligned to other known sequences deposited and available in public databases such as GenBank or other private sequence databases. Sequence identity (at either the amino acid or nucleotide level) within defined regions of the molecule or across the full-length sequence can be determined through sequence alignment using computer software programs such as ALIGN, DNAstar, and INHERIT. Nucleic acid having protein coding sequence may be obtained by screening selected cDNA or genomic libraries using the deduced amino acid sequence disclosed herein for the first time, and, if necessary, using conventional primer extension procedures as described in Sambrook et al, supra, to detect precursors and processing intermediates of mRNA that may not have been reverse- transcribed into cDNA. In addition to the full-length native sequence PR0364 or PRO 175 polypeptide described herein, it is contemplated that PR0364 or PRO 175 variants can be prepared. PR0364 or PRO 175 variants can be prepared bv introducing appropriate nucleotide changes into the PR0364- or PR0175-encodιng DNA or bv synthesis of the desired PR0364 or PRO 175 polypeptide Those skilled in the art will appreciate that amino acid changes mav alter post-translational processes ol the PR0364 or PRO 175 polypeptide. such as changing the number or position ot glycosylation sites or altering the membrane anchoring characteristics Vanations in the native full-length sequence PR0364 or PR0175 or in vanous domains of the PR0364 or PRO 175 polypeptide descnbed herein, can be made, for example, using any of the techniques and guidelines for conservative and non-conservative mutations set forth, for instance, in U S Patent No 5,364,934 Variations may be a substitution, deletion or insertion of one or more codons encoding the PR0364 or PRO 175 polypeptide that results in a change in the amino acid sequence of the PR0364 or PRO 175 polypeptide as compared with the native sequence PR0364 or PR0175 Optionally the vanation is by substimtion of at least one ammo acid with any other ammo acid in one or more of the domains of the PR0364 or PRO 175 polypeptide Guidance in determining which ammo acid residue may be inserted, substituted or deleted without adversely affectmg the desired activity may be found by compaπng the sequence of the PR0364 or PRO 175 polypeptide with that of homologous known protein molecules and minimizing the number of ammo acid sequence changes made in regions of high homology Amino acid substimtions can be the result of replacing one amino acid with another ammo acid having similar structural and/or chemical properties, such as the replacement of a leucme with a serine, l e , conservative amino acid replacements Insertions or deletions may optionally be in the range of 1 to 5 ammo acids The vanation allowed may be determined by systematically making insertions, deletions or substimtions of ammo acids m the sequence and testmg the resultmg vanants for activity in any of the in vitro assays descπbed m the Examples below The vanations can be made using methods known in the art such as ohgonucleotide-mediated (site- directed) mutagenesis, alanme scanning, and PCR mutagenesis Site-directed mutagenesis [Carter et al , Nucl Acids Res . J3 4331 (1986), Zoller et al , Nucl Acids Res , JO 6487 (1987)], cassette mutagenesis [Wells et al , Gene, 34 315 (1985)], restnction selection mutagenesis [Wells et al , Philos Trans R Soc London SerA, 317 415 (1986)] or other known techniques can be performed on the cloned DNA to produce the PR0364- encoding vanant DNA Scanning amino acid analysis can also be employed to identify one or more ammo acids along a contiguous sequence Among the prefeπed scanning amino acids are relatively small, neutral amino acids Such ammo acids mclude alanme, glycine, serine. and cysteine Alanme is typically a prefeπed scanning ammo acid among this group because it eliminates the side-cham beyond the beta-carbon and is less likely to alter the main- chain conformation of the vaπant Alanme is also typically prefeπed because it is the most common ammo acid Further, it is frequently found m both buπed and exposed positions [Creighton, The Proteins, (W H Freeman & Co , N Y ), Chothia, J Mol Biol , 150 1 (1976)] If alanme substimtion does not yield adequate amounts of vaπant. an isotenc ammo acid can be used Modifications of PRQ364 Covalent modifications of PR0364 or PR0175 polypeptides are mcluded within the scope of this mvention One type of covalent modification mcludes reactmg targeted amino acid residues of a PR0364 or PRO 175 polypeptide with an organic denvatizmg agent that is capable of reacting with selected side chams or the N- or C- terminal residues of a PR0364 or PROl 75 polypeptide Deπvatization with bifunctional agents is useful for instance for crosslmking PR0364 or PRO 175 to a water-insoluble support matrix or surface for use in the method for purifying antι-PR0364 or -PROl 75 antibodies, and vice-versa Commonly used crosslmking agents include, e g . 1 1 -bιs(dιazoacetvl)-2-phenvlethane glutaraldehyde N-hydroxvsuccimmide esters, for example, esters with 4-azιdosalιcvhc acid homobifunctional lmidoesters including disuccmimidyl esters such as 3 3'-dιfhιobιs(succmιmιdylpropιonate), bifunctional maleimides such as bis-N-maleimido- 1 8-octane and agents such as methyl-3-[(p-azιdophenvl)dιthιo]propιoιmιdate Other modifications include deamidation of glutaminyl and asparaginyl residues to the coπespondmg glutamyl and aspartvl residues, respectively, hvdroxvlation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the alpha-ammo groups of lysine, arginme, and histidine side chains [T E Creighton Proteins Structure and Molecular Properties. W H Freeman & Co , San Francisco, pp 79-86 (1983)], acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group Another type of covalent modification of the PR0364 or PRO 175 polypeptide included within the scope of this invention compnses altenng the native glycosylation pattern of the polypeptide "Altenng the native glycosylation pattern" is mtended for purposes herem to mean deleting one or more carbohydrate moieties found in native sequence PR0364 or PR0175 polypeptide. and/or adding one or more glycosylation sites that are not present in the native sequence PR0364 or PROl 75 polypeptide Addition of glycosylation sites to PR0364 or PRO 175 polypeptides may be accomplished by altenng the amino acid sequence thereof The alteration may be made, for example, by the addition of, or substimtion by, one or more serine or threonme residues to the native sequence PR0364 or PR0175 polypeptide (for O-linked glycosylation sites) The PR0364 or PRO 175 amino acid sequence may optionally be altered through changes at the DNA level, particularly by mutatmg the DNA encodmg the PR0364 or PRO 175 polypeptide at preselected bases such that codons are generated that will translate into the desired ammo acids Another means of increasing the number of carbohvdrate moieties on the PR0364 or PRO 175 polypeptide is bv chemical or enzvmatic coupling of glycosides to the polypeptide Such methods are descnbed in the art, e g , in WO 87/05330 published 11 September 1987, and in Aplin and Wπston, CRC Cnt Rev Biochem , pp 259-306 (1981) Removal of carbohydrate moieties present on the PR0364 or PRO 175 polypeptide may be accomplished chemically or enzymatically or bv mutational substimtion of codons encoding for amino acid residues that serve as targets for glycosylation Chemical deglycosylation techniques are known in the art and descnbed, for instance, by Hakimuddm, et al . Arch Biochem Biophvs . 259 52 (1987) and by Edge et al , Anal Biochem . 118 131 (1981) Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a vanety of endo- and exo-glycosidases as descnbed by Thotakura et al , Meth Enzvmol , 138 350 (1987) Another type of covalent modification of PR0364 or PROl 75 compnses linking the PR0364 or PROl 75 polypeptide to one of a vaπety of nonprotemaceous polymers, e g , polyethylene glycol polypropylene glycol, or polyoxyalkvlenes, m the manner set forth in U S Patent Nos 4,640 835, 4,496,689, 4,301,144, 4,670,417 4,791,192 or 4,179,337 PR0364 or PROl 75 polypeptides ot the present mvention mav also be modified m a vvav to form chimenc molecules compnsmg a PR0364 or PRO 175 polypeptide fused to another, heterologous polypeptide or ammo acid sequence In one embodiment, such a chimenc molecule comprises a fusion of a PR0364 or PR0175 polypeptide with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectiv ely bind The epitope tag is generally placed at the amino- or carboxyl- terminus of the PR0364 or PRO 175 polypeptide The presence of such epitope-tagged forms ot a PR0364 or PRO 175 polypeptide can be detected using an antibody against the tag polypeptide Also, provision of the epitope tag enables the PR0364 or PR0175 polypeptide to be readily puπfied by affinity punfication using an anti-tag antibody or another type of affinity matrix that bmds to the epitope tag In an alternative embodiment, the chimenc molecule may compnse a fusion of a PR0364 or PR0175 polypeptide with an immunoglobulm or a particular region of an immunoglobulin For a bivalent form of the chimenc molecule, such a fusion could be to the Fc region of an IgG molecule Optionally, the chimenc molecule will compnse a PR0364 or PRO 175 ECD sequence fused to an Fc region of an IgG molecule Vanous tag polypeptides and their respective antibodies are well known in the art Examples include poly-histidine (poly-his) or poly-histidine-glycine (poly-his-gly) tags, the flu HA tag polypeptide and its antibody 12CA5 [Field et al , Mol Cell Biol , 8 2159-2165 (1988)], the c-myc tag and the 8F9, 3C7, 6E10. G4. B7 and 9E10 antibodies thereto [Evan et al , Molecular and Cellular Biology, 5 3610-3616 (1985)], and the Herpes Simplex virus glycoprotem D (gD) tag and its antibody [Paborsky et al , Protein Engineering, 3(6) 547-553 (1990)] Other tag polypeptides include the Flag-peptide [Hopp et al , BioTechnology, 6 1204-1210 (1988)], the KT3 epitope peptide [Martm et al , Science, 255 192-194 (1992)], an alpha-mbulm epitope peptide [Skmner et al., J Biol Chem . 266 15163-15166 (1991)], and the T7 gene 10 protein peptide tag [Lutz-Freyermuth et al , Proc Natl Acad Sci USA. 87 6393-6397 (1990)] The PR0364 or PRO 175 polypeptide of the present invention may also be modified m a way to form a chimenc molecule compnsmg a PR0364 or PRO 175 polypeptide fused to a leucme zipper Vanous leucme zipper polypeptides have been descπbed in the art See, e g , Landschulz et al , Science 240 1759 (1988), WO 94/10308, Hoppe et al , FEBS Letters 344 1991 (1994), Mamatis et al , Nature 341 24 (1989) It is believed that use of a leucme zipper fused to a PR0364 or PRO 175 polypeptide may be desirable to assist in dimenzmg or tπmenzing soluble PR0364 or PRO 175 polypeptide in solution Those skilled in the art will appreciate that the leucme zipper may be fused at either the N- or C-termmal end of the PR0364 or PRO 175 molecule Selection and Transformation of Host Cells Host cells are transfected or transformed with expression or clonmg vectors descnbed herein for PR0364 or PRO 175 production and cultured in conventional nutπent media modified as appropπate for mducmg promoters, selectmg transformants, or amplifying the genes encodmg the desired sequences The culture conditions, such as media, temperature, pH, and the like, can be selected by the skilled artisan without undue experimentation In general, principles, protocols, and practical techniques for maximizing the productivity of cell cultures can be found in Mammalian Cell Biotechnology A Practical Approach. M Butler, ed (IRL Press, 1991) and Sambrook et al , supra Methods of transfection are known to the ordmaπly skilled artisan, for example, CaP0 4 treatment and electroporation Dependmg on the host cell used, transformation is performed usmg standard techniques appropriate to such cells The calcium treatment employing calcium chloride as descπbed in Sambrook et al supra, or electroporation is generally used tor prokaryotes or other cells that contain substantial cell-wall barners Infection with Agrobacterium tumefaciens is used for transformation of certain plant cells, as described by Shaw et al . Gene. 23 315 (1983) and WO 89/05859 published 29 June 1989 For mammalian cells without such cell walls, the calcium phosphate precipitation method of Graham and van der Eb, Virology. 52 456-457 (1978) can be employed General aspects of mammalian cell host system transformations have been described in U S Patent No 4,399,216 Transformations into yeast are typically caπied out according to the method of Van Sohngen et al , J Bact , 130 946 (1977) and Hsiao et al . Proc Natl Acad Sci (USA), 76 3829 (1979) However, other methods for introducing DNA into cells, such as by nuclear micromjection. electroporation, bacterial protoplast fusion with intact cells, or polycations, e g , polybrene or polyomithine, may also be used For vanous techniques for transforming mammalian cells, see Keown et al , Methods in Enzvmology, 185 527-537 (1990) and Mansour et al . Nature. 336 348-352 (1988) Suitable host cells for cloning or expressing the DNA in the vectors herem include prokaryote, yeast, or higher eukaryote cells Suitable prokaryotes include, but are not limited to. eubacteπa, such as Gram-negative or Gram-positive organisms, for example, Enterobactenaceae such as E coli Vanous E colt strains are publicly available, such as E colt K12 stram MM294 (ATCC 31,446), E coli X1776 (ATCC 31,537). E coli strain W3110 (ATCC 27,325), and K5 772 (ATCC 53,635) In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable clonmg or expression hosts for vectors encodmg PR0364 or PRO 175 Saccharomyces cerevtsiae is a commonly used lower eukaryotic host microorganism Suitable host cells for the expression of nucleic acid encoding glycosylated PR0364 or PRO 175 are deπved from multicellular organisms Examples of invertebrate cells include msect cells such as Drosophila S2 and Spodoptera Sf9, as well as plant cells Examples of useful mammalian host cell lines mclude Chmese hamster ovary (CHO) and COS cells More specific examples include monkey kidney CV1 lme transformed by SV40 (COS-7, ATCC CRL 1651), human embryonic kidney line (293 or 293 cells subcloned for growth m suspension culture, Graham et al , J Gen Virol . 36 59 (1977)), Chinese hamster ovary cellsΛDHFR (CHO, Urlaub and Chasm, Proc Natl Acad Sci USA. 77 4216 (1980)), mouse sertoh cells (TM4, Mather, Biol Reprod . 23 243- 251 (1980)), human lung cells (W138, ATCC CCL 75), human liver cells (Hep G2, HB 8065). and mouse mammary tumor (MMT 060562, ATCC CCL51) The selection of the appropnate host cell is deemed to be within the skill m the art Selection and Use of a Rephcable Vector The nucleic acid (e , cDNA or genomic DNA) encoding PR0364 or PRO 175 may be inserted mto a rephcable vector for cloning (amplification of the DNA) or for expression Vanous vectors are publicly available The vector may, for example, be m the form of a plasmid, cosmid. viral particle, or phage The appropnate nucleic acid sequence may be inserted mto the vector by a vaπety of procedures In general, DNA is inserted into an appropnate restriction endonuclease sιte(s) using techniques known in the art Vector components generally mclude, but are not limited to, one or more of a signal sequence if the sequence is to be secreted, an oπgm of replication, one or more marker genes, an enhancer element, a promoter, and a transcnption termination sequence Construction of suitable vectors containing one or more of these components employs standard ligation techniques that are known to the skilled artisan The PR0364 or PRO 175 may be produced recombmantly not only directly, but also as a fusion polypeptide with a heterologous polypeptide, which mav be a signal sequence or other polypeptide having a specific cleavage sue at the N-termmus of the mature protein or polvpeptide In general the signal sequence mav be a component of the vector or it mav be a part of the DNA PR0364 or PR0175 that is inserted into the vector The signal sequence mav be a prokaryotic signal sequence selected for example from the group of the alkaline phosphatase, penicil nase lpp, or heat-stable enterotoxm II leaders For veast secretion the signal sequence may be, e g , the yeast mvertase leader, alpha factor leader (including Saccharonnces and Kluyvet onnces α-factor leaders the latter described in U S Patent No 5 010,182) or acid phosphatase leader, the C albicans glucoamylase leader (EP 362 179 published 4 April 1990), or the signal descnbed in WO 90/13646 published 15 November 1990 In mammalian cell expression mammalian signal sequences mav be used to direct secretion of the protein, such as signal sequences from secreted polypeptides of the same or related species, as well as viral secretory leaders Both expression and cloning vectors contam a nucleic acid sequence that enables the vector to replicate in one or more selected host cells Such sequences are well known for a vaπetv of bacteπa, yeast and viruses The ongm of replication from the plasmid pBR322 is suitable for most Gram-negative bacteπa, the 2μ plasmid oπgm is suitable for yeast, and vanous viral ongms (SV40, polyoma, adenovirus, VSV, or BPV) are useful for clonmg vectors in mammalian cells Expression and cloning vectors will typically contam a selection gene also termed a selectable marker Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins e g , ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies or (c) supply cntical nutnents not available from complex media, e g , the gene encodmg D-alanme racemase for Bacilli An example of suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up the nucleic acid encoding PR0364 or PRO 175 such as DHFR or thymidme kmase An appropnate host cell when wild-type DHFR is employed is the CHO cell line deficient in DHFR activity, prepared and propagated as descnbed by Urlaub et al , Proc Natl Acad Sci USA, 77 4216 (1980) A suitable selection gene for use m yeast is the trp\ gene present m the yeast plasmid YRp7 Stmchcomb et al , Nature. 282 39 (1979), Kingsman et al , Gene, 7 141 (1979), Tschemper et al , Gene, JO 157 (1980) The trpϊ gene provides a selection marker for a mutant stram of yeast lackmg the ability to grow m tryptophan for example, ATCC No 44076 or PEP4-1 Jones, Genetics, 85 12 (1977) Expression and cloning vectors usually contam a promoter operably linked to the nucleic acid sequence encoding PR0364 or PRO 175 to direct mRNA synthesis Promoters recognized bv a vanety of potential host cells are well known Promoters suitable for use with prokaryotic hosts include the β-lactamase and lactose promoter systems (Chang et al , Nature, 275 615 (1978), Goeddel et al , Nature, 281 544 (1979)), alkalme phosphatase, a tryptophan (trp) promoter system (Goeddel, Nucleic Acids Res , 8 4057 (1980), EP 36,776), and hybπd promoters such as the tac promoter deBoer et al . Proc Natl Acad Sci USA. 80 21-25 (1983) Promoters for use m bactenal systems also will contain a Shine-Dalgarno (S D ) sequence operably linked to the DNA encodmg PR0364 or PRO 175 Examples of suitable promoting sequences for use with yeast hosts mclude the promoters for 3- phosphoglycerate kmase (Hitzeman et al J Biol Chem . 255 2073 (1980)) or other glycolytic enzymes (Hess et al , J Adv Enzyme Reg . 7 149 (1968), Holland Biochemistry. J7 4900 (1978)), such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase pyravate decarboxvlase, phosphofructokinase, glucose- 6-phosphate isomerase, 3-phosphoglycerate mutase, pyravate kmase tπosephosphate isomerase, phosphoglucose isomerase, and glucokinase Other yeast promoters that are inducible promoters having the additional advantage of transcπption controlled by growth conditions are the promoter regions for alcohol dehvdrogenase 2 lsocvtochrome C acid phosphatase degradative enzvmes associated with nitrogen metabolism metallothionein glvceraldehvde-3-phos- phate dehydrogenase and enzvmes responsible for maltose and galactose utilization Suitable v ectors and promoters for use in yeast expression are further described in EP 73,657 PR0364 or PRO 175 nucleic acid transcription from vectors in mammalian host cells is controlled, for example, by promoters obtained from the genomes of viruses such as polyoma virus fowlpox virus (UK 2,21 1,504 published 5 July 1989), adenovirus (such as Adenovirus 2), bovine papilloma virus avian sarcoma virus, cytomegalovirus, a retroviras, hepatitis-B virus and Simian Virus 40 (SV40), by heterologous mammalian promoters, e g , the actin promoter or an immunoglobulm promoter, and by heat-shock promoters, provided such promoters are compatible with the host cell systems Transcription of a DNA encodmg the PR0364 or PR0175 by higher eukaryotes may be increased by inserting an enhancer sequence into the vector Enhancers are cis-actmg elements of DNA. usually about from 10 to 300 bp, that act on a promoter to mcrease its transcnption Many enhancer sequences are now known from mammalian genes (globm, elastase, albumin, α-fetoprotein, and insulin) Typically, however, one will use an enhancer from a eukaryotic cell virus Examples include the SV40 enhancer on the late side of the replication oπgin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication oπgm, and adenovirus enhancers The enhancer may be spliced into the vector at a position 5' or 3' to the sequence coding for PR0364 or PROl 75, but is preferably located at a site 5' from the promoter Expression vectors used in eukaryotic host cells (yeast, fungi, msect, plant, animal, human, or nucleated cells from other multicellular organisms) will also contam sequences necessary for the termination of transcnption and for stabilizing the mRNA Such sequences are commonly available from the 5' and, occasionally 3', untranslated regions of eukaryotic or viral DNAs or cDNAs These regions contain nucleotide segments transcnbed as polyadenylated fragments m the untranslated portion of the mRNA encodmg PR0364 or PRO 175 Still other methods, vectors, and host cells suitable for adaptation to the synthesis of PR0364 or PR0175 m recombinant vertebrate cell culture are descnbed in Gethmg et al , Nature, 293 620-625 (1981), Mantel et al , Nature. 281 40-46 (1979), EP 117,060, and EP 117.058 Detecting Gene Amplification/Expression Gene amplification and/or expression mav be measured m a sample directly, for example, by conventional Southern blottmg, Northern blottmg to quantitate the transcnption of mRNA (Thomas. Proc Natl Acad Sci USA. 77 5201-5205 (1980)), dot blottmg (DNA analysis), or in situ hybridization, usmg an appropnately labeled probe, based on the sequences provided herein Alternatively, antibodies may be employed that can recognize specific duplexes, mcludmg DNA duplexes, RNA duplexes, and DNA-RNA hybnd duplexes or DNA-protem duplexes The antibodies m turn may be labeled and the assay may be earned out where the duplex is bound to a surface, so that upon the formation of duplex on the surface, the presence of antibody bound to the duplex can be detected Gene expression, alternatively, may be measured by immunological methods, such as lmmunohistochemical staining of cells or tissue sections and assay of cell culture or body fluids, to quantitate directly the expression of gene product Antibodies useful for lmmunohistochemical staining and/or assay of sample fluids may be either monoclonal or polyclonal, and may be prepared in anv mammal Conveniently, the antibodies may be prepared against a native- sequence PR0364 or PRO 175 polypeptide or agamst a synthetic peptide based on the DNA sequences provided herein or against exogenous sequence fused to DNA encoding PR0364 or PRO 175 and encoding a specific antibody epitope Puπfication of Polypeptide Forms of PR0364 or PRO 175 may be recovered from culture medium or from host cell lvsates If membrane-bound, it can be released from the membrane using a suitable detergent solution (e g , TRITON-X™ 100) or by enzymatic cleavage Cells employed in expression of nucleic acid encoding PR0364 or PRO 175 can be disrupted by vanous physical or chemical means, such as freeze-thaw cycling, somcation, mechanical disruption, or cell-lysing agents It may be desired to purify PR0364 or PRO 175 polypeptide from recombmant cell proteins or polypeptides The following procedures are exemplary of suitable puπfication procedures by fractionation on an ion-exchange column, ethanol precipitation, reverse phase HPLC, chromatography on silica or on a cation-exchange resm such as DEAE, chromatofocusing, SDS-PAGE, ammonium sulfate precipitation, gel filtration using, for example, Sephadex G-75, protem A Sepharose columns to remove contammants such as IgG, and metal chelatmg columns to bind epitope-tagged forms of the PR0364 or PRO 175 Vanous methods of protem purification may be employed and such methods are known in the art and descnbed, for example, m Deutscher, Methods in Enzvmology, 182 (1990), Scopes, Protein Punfication Principles and Practice (Spπnger-Verlag New York, 1982) The puπfication steρ(s) selected will depend, for example, on the nature of the production process used and the particular PR0364 or PRO 175 produced Uses of the PRQ364 or PRO 175 Polypeptides l Assays for Cardiovascular. Endothelial, and Angiogenic Activity Vanous assays can be used to test the polypeptide herein for cardiovascular, endothelial, and angiogenic activity Such assays mclude those provided in the Examples below Assays for testmg for endothelm antagonist activity, as disclosed m U S Pat No 5,773,414. include a rat heart ventncle bindmg assay where the polypeptide is tested for its ability to inhibit lodmized endothelm- 1 bmdmg m a receptor assay, an endothelm receptor bmdmg assay testmg for intact cell bmdmg of radiolabeled endothelm- 1 usmg rabbit renal artery vascular smooth muscle cells, an mositol phosphate accumulation assay where functional activity is determined in Rat-1 cells by measuring intra-cellular levels of second messengers, an arachidomc acid release assay that measures the ability of added compounds to reduce endothelin-stimulated arachidonic acid release in cultured vascular smooth muscles, in vitro (isolated vessel) studies using endothelium from male New Zealand rabbits, and in vivo studies usmg male Sprague-Dawley rats Assays for tissue generation activity include, without limitation, those descπbed m WO 95/16035 (bone, cartilage, tendon), WO 95/05846 (nerve, neuronal), and WO 91/07491 (skin, endothelium) Assays for wound-healmg activity include, for example, those descπbed in Winter, Epidermal Wound Healmg. Maibach, HI and Rovee, DT, eds (Year Book Medical Publishers, Inc , Chicago), pp 71-112, as modified by the article of Eaglstein and Mertz, J Invest Dermatol . 71 382-384 (1978) An assay to screen for a test molecule relatmg to a PR0364 or PRO 175 polypeptide that binds an endothelm B ] (ETB | ) receptor polypeptide and modulates signal transduction activity involves providmg a host cell transformed with a DNA encodmg endothelm B ! receptor polypeptide, exposing the cells to the test candidate, and measurmg endothelm B, receptor signal transduction activity, as descnbed, e g , in U S Pat No 5,773,223 There are several cardiac hypertrophy assays In vitro assays include induction of spreading of adult rat cardiac myocytes In this assay, ventncular myocytes are isolated from a single (male Sprague-Dawley) rat, essentially followmg a modification of the procedure described in detail by Piper et al , "Adult ventncular rat heart muscle cells" in Cell Culture Techniques in Heart and Vessel Research. H M Piper, ed (Berlin Spnnger- Verlag 1990) pp 36-60 This procedure permits the isolation of adult ventricular mvocvtes and the long-term culture ot these cells in the rod-shaped phenotype Phenvlephπne and Prostaglandm Fι α (PGFι α ) have been shown to induce a spreading response in these adult cells The inhibition of mvocyte spreading induced bv PGF 2α or PGF ^α analogs (e g fluprostenol) and phenvlephrme by various potential inhibitors of cardiac hypertrophy is then tested One example of an in \ ivo assay is a test for inhibiting cardiac hypertrophy induced by fluprostenol in vtx o This pharmacological model tests the ability of the PR0364 or PRO 175 polypeptide to inhibit cardiac hypertrophy induced m rats (e g , male Wistar or Sprague-Dawley) by subcutaneous injection of fluprostenol (an agonist analog of PGF 2α ) It is known that rats with pathologic cardiac hypertrophy induced by myocardial infarction have chronically elevated levels of extractable PGF 2α in their myocardium Lai et al , Am J Physiol (Heart Circ Phvsiol ). 271 H2197-H2208 (1996) Accordingly, factors that can inhibit the effects of fluprostenol on myocardial growth in vivo are potentially useful for treating cardiac hypertrophy The effects of the PR0364 or PRO 175 polypeptide on cardiac hypertrophy are determined by measuring the weight of heart, ventπcles, and left ventncle (normalized by body weight) relative to fluprostenol-treated rats not receiving the PR0364 or PRO 175 polypeptide Another example of an in vivo assay is the pressure-overload cardiac hypertrophy assay For in vivo testmg it is common to induce pressure-overload cardiac hypertrophy by constπction of the abdominal aorta of test animals In a typical protocol, rats (e g , male Wistar or Sprague-Dawley) are treated under anesthesia, and the abdominal aorta of each rat is narrowed down just below the diaphragm Beznak M , Can J Biochem Physiol , 33 985-94 (1955) The aorta is exposed through a surgical incision, and a blunted needle is placed next to the vessel The aorta is constπcted with a ligature of silk thread around the needle, which is immediately removed and which reduces the lumen of the aorta to the diameter of the needle This approach is descπbed, for example, in Rossi et al Am Heart J , 124 700-709 (1992) and O'Rourke and Reibel, P S E M B , 200 95-100 (1992) In yet another in vivo assay, the effect on cardiac hypertrophy following experimentally induced myocardial infarction (MI) is measured Acute MI is induced in rats by left coronary artery ligation and confirmed bv electrocardiographic exammation A sham-operated group of animals is also prepared as control animals Earlier data have shown that cardiac hypertrophy is present in the group of animals with MI, as evidenced by an 18% increase in heart weight-to-body weight ratio Lai et al , supra Treatment of these animals with candidate blockers of cardiac hypertrophy, e g , PR0364 or PRO 175 polypeptide, provides valuable information about the therapeutic potential of the candidates tested One further such assay test for induction of cardiac hypertrophy is disclosed in U S Pat No 5,773,415, using Sprague-Dawley rats For cancer, a vanety of well-known animal models can be used to further understand the role of the genes identified herem m the development and pathogenesis of tumors, and to test the efficacy of candidate therapeutic agents, mcludmg antibodies and other antagonists of the native PR0364 or PRO 175 polypeptides such as small- molecule antagomsts The in vivo nature of such models makes them particularly predictive of responses m human patients Animal models of tumors and cancers (e g , breast cancer, colon cancer prostate cancer, lung cancer, etc ) mclude both non-recombinant and recombmant (transgenic) animals Non-recombinant animal models mclude, for example, rodent, e g , munne models Such models can be generated bv introducing tumor cells into syngeneic mice using standard techniques, e g , subcutaneous injection, tail vein injection spleen implantation mtrapeπtoneal implantation, implantation under the renal capsule, or orthopm implantation, e g , colon cancer cells implanted in colomc tissue See c g PCT publication No WO 97/335 1 published September 18, 1997 Probably the most often used animal species in oncological studies are immunodeficient mice and, in particular, nude mice The observation that the nude mouse with thvmic hypo/aplasia could successfully act as a host for human tumor xenografts has lead to its widespread use for this purpose The autosomal recessive nu gene has been introduced into a very large number of distmct congemc strains of nude mouse, mcludmg, for example, ASW, A/He, AKR, BALB/c, BIO LP, C17, C3H, C57BL, C57, CBA, DBA, DDD, I/st, NC, NFR, NFS, NFS/N NZB, NZC, NZW, P, RIII. and SJL In addition, a wide vanety of other animals with mheπted lmmunological defects other than the nude mouse have been bred and used as recipients of tumor xenografts For further details see, e g , The Nude Mouse in Oncology Research. E Boven and B Winograd, eds (CRC Press, Inc , 1991) The cells mtroduced into such animals can be deπved from known tumor/cancer cell lmes, such as any of the above-listed tumor cell lines, and, for example, the B 104- 1-1 cell lme (stable NIH-3T3 cell lme transfected with the neu protooncogene), ras-transfected NIH-3T3 cells, Caco-2 (ATCC HTB-37), or a moderately well- differentiated grade II human colon adenocarcinoma cell lme, HT-29 (ATCC HTB-38), or from tumors and cancers Samples of tumor or cancer cells can be obtamed from patients undergoing surgery, using standard conditions involving freezmg and storing in liquid nitrogen Karmah et al , Br J Cancer 48 689-696 (1983) Tumor cells can be introduced mto animals such as nude mice by a vaπety of procedures The subcutaneous (s c ) space m mice is very suitable for tumor implantation Tumors can be transplanted s c as solid blocks, as needle biopsies by use of a trochar, or as cell suspensions For solid-block or trochar implantation, tumor tissue fragments of suitable size are mtroduced mto the s c space Cell suspensions are freshly prepared from primary tumors or stable tumor cell lmes, and mjected subcutaneously Tumor cells can also be mjected as subdermal implants In this location, the moculum is deposited between the lower part of the dermal connective tissue and the s c tissue Animal models of breast cancer can be generated, for example, by implanting rat neuroblastoma cells (from which the neu oncogene was initially isolated), or «ew-transformed NIH-3T3 cells into nude mice, essentially as descnbed by Drebm et al Proc Nat Acad Sci USA 83 9129-9133 (1986) Similarly, animal models of colon cancer can be generated by passagmg colon cancer cells m animals, e g , nude mice, leading to the appearance of tumors in these animals An orthotopic transplant model of human colon cancer m nude mice has been descnbed, for example, by Wang et al , Cancer Research. 54 4726-4728 (1994) and Too et al , Cancer Research, 55 681-684 (1995) This model is based on the so-called DMETAMOUSED™ sold by AntiCancer, Inc (San Diego, California) Tumors that anse m animals can be removed and cultured in vitro Cells from the in vitro cultures can then be passaged to animals Such tumors can serve as targets for further testmg or drag screenmg Alternatively, the tumors resultmg from the passage can be isolated and RNA from pre-passage cells and cells isolated after one or more rounds of passage analyzed for differential expression of genes of interest Such passagmg techniques can be performed with any known tumor or cancer cell lines For example, Meth A, CMS4, CMS5, CMS21, and WEHI-164 are chemically induced fibrosarcomas of BALB/c female mice (DeLeo et al , J Exp Med . 146 720 (1977)), which provide a highly controllable model system for studying the anti-tumor activities of vanous agents Palladino et al , J Immunol , 138 4023-4032 (1987) Bπefly, tumor cells are propagated in vitro m cell culture Pnor to injection mto the animals, the cell lines are washed and suspended in buffer at a cell density of about lOxlO 6 to 10x10 cells/ml The animals are then infected subcutaneouslv w ith 10 to 100 μl of the cell suspension allowing one to three weeks for a mmor to appear In addition, the Lewis lung (3LL) carcinoma of mice, which is one of the most thoroughly studied experimental tumors, can be used as an investigational tumor model Efficacy in this tumor model has been coπelated with beneficial effects in the treatment of human patients diagnosed with small-cell carcinoma of the lung (SCCL) This mmor can be introduced in normal mice upon injection of mmor fragments from an affected mouse or of cells maintained in culture Zupi et al Br J Cancer 4J suppl 4 30 (1980) Evidence indicates that tumors can be started from injection of even a single cell and that a very high proportion ot infected mmor cells survive For further information about this mmor model see Zacharski, Haemostasis. 16 300-320 (1986) One way of evaluating the efficacy of a test compound in an animal model with an implanted mmor is to measure the size of the mmor before and after treatment Traditionally, the size of implanted tumors has been measured with a slide cahper in two or three dimensions The measure limited to two dimensions does not accurately reflect the size of the mmor, therefore, it is usually converted mto the coπespondmg volume by usmg a mathematical formula However, the measurement of mmor size is very inaccurate The therapeutic effects of a drag candidate can be better descπbed as treatment-induced growth delay and specific growth delay Another important vanable in the descnption of tumor growth is the mmor volume doublmg time Computer programs for the calculation and description of mmor growth are also available, such as the program reported by Rygaard and Spang-Thomsen, Proc 6th Int Workshop on Immune-Deficient Animals, Wu and Sheng eds (Basel, 1989), p 301 It is noted, however, that necrosis and inflammatory responses followmg treatment may actually result m an mcrease in mmor size, at least initially Therefore, these changes need to be carefully monitored, by a combmation of a morphometnc method and flow cytometπc analysis Further, recombmant (transgemc) animal models can be engineered by introducing the coding portion of the PR0364 or PR0175 genes identified herem into the genome of animals of mterest, using standard techniques for producmg transgemc animals Animals that can serve as a target for transgemc manipulation include, without limitation, mice, rats, rabbits, gumea pigs, sheep, goats, pigs, and non-human primates, e g , baboons, chimpanzees and monkeys Techniques known m the art to introduce a transgene into such animals mclude pronucleic micromjection (U S Patent No 4,873,191), retroviras-mediated gene transfer mto germ lmes (e g , Van der Putten et al Proc Natl Acad Sci USA, 82 6148-615 (1985)), gene targeting in embryonic stem cells (Thompson et al , Cell, 56 313-321 (1989)), electroporation of embryos (Lo Mol Cell Biol , 3 1803-1814 (1983)), and sperm-mediated gene transfer Lavitrano et al Cell, 57 717-73 (1989) For a review, see, for example. U S Patent No 4,736,866 For the purpose of the present invention, transgemc animals include those that carry the transgene only m part of their cells ("mosaic animals") The transgene can be integrated either as a single transgene, or m concatamers, e g , head-to-head or head-to-tail tandems Selective introduction of a transgene mto a particular cell type is also possible by following, for example, the technique of Lasko et al Proc Natl Acad Sci USA. 89 6232-636 (1992) The expression of the transgene in transgemc animals can be monitored bv standard techniques For example. Southern blot analysis or PCR amplification can be used to verify the integration of the transgene The level of mRNA expression can then be analyzed using techniques such as in situ hybπdization Northern blot analysis, PCR, or lmmunocytochemistry The animals are further examined for signs of mmor or cancer development Alternatively, "knock-out" animals can be constructed that have a detective or altered gene encoding a PR0364 or PRO 175 polypeptide identified herem. as a result of homologous recombination between the endogenous gene encoding the PR0364 or PRO 175 polypeptide and altered genomic DNA encoding the same polypeptide introduced into an embryonic cell of the animal For example, cDNA encoding a particular PR0364 or PRO 175 polypeptide can be used to clone genomic DNA encoding that polypeptide in accordance with established techniques A portion of the genomic DNA encoding a particular PR0364 or PRO 175 polypeptide can be deleted or replaced with another gene, such as a gene encoding a selectable marker that can be used to monitor integration Typically, several kilobases of unaltered flanking DNA (both at the 5' and 3' ends) are included in the vector See, e g , Thomas and Capecchi, Cell. 51 503 (1987) for a descπption of homologous recombination vectors. The vector is introduced into an embryonic stem cell lme (e g , by electroporation) and cells in which the mtroduced DNA has homologously recombined with the endogenous DNA are selected See, e g , Li et al , Cell. 69 915 (1992) The selected cells are then mjected into a blastocyst of an animal (e g , a mouse or rat) to form aggregation chimeras See. e g , Bradley, m Teratocarcmomas and Embryonic Stem Cells A Practical Approach, E. J Robertson, ed (IRL Oxford. 1987), pp 113-152 A chimenc embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term to create a "knock-out" animal Progeny harboπng the homologously recombmed DNA in their germ cells can be identified by standard techniques and used to breed animals in which all cells of the animal contain the homologously recombmed DNA. Knockout animals can be charactenzed. for instance, by their ability to defend agamst certam pathological conditions and by their development of pathological conditions due to absence of the PR0364 or PRO 175 polypeptide. The efficacy of antibodies specifically bmdmg the PR0364 or PRO 175 polypeptides identified herem, and other drug candidates, can be tested also in the treatment of spontaneous animal tumors A suitable target for such studies is the felme oral squamous cell carcmoma (SCC) Felme oral SCC is a highly invasive, malignant mmor that is the most common oral malignancy of cats, accountmg for over 60% of the oral tumors reported in this species It rarely metastasizes to distant sites, although this low incidence of metastasis may merely be a reflection of the short survival times for cats with this mmor These tumors are usually not amenable to surgery, pnmaπly because of the anatomy of the felme oral cavity At present, there is no effective treatment for this mmor Pπor to entry into the study, each cat undergoes complete clinical exammation and biopsy, and is scanned by computed tomography (CT) Cats diagnosed with sublmgual oral squamous cell tumors are excluded from the study The tongue can become paralyzed as a result of such mmor, and even if the treatment kills the mmor, the animals may not be able to feed themselves Each cat is treated repeatedly, over a longer penod of time. Photographs of the tumors will be taken daily duπng the treatment period, and at each subsequent recheck After treatment, each cat undergoes another CT scan CT scans and thoracic radiograms are evaluated every 8 weeks thereafter. The data are evaluated for differences in survival, response, and toxicity as compared to control groups. Positive response may require evidence of mmor regression, preferably with improvement of quality of life and/or mcreased life span In addition, other spontaneous annual tumors, such as fibrosarcoma, adenocarcinoma, lymphoma, chondroma, or leiomyosarcoma of dogs, cats, and baboons can also be tested Of these, mammary adenocarcmoma m dogs and cats is a prefeπed model as its appearance and behavior are very similar to those in humans However, the use of this model is limited by the rare occuπence of this type of mmor m animals Other in vitro and in vivo cardiovascular, endothelial, and angiogenic tests known in the art are also suitable herem n Tissue Distribution The results of the cardiovascular, endothelial and angiogenic assavs herein can be verified bv further smdies, such as by determining mRNA expression in vanous human tissues As noted before, gene amplification and or gene expression in various tissues may be measured bv conventional Southern blotting, Northern blotting to quantitate the transcription of mRNA (Thomas, Proc Natl Acad Sci USA, 77 5201-5205 (1980)), dot blotting (DNA analysis), or in situ hybridization, using an appropriately labeled probe, based on the sequences provided herein Alternatively, antibodies mav be employed that can recognize specific duplexes, including DNA duplexes. RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protem duplexes Gene expression in vanous tissues, alternatively, may be measured by lmmunological methods, such as lmmunohistochemical staining of tissue sections and assay of cell culture or body fluids, to quantitate directly the expression of gene product Antibodies useful for lmmunohistochemical staining and/or assay of sample fluids may be either monoclonal or polyclonal, and may be prepared in any mammal Conveniently, the antibodies may be prepared against a native-sequence PR0364 or PR0175 polypeptide or agamst a synthetic peptide based on the DNA sequences provided herein or agamst exogenous sequence fused to PR0364 or PR0175 DNA and encoding a specific antibody epitope General techniques for generating antibodies, and special protocols for in situ hybridization are provided hereinbelow in Antibodv Bmdmg Smdies The results of the cardiovascular, endothelial, and angiogenic study can be further venfied by antibody bmdmg smdies, in which the ability of anti- PR0364 or -PRO 175 antibodies to inhibit the effect of the PR0364 or PRO 175 polypeptides on endothelial cells or other cells used m the cardiovascular, endothelial, and angiogenic assays is tested Exemplary antibodies include polyclonal, monoclonal, humanized, bispecific, and heteroconjugate antibodies, the preparation of which will be descnbed hereinbelow Antibody bmdmg smdies may be earned out in any known assay method, such as competitive bmdmg assays, direct and indirect sandwich assays, and immunoprecipitation assays Zola, Monoclonal Antibodies A Manual of Techniques (CRC Press, Inc . 1987), pp 147-158 Competitive bmdmg assays relv on the ability of a labeled standard to compete with the test sample analyte for binding with a limited amount of antibody The amount of target protem in the test sample is inversely proportional to the amount of standard that becomes bound to the antibodies To facilitate determining the amount of standard that becomes bound, the antibodies preferably are insolubihzed before or after the competition, so that the standard and analyte that are bound to the antibodies may conveniently be separated from the standard and analyte that remam unbound Sandwich assays mvolve the use of two antibodies, each capable of binding to a different lmmunogemc portion, or epitope, of the protein to be detected In a sandwich assay, the test sample analyte is bound by a first antibody that is immobilized on a solid support, and thereafter a second antibody binds to the analyte, thus forming an insoluble three-part complex See, e g , US Pat No 4,376,110 The second antibody may itself be labeled with a detectable moiety (direct sandwich assays) or may be measured using an anti-immunoglobulin antibody that is labeled with a detectable moiety (indirect sandwich assay) For example, one type of sandwich assay is an ELISA assay, in which case the detectable moiety is an enzyme For lmmunohistochemistry, the tissue sample may be fresh or frozen or may be embedded in paraffin and fixed with a preservative such as formalin, for example iv Cell-Based Tumor Assays Cell-based assays and animal models for cardiovascular, endothelial. and angiogenic disorders, such as tumors, can be used to venfy the findings of a cardiovascular, endothelial, and angiogenic assay herein, and further to understand the relationship between the genes identified herein and the development and pathogenesis of undesirable cardiovascular, endothelial, and angiogenic cell growth The role of gene products identified herein in the development and pathology of undesirable cardiovascular, endothelial. and angiogenic cell growth, e g , mmor cells, can be tested by using cells or cells lines that have been identified as being stimulated or inhibited by the PR0364 or PROl 75 polypeptide herein Such cells include, for example, those set forth in the Examples below In a different approach, cells of a cell type known to be mvolved in a particular cardiovascular, endothelial, and angiogenic disorder are transfected with the cDNAs herem, and the ability of these cDNAs to mduce excessive growth or inhibit growth is analyzed If the cardiovascular, endothelial. and angiogenic disorder is cancer, suitable mmor cells include, for example, stable mmor cells lines such as the B104- 1-1 cell lme (stable NIH-3T3 cell lme transfected with the neu protooncogene) and ras-transfected NIH-3T3 cells, which can be transfected with the desired gene and monitored for mmongemc growth Such transfected cell lmes can then be used to test the ability of poly- or monoclonal antibodies or antibody compositions to inhibit tumorogenic cell growth by exerting cytostatic or cytotoxic activity on the growth of the transformed cells, or by mediatmg antibody-dependent cellular cytotoxicity (ADCC) Cells transfected with the coding sequences of the genes identified herem can further be used to identify drug candidates for the treatment of cardiovascular, endothelial, and angiogenic disorders such as cancer. In addition, primary cultures deπved from tumors m transgemc animals (as descπbed above) can be used m the cell-based assays herem, although stable cell lmes are prefeπed Techniques to deπve contmuous cell lmes from transgemc animals are well known m the art See, e g , Small et al , Mol Cell Biol 5 642-648 (1985) v Gene Therapy The PR0364 or PRO 175 polypeptide herem and polypeptidyl agonists and antagonists may be employed m accordance with the present invention by expression of such polypeptides in vivo, which is often refeπed to as gene therapy There are two major approaches to getting the nucleic acid (optionally contamed m a vector) mto the patient's cells in vivo and ex vivo For in vivo delivery the nucleic acid is mjected directly into the patient, usually at the sites where the PR0364 or PRO 175 polypeptide is required, i e , the site of synthesis of the PR0364 or PRO 175 polypeptide, if known, and the site (e g , wound) where biological activity of PR0364 or PRO 175 polypeptide is needed For ex vivo treatment, the patient's cells are removed, the nucleic acid is mtroduced mto these isolated cells, and the modified cells are admmistered to the patient either directly or, for example, encapsulated within porous membranes that are implanted mto the patient (see, e g , U S Pat Nos 4,892,538 and 5,283,187) There are a vaπety of techniques available for introducing nucleic acids into viable cells The techniques vary depending upon whether the nucleic acid is transfeπed mto cultured cells in vitro, or transfeπed in vivo m the cells of the mtended host Techniques suitable for the transfer of nucleic acid mto mammalian cells in vitro mclude the use of hposomes, electroporation, microinjection. transduction, cell fusion, DEAE-dextran, the calcium phosphate precipitation method, etc Transduction mvolves the association of a replication-defective, recombmant viral (preferably retroviral) particle with a cellular receptor followed by introduction of the nucleic acids contained bv the particle into the cell delivery of the gene is a retroviras The cuπently prefeπed in \ ivo nucleic acid transfer techniques include transfection with viral or non- viral vectors (such as adenovirus, lentiviras Herpes simplex I virus, or adeno-associated virus (AAV)) and pid-based systems (useful hpids for hpid-mediated transfer of the gene are, for example, DOTMA DOPE and DC-Choi, see, e g , Tonkinson et al , Cancer Investigation, 14(1) 54-65 (1996)) The most prefeπed vectors for use in gene therapy are viruses, most preferably adenoviruses AAV, lentivirases or retrovirases A viral vector such as a retroviral vector includes at least one transcriptional promoter/enhancer or locus-defining element(s), or other elements that control gene expression by other means such as alternate splicing, nuclear RNA export, or post-translational modification of messenger In addition, a viral vector such as a retroviral vector includes a nucleic acid molecule that, when transcπbed in the presence of a gene encoding PR0364 or PR0175 polypeptide, is operably linked thereto and acts as a translation initiation sequence Such vector constructs also mclude a packaging signal, long terminal repeats (LTRs) or portions thereof, and positive and negative strand primer binding sites appropnate to the virus used (if these are not already present in the viral vector) In addition, such vector typically includes a signal sequence for secretion of the PR0364 or PRO 175 polypeptide from a host cell in which it is placed Preferably the signal sequence for this purpose is a mammalian signal sequence, most preferably the native signal sequence for PR0364 or PRO 175 polypeptide Optionally, the vector construct may also include a signal that directs polyadenylation, as well as one or more restπction sites and a translation termination sequence By way of example, such vectors will typically include a 5' LTR, a tRNA bmdmg site, a packaging signal, an oπgm of second-strand DNA synthesis, and a 3' LTR or a portion thereof Other vectors can be used that are non-viral, such as cationic hpids, polylysine, and dendrimers In some situations, it is desirable to provide the nucleic acid source with an agent that targets the target cells, such as an antibody specific for a cell-surface membrane protem or the target cell, a ligand for a receptor on the target cell, etc Where posomes are employed, proteins that bmd to a cell-surface membrane protem associated with endocytosis may be used for targeting and/or to facilitate uptake, e g, capsid protems or fragments thereof tropic for a particular cell type, antibodies for protems that undergo lnternahzation in cycling, and protems that target mtracellular localization and enhance mtracellular half-life The technique of receptor-mediated endocytosis is descnbed, for example by Wu et al J Biol Chem . 262 4429-4432 (1987), and Wagner et al , Proc Natl Acad Sci USA, 87 3410-3414 (1990) For a review of the cuπently known gene marking and gene therapy protocols, see Anderson et al , Science. 256 808-813 (1992) See also WO 93/25673 and the references cited therein Suitable gene therapy and methods for making retroviral particles and structural proteins can be found m, e g , U S Pat No 5,681,746 vi Use of Gene as Diagnostic This invention is also related to the use of the gene encoding the PR0364 or PRO 175 polypeptide as a diagnostic Detection of a mutated form of the PR0364 or PRO 175 polypeptide will allow a diagnosis of a cardiovascular, endothelial, and angiogenic disease or a susceptibility to a cardiovascular, endothelial, and angiogenic disease such as a mmor, since mutations in the PR0364 or PRO 175 polypeptide mav cause tumors Individuals carrying mutations in the genes encoding human PR0364, or human PRO 175 polypeptide may be detected at the DNA level by a varietv of techniques Nucleic acids for diagnosis may be obtained from a patient's cells, such as from blood, urine saliva, tissue biopsy, and autopsy mateπal The genomic DNA may be used directly for detection or may be amplified enzvmaticallv bv using PCR (Saiki et al , Nature 324 163-166 ( 1986)) prior to analysis RNA or cDNA mav also be used for the same purpose As an example PCR pnmers complementary to the nucleic acid encoding the PR0364 or PRO 175 polypeptide can be used to identify and PR0364 or PRO 175 polypeptide mutations For example, deletions and insertions can be detected by a change in size of the amplified product in companson to the normal genotype Point mutations can be identified by hvbndizmg amplified DNA to radiolabeled RNA encoding PR0364 or PRO 175 polypeptide. or alternatively, radiolabeled antisense DNA sequences encoding PR0364 or PRO 175 polypeptide Perfectly matched sequences can be distinguished from mismatched duplexes by RNase A digestion or by differences in melting temperatures Genetic testing based on DNA sequence differences may be achieved by detection of alteration in electrophoretic mobility of DNA fragments m gels with or without denaturing agents Small sequence deletions and insertions can be visualized by high resolution gel electrophoresis DNA fragments of different sequences may be distinguished on denaturing formamidme gradient gels in which the mobilities of different DNA fragments are retarded m the gel at different positions accordmg to their specific meltmg or partial meltmg temperatures See, e g , Myers et al , Science. 230 1242 (1985) Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S 1 protection or the chemical cleavage method, for example, Cotton et al , Proc Natl Acad Sci USA, 85 4397-4401 (1985) Thus, the detection of a specific DNA sequence may be achieved by methods such as hybπdization, RNase protection, chemical cleavage, direct DNA sequencing, or the use of restπction enzymes, e g , restnction fragment length polymorphisms (RFLP), and Southern blottmg of genomic DNA vu Use to Detect PRQ364 or PRO 175 Polypeptide Levels In addition to more conventional gel-electrophoresis and DNA sequencmg, mutations can also be detected by in situ analysis. Expression of nucleic acid encodmg PR0364 or PRO 175 polypeptide may be linked to vascular disease or neovasculaπzation associated with mmor formation If the PR0364 or PRO 175 polypeptide has a signal sequence and the mRNA is highly expressed m endothelial cells and to a lesser extent in smooth muscle cells, this indicates that the PR0364 or PR0175 polypeptide is present in serum Accordmgly, an anti- PR0364 or - PRO 175 polypeptide antibody could be used to diagnose vascular disease or neovasculaπzation associated with mmor formation, since an altered level of this PR0364 or PRO 175 polypeptide may be indicative of such disorders A competition assay may be employed wherein antibodies specific to the PR0364 or PRO 175 polypeptide are attached to a solid support and labeled PR0364 or PRO 175 polypeptide and a sample deπved from the host are passed over the solid support and the amount of label detected attached to the solid support can be coπelated to a quantity of PR0364 or PRO 175 polypeptide in the sample vin Chromosome Mapping The sequences of the present mvention are also valuable for chromosome identification The sequence is specifically targeted to and can hybndize with a particular location on an individual human chromosome Moreover, there is a cuπent need for identifying particular sites on the chromosome Few chromosome marking reagents based on actual sequence data (repeat polymorphisms) are presently available for marking chromosomal location The mappmg of DNAs to chromosomes accordmg to the present mvention is an important first step in coπelatmg those sequences with genes associated with disease Bπefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the cDNA Computer analysis for the 3 untranslated region is used to rapidly select pnmers that do not span more than one exon in the genomic DNA thus complicating the amplification process These pnmers are then used for PCR screenmg of somatic cell hybrids containing individual human chromosomes Only those hvbnds containing the human gene coπesponding to the primer will yield an amplified fragment PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular DNA to a particular chromosome Using the present invention with the same oligonucleotide pnmers. sublocahzation can be achieved with panels of fragments from specific chromosomes or pools of large genomic clones in an analogous manner Other mapping strategies that can similarly be used to map to its chromosome mclude in situ hybridization, prescreemng with labeled flow-sorted chromosomes and preselection by hybπdization to construct chromosome-specific cDNA libranes Fluorescence in situ hybndization (FISH) of a cDNA clone to a metaphase chromosomal spread can be used to provide a precise chromosomal location m one step This technique can be used with cDNA as short as 500 or 600 bases, however, clones larger than 2,000 bp have a higher likelihood of bindmg to a unique chromosomal location with sufficient signal intensity for simple detection FISH requires use of the clones from which the gene encoding PR0364 or PROl 75 polypeptide was deπved, and the longer the better For example, 2.000 bp is good, 4,000 bp is better, and more than 4,000 is probably not necessary to get good results a reasonable percentage of the tune For a review of this technique, see Verma et al , Human Chromosomes a Manual of Basic Techniques (Pergamon Press, New York, 1988) Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be coπelated with genetic map data Such data are found, for example, in V McKusick, Mendelian Inhentance in Man (available on lme through Johns Hopkins University Welch Medical Library) The relationship between genes and diseases that have been mapped to the same chromosomal region is then identified through linkage analysis (coinhentance of physically adjacent genes) Next, it is necessary to determine the differences m the cDNA or genomic sequence between affected and unaffected individuals If a mutation is observed in some or all of the affected individuals but not m any normal individuals, then the mutation is likely to be the causative agent of the disease With cuπent resolution of physical mapping and genetic mappmg techniques, a cDNA precisely localized to a chromosomal region associated with the disease could be one of between 50 and 500 potential causative genes (This assumes 1 megabase mappmg resolution and one gene per 20 kb) lx Screenmg Assays for Drug Candidates This invention encompasses methods of screenmg compounds to identify those that mimic the PR0364 or PR0175 polypeptide (agomsts) or prevent the effect of the PR0364 or PR0175 polypeptide (antagonists) Screening assays for antagonist drug candidates are designed to identify compounds that bind or complex with the PR0364 or PRO 175 polypeptides encoded by the genes identified herem, or otherwise interfere with the interaction of the encoded polypeptides with other cellular proteins Such screening assays will mclude assays amenable to high-throughput screenmg of chemical libranes, makmg them particularly suitable for identifymg small molecule drug candidates The assays can be performed in a vaπety of formats, including protein-protein binding assays, biochemical screenmg assays, immunoassays, and cell- based assays, which are well charactenzed in the art All assays for antagonists are common in that they call for contacting the drag candidate with a PR0364 or PRO 175 polypeptide encoded by a nucleic acid identified herein under conditions and for a tune sufficient to allow these two components to interact In binding assays, the interaction is binding and the complex formed can be isolated or detected in the reaction mixture In a particular embodiment the PR0364 or PRO 175 polypeptide encoded bv the gene identified herem or the drag candidate is immobilized on a solid phase, e g , on a microtiter plate bv covalent or non-covalent attachments Non-covalent attachment generally is accomplished by coating the solid surface with a solution of the PR0364 or PRO 175 polypeptide and drying Alternatively, an immobilized antibody, e , a monoclonal antibody, specific for PR0364 or PRO 175 polypeptide to be immobilized can be used to anchor it to a solid surface The assay is performed by adding the non-immobilized component, which may be labeled by a detectable label, to the immobilized component, e g , the coated surface containing the anchored component When the reaction is complete, the non-reacted components are removed, e g , by washmg, and complexes anchored on the solid surface are detected When the oπgmally non-immobilized component cames a detectable label, the detection of label immobilized on the surface mdicates that complexing occuπed Where the originally non-immobilized component does not cany a label, complexmg can be detected, for example, by usmg a labeled antibody specifically bmdmg the immobilized complex If the candidate compound interacts with but does not b d to a particular PR0364 or PRO 175 polypeptide encoded by a gene identified herem, its mteraction with that polypeptide can be assayed by methods well known for detectmg protem-protem interactions Such assays mclude traditional approaches, such as, e g , cross-linking, co-immunoprecipitation, and co-puπfication through gradients or chromatographic columns In addition, protem-protem mteractions can be monitored by usmg a yeast-based genetic system descπbed by Fields and co- workers (Fields and Song, Nature (London), 340 245-246 (1989), Chien et al , Proc Natl Acad Sci USA, 88 9578-9582 (1991)) as disclosed by Chevray and Nathans, Proc Natl Acad Sci USA, 89 5789-5793 (1991) Many transcπptional activators, such as yeast GAL4, consist of two physically discrete modular domams, one actmg as the DNA-bmdmg domam, the other one functioning as the transcnption-activation domam The yeast expression system descπbed m the foregomg publications (generally refeπed to as the "two-hybπd system") takes advantage of this property, and employs two hybπd protems, one m which the target protem is fused to the DNA- bmdmg domam of GAL4, and another, in which candidate activating proteins are fused to the activation domam The expression of a GALl-/αcZ reporter gene under control of a GAL4-actιvated promoter depends on reconstitution of GAL4 activity via protein-protein interaction Colonies contammg mteracting polypeptides are detected with a chromogemc substrate for β-galactosidase A complete kit (MATCHMAKER™) for identifymg protein-protein interactions between two specific protems usmg the two-hybnd technique is commercially available from Clontech This system can also be extended to map protem domams involved m specific protem interactions as well as to pmpomt amino acid residues that are crucial for these mteractions Compounds that interfere with the interaction of a gene encoding a PR0364 or PR0175 polypeptide identified herem and other mtra- or extracellular components can be tested as follows usually a reaction mixture is prepared contammg the product of the gene and the mtra- or extracellular component under conditions and for a time allowing for the mteraction and bmdmg of the two products To test the ability of a candidate compound to inhibit bmdmg, the reaction is run in the absence and in the presence of the test compound In addition, a placebo may be added to a third reaction mixture, to serve as positive control The bmdmg (complex formation) between the test compound and the intra- or extracellular component present m the mixture is monitored as descπbed heremabove The formation of a complex in the control reactιon(s) but not m the reaction mixture contammg the test compound indicates that the test compound interferes with the interaction of the test compound and its reaction partner If the PR0364 or PRO 175 polypeptide has the ability to stimulate the proliferation of endothelial cells in the presence of the co-mitogen ConA, then one example of a screening method takes advantage of this ability Specifically, in the proliferation assay, human umbilical vein endothelial cells are obtained and cultured in 96- well flat-bottomed culture plates (Costar. Cambndge, MA) and supplemented with a reaction mixture appropnate for facilitating proliferation of the cells, the mixture containing Con-A (Calbiochem La Jolla, CA) Con-A and the compound to be screened are added and after incubation at 37°C cultures are pulsed with H-thymidine and harvested onto glass fiber filters (phD, Cambndge Technology, Watertown, MA) Mean (H)thymιdme incorporation (cpm) of tπp cate cultures is determined usmg a liquid scintillation counter (Beckman Instruments, Irvine, CA) Significant (H)thymιdιne incorporation mdicates stimulation of endothelial cell proliferation To assay for antagonists, the assay descπbed above is performed, however, in this assay the PR0364 or PRO 175 polypeptide is added along with the compound to be screened and the ability of the compound to inhibit (H)thymιdme incorporation m the presence of the PR0364 or PRO 175 polypeptide indicates that the compound is an antagonist to the PR0364 or PRO 175 polypeptide Alternatively, antagonists may be detected by combining the PR0364 or PRO 175 polypeptide and a potential antagonist with membrane-bound PR0364 or PRO 175 polypeptide receptors or recombmant receptors under appropnate conditions for a competitive inhibition assay The PR0364 or PR0175 polypeptide can be labeled, such as by radioactivity, such that the number of PR0364 or PR0175 polypeptide molecules bound to the receptor can be used to determine the effectiveness of the potential antagonist The gene encodmg the receptor can be identified by numerous methods known to those of skill m the art, for example, ligand panning and FACS sorting Coligan et al , Current Protocols in Immun . J(2) Chapter 5 (1991) Preferably, expression cloning is employed wherem polyadenylated RNA is prepared from a cell responsive to the PR0364 or PRO 175 polypeptide and a cDNA library created from this RNA is divided into pools and used to transfect COS cells or other cells that are not responsive to the PR0364 or PRO 175 polypeptide Transfected cells that are grown on glass slides are exposed to labeled PR0364 or PRO 175 polypeptide The PR0364 or PRO 175 polypeptide can be labeled by a vanety of means mcludmg lodmation or inclusion of a recognition site for a site-specific protem kmase Followmg fixation and mcubation, the slides are subjected to autoradiographic analysis Positive pools are identified and sub-pools are prepared and re- transfected usmg an mteractive sub-poolmg and re-screening process, eventually yielding a single clone that encodes the putative receptor As an alternative approach for receptor identification, labeled PR0364 or PRO 175 polypeptide can be photoaffinity-linked with cell membrane or extract preparations that express the receptor molecule Cross-linked matenal is resolved by PAGE and exposed to X-ray film The labeled complex contammg the receptor can be excised, resolved into peptide fragments, and subjected to protem micro-sequencing The ammo acid sequence obtamed from micro- sequencing would be used to design a set of degenerate oligonucleotide probes to screen a cDNA library to identify the gene encodmg the putative receptor In another assay for antagonists, mammalian cells or a membrane preparation expressmg the receptor would be mcubated with labeled PR0364 or PRO 175 polypeptide m the presence of the candidate compound The ability of the compound to enhance or block this interaction could then be measured The compositions useful in the treatment of cardiovascular, endothelial and angiogenic disorders mclude, without limitation, antibodies, small organic and inorganic molecules, peptides, phosphopeptides, antisense and ribozyme molecules, tnple-helix molecules, etc , that inhibit the expression and/or activity of the target gene product More specific examples of potential antagonists include an oligonucleotide that binds to the fusions ol immunoglobulm with PR0364 polvpeptide or PRO 175 polypeptide and. in particular, antibodies mcludmg, without limitation, poly- and monoclonal antibodies and antibody fragments, single-chain antibodies, anti- ldiotypic antibodies, and chimenc or humanized versions of such antibodies or fragments, as well as human antibodies and antibody fragments Alternatively, a potential antagonist may be a closely related protem, for example, a mutated form of the PR0364 or PRO 175 polypeptide that recognizes the receptor but imparts no effect, thereby competitively inhibiting the action of the PR0364 or PRO 175 polypeptide Another potential PR0364 or PRO 175 polypeptide antagonist is an antisense RNA or DNA construct prepared using antisense technology, where, e g , an antisense RNA or DNA molecule acts to block directly the translation of mRNA by hybndizing to targeted mRNA and preventmg protem translation Antisense technology can be used to control gene expression through tnple-helix formation or antisense DNA or RNA, both of which methods are based on bmdmg of a polynucleotide to DNA or RNA For example, the 5' codmg portion of the polynucleotide sequence, which encodes the mature PR0364 or PR0175 polypeptides herem, is used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcnption (tnple helix - see Lee et al , Nucl Acids Res . 6 3073 (1979), Cooney et al , Science. 241 456 (1988), Dervan et al . Science. 251 1360 (1991)), thereby preventmg transcnption and the production of the PR0364 or PRO 175 polypeptide The antisense RNA oligonucleotide hybπdizes to the mRNA in vivo and blocks translation of the mRNA molecule mto the PR0364 or PR0175 polypeptide (antisense - Okano, Neurochem . 56 560 (1991), Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression (CRC Press Boca Raton, FL, 1988) The oligonucleotides descnbed above can also be delivered to cells such that the antisense RNA or DNA may be expressed in vivo to inhibit production of the PR0364 or PRO 175 polypeptide When antisense DNA is used, ohgodeoxyπbonucleotides denved from the translation- initiation site, eg , between about -10 and +10 positions of the target gene nucleotide sequence, are prefeπed Potential antagonists mclude small molecules that bind to the active site, the receptor bindmg site, or growth factor or other relevant bindmg site of the PR0364 or PR0175 polypeptide, thereby blocking the normal biological activity of the PR0364 or PROl 75 polypeptide Examples of small molecules mclude, but are not limited to, small peptides or peptide- ke molecules, preferably soluble peptides, and synthetic non-peptidyl organic or inorganic compounds Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA Ribozymes act by sequence-specific hybπdization to the complementary target RNA, followed by endonucleolytic cleavage Specific πbozyme cleavage sites within a potential RNA target can be identified by known techniques For further details see, e g , Rossi. Cuπent Biology, 4 469-471 (1994), and PCT publication No WO 97/33551 (published September 18, 1997) Nucleic acid molecules m tnple-helix formation used to inhibit transcnption should be single-stranded and composed of deoxynucleotides The base composition of these oligonucleotides is designed such that it promotes tnple-helix formation via Hoogsteen base-paiπng rules, which generally require sizeable stretches of punnes or pynmidines on one strand of a duplex For further details see, e g , PCT publication No WO 97/33551 , supra These small molecules can be identified by any one or more of the screenmg assays discussed hereinabove and/or by any other screening techniques well known for those skilled in the art x Types of Cardiovascular Endothelial and Angiogenic Disorders to be Treated The PR0364 or PRO 175 polypeptides or agonists or antagonists thereto that have activity in the cardiovascular, angiogenic, and endothelial assays descπbed herein, and/or whose gene product has been found to be localized to the cardiovascular system, are likely to have therapeutic uses in a vaπety of cardiovascular, endothelial, and angiogenic disorders, including systemic disorders that affect vessels such as diabetes melhtus Their therapeutic utility could include diseases of the artenes, capillanes, veins, and/or lymphatics Examples of treatments hereunder include treatmg muscle wastmg disease, treating osteoporosis, aiding in implant fixation to stimulate the growth of cells around the implant and therefore facilitate its attachment to its mtended site, increasing IGF stability in tissues or in serum, if applicable, and increasmg binding to the IGF receptor (since IGF has been shown in vitro to enhance human marrow erythroid and granulocvtic progenitor cell growth) The PR0364 or PRO 175 polypeptides or agonists or antagonists thereto may also be employed to stimulate erythropoiesis or granulopoiesis, to stimulate wound healmg or tissue regeneration and associated therapies concerned with re-growth of tissue, such as connective tissue, skin, bone, cartilage, muscle, lung, or kidney, to promote angiogenesis, to stimulate or inhibit migration of endothelial cells, and to proliferate the growth of vascular smooth muscle and endothelial cell production The mcrease in angiogenesis mediated by PR0364 or PRO 175 polypeptide or antagonist would be beneficial to lschemic tissues and to collateral coronary development in the heart subsequent to coronary stenosis Antagonists are used to inhibit the action of such polypeptides, for example, to limit the production of excess connective tissue during wound healmg or pulmonary fibrosis if the PR0364 or PR0175 polypeptide promotes such production This would include treatment of acute myocardial infarction and heart failure Moreover, the present mvention concerns the treatment of cardiac hypertrophy, regardless of the underlymg cause, by administering a therapeutically effective dose of PR0364 or PRO 175 polypeptide, or agonist or antagonist thereto If the objective is the treatment of human patients, the PR0364 or PR0175 polypeptide preferably is recombmant human PR0364 or PROl 75 polypeptide (rhPR0364 or rhPR0175 polypeptide) The treatment for cardiac hypertrophy can be performed at any of its vanous stages, which may result from a vaπety of diverse pathologic conditions, mcludmg myocardial mfarction, hypertension, hypertrophic cardiomyopathy, and valvular regurgitation The treatment extends to all stages of the progression of cardiac hypertrophy, with or without structural damage of the heart muscle, regardless of the underlying cardiac disorder The decision of whether to use the molecule itself or an agonist thereof for any particular indication, as opposed to an antagonist to the molecule, would depend mamly on whether the molecule herem promotes cardiovasculaπzation, genesis of endothelial cells, or angiogenesis or inhibits these conditions For example, if the molecule promotes angiogenesis, an antagonist thereof would be useful for treatment of disorders where it is desired to limit or prevent angiogenesis Examples of such disorders include vascular tumors such as haemangioma, mmor angiogenesis, neovasculanzation m the retma, choroid, or cornea, associated with diabetic retinopathy or premamre infant retmopathy or macular degeneration and prohferative vitreoretinopathy, rheumatoid arthπtis, Crohn's disease, atherosclerosis, ovaπan hyperstimulation, psonasis, endometπosis associated with neovasculanzation, restenosis subsequent to balloon angioplasty, scar tissue overproduction, for example, that seen m a keloid that forms after surgery, fibrosis after myocardial infarction, or fibrotic lesions associated with pulmonary fibrosis If, however, the molecule inhibits angiogenesis, it would be expected to be used directly for treatment of the above conditions On the other hand, if the molecule stimulates angiogenesis it would be used itself (or an agonist thereof) for indications where angiogenesis is desired such as peripheral vascular disease, hypertension, inflammatory vasculitides. Reynaud's disease and Reynaud's phenomenon, aneurysms. arterial restenosis, thrombophlebitis, lymphangitis, lymphedema, wound healing and tissue repair, ischemia reperfusion injury, angina, myocardial infarctions such as acute myocardial infarctions, chronic heart conditions, heart failure such as congestive heart failure, and osteoporosis. If, however, the molecule inhibits angiogenesis, an antagonist thereof would be used for treatment of those conditions where angiogenesis is desired. Specific types of diseases are described below, where the PR0364 or PRO 175 polypeptide herein or antagonists thereof may serve as useful for vascular-related drag targeting or as therapeutic targets for the treatment or prevention of the disorders. Atherosclerosis is a disease characterized by accumulation of plaques of intimal thickening in arteries, due to accumulation of Hpids, proliferation of smooth muscle cells, and formation of fibrous tissue within the arterial wall. The disease can affect large, medium, and small arteries in any organ. Changes in endothelial and vascular smooth muscle cell function are known to play an important role in modulating the accumulation and regression of these plaques. Hypertension is characterized by raised vascular pressure in the systemic arterial, pulmonary arterial, or portal venous systems. Elevated pressure may result from or result in impaired endothelial function and/or vascular disease. Inflammatory vasculitides include giant cell arteritis, Takayasu's arteritis, polyarteritis nodosa (including the microangiopathic form), Kawasaki's disease, microscopic polyangiitis, Wegener's granulomatosis, and a variety of infectious-related vascular disorders (including Henoch-Schonlein prupura). Altered endothelial cell function has been shown to be important in these diseases. Reynaud's disease and Reynaud's phenomenon are characterized by intermittent abnormal impairment of the circulation through the extremities on exposure to cold. Altered endothelial cell function has been shown to be important in this disease. Aneurysms are saccular or fusiform dilatations of the arterial or venous tree that are associated with altered endothelial cell and/or vascular smooth muscle cells. Arterial restenosis (restenosis of the arterial wall) may occur following angioplasty as a result of alteration in the function and proliferation of endothelial and vascular smooth muscle cells. Thrombophlebitis and lymphangitis are inflammatory disorders of veins and lymphatics, respectively, that may result from, and/or in, altered endothelial cell function. Similarly, lymphedema is a condition involving impaired lymphatic vessels resulting from endothelial cell function. The family of benign and malignant vascular tumors are characterized by abnormal proliferation and growth of cellular elements of the vascular system. For example, lymphangiomas are benign tumors of the lymphatic system that are congenital, often cystic, malformations of the lymphatics that usually occur in newborns. Cystic tumors tend to grow into the adjacent tissue. Cystic tumors usually occur in the cervical and axillary region. They can also occur in the soft tissue of the extremities. The main symptoms are dilated, sometimes reticular, structured lymphatics and lymphocysts suπounded by connective tissue. Lymphangiomas are assumed to be caused by improperly connected embryonic lymphatics or their deficiency. The result is impaired local lymph drainage. Griener et al.. Lymphology. 4: 140-144 (1971). Another use for the PR0364 or PRO 175 polypeptides herein or antagonists thereto is in the prevention of mmor angiogenesis, which involves vascularization of a mmor to enable it to growth and or metastasize. This process is dependent on the growth of new blood v essels Examples ot neoplasms and related conditions that involve mmor angiogenesis include breast carcinomas, lung carcinomas, gastric carcinomas esophageal carcmomas. colorectal carcinomas, liver carcinomas, ovarian carcinomas, thecomas, aπhenoblastomas, cervical carcinomas, endometπal carcmoma. endometnal hyperplasia, endometπosis, fibrosarcomas, choπocarcinoma, head and neck cancer, nasopharyngeal carcinoma laryngeal carcinomas, hepatoblastoma, Kaposi's sarcoma, melanoma, skin carcinomas, hemangioma. cavernous hemangioma, hemangioblastoma, pancreas carcmomas, retmoblastoma, astrocytoma, ghoblastoma. Schwannoma, o godendroglioma, medulloblastoma, neuroblastomas, rhabdomyosarcoma. osteogemc sarcoma, leiomyosarcomas, urinary tract carcinomas, thyroid carcinomas. Wilm's mmor, renal cell carcinoma, prostate carcinoma, abnormal vascular proliferation associated with phakomatoses, edema (such as that associated with brain tumors), and Meigs' syndrome Age-related macular degeneration (AMD) is a leadmg cause of severe visual loss in the elderly population The exudative form of AMD is charactenzed by choroidal neovasculanzation and retmal pigment epithelial cell detachment Because choroidal neovasculaπzation is associated with a dramatic worsenmg in prognosis, the PR0364 or PR0175 polypeptides or antagonist thereto is expected to be useful in reducmg the seventy of AMD Healmg of trauma such as wound healing and tissue repair is also a targeted use for the PR0364 or PR0175 polypeptides herem or their antagonists Formation and regression of new blood vessels is essential for tissue healing and repair This category includes bone, cartilage, tendon, ligament, and/or nerve tissue growth or regeneration, as well as wound healmg and tissue repair and replacement, and in the treatment of burns, incisions, and ulcers A PR0364 or PRO 175 polypeptide or antagonist thereof that mduces cartilage and/or bone growth in circumstances where bone is not normally formed has application m the healmg of bone fractures and cartilage damage or defects m humans and other animals Such a preparation employing a PR0364 or PRO 175 polypeptide or antagonist thereof may have prophylactic use m closed as well as open fracture reduction and also m the improved fixation of artificial jomts De novo bone formation mduced by an osteogemc agent contπbutes to the repair of congenital, trauma-induced, or oncologic, resection-induced craniofacial defects, and also is useful in cosmetic plastic surgery PR0364 or PRO 175 polypeptides or antagonists thereto may also be useful to promote better or faster closure of non-healmg wounds, including without limitation pressure ulcers, ulcers associated with vascular insufficiency, surgical and traumatic wounds and the like It is expected that a PR0364 or PRO 175 polypeptide or antagonist thereto may also exhibit activity for generation or regeneration of other tissues, such as organs (mcludmg, for example, pancreas, liver, intestme, kidney, skin, or endothelium), muscle (smooth, skeletal, or cardiac), and vascular (mcludmg vascular endothelium) tissue, or for promotmg the growth of cells compnsmg such tissues Part of the desired effects may be by inhibition or modulation of fibrotic scarring to allow normal tissue to regenerate A PR0364 or PR0175 polypeptide herein or antagonist thereto may also be useful for gut protection or regeneration and treatment of lung or liver fibrosis, reperfiision injury m vanous tissues, and conditions resultmg from systemic cytokine damage Also, the PR0364 or PR0175 polypeptide or antagonist thereto may be useful for promotmg or inhibiting differentiation of tissues descnbed above from precursor tissues or cells, or for inhibiting the growth of tissues described above A PR0364 or PRO 175 polypeptide or antagonist thereto may also be used m the treatment of penodontal diseases and m other tooth-repair processes Such agents may provide an environment to attract bone-formmg cells, stimulate growth of bone-forming cells, or induce differentiation of progenitors of bone-forming cells A PR0364 or PRO 175 polypeptide herein or an antagonist thereto may also be useful m the treatment of osteoporosis or osteoarthπtis such as through stimulation of bone and/or cartilage repair or by blocking inflammation or processes of tissue destruction (collagenase activity, osteoclast activity, etc ) mediated by inflammatory processes, since blood vessels play an important role in the regulation of bone turnover and growth Another category of tissue regeneration activity that may be attributable to the PR0364 or PRO 175 polypeptide herein or antagonist thereto is tendon/ligament formation A protein that induces tendon/hgament- ke tissue or other tissue formation in circumstances where such tissue is not normally formed has application in the healmg of tendon or ligament tears, deformities, and other tendon or ligament defects m humans and other animals Such a preparation may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use m the improved fixation of tendon or ligament to bone or other tissues, and in repairing defects to tendon or ligament tissue De novo tendon/ligament-like tissue formation induced by a composition of the PR0364 or PRO 175 polypeptide herein or antagonist thereto contnbutes to the repair of congenital, trauma- induced, or other tendon or ligament defects of other ongm, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments The compositions herein may provide an environment to attract tendon- or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce differentiation of progenitors of tendon- or ligament- forming cells, or mduce growth of tendon/ligament cells or progenitors ex vivo for return in vivo to effect tissue repair The compositions herein may also be useful m the treatment of tendomtis, carpal tunnel syndrome, and other tendon or ligament defects The compositions may also include an appropnate matrix and or sequestenng agent as a earner as is well known in the art The PR0364 or PRO 175 polypeptide or its antagonist may also be useful for proliferation of neural cells and for regeneration of nerve and bram tissue, i e , for the treatment of central and peπpheral nervous system disease and neuropathies, as well as mechanical and traumatic disorders, that mvolve degeneration, death, or trauma to neural cells or nerve tissue More specifically, a PR0364 or PRO 175 polypeptide or its antagonist may be used m the treatment of diseases of the peπpheral nervous system, such as peπpheral nerve injunes, peπpheral neuropathy and localized neuropathies, and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntmgton's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome Further conditions that may be treated in accordance with the present invention include mechanical and traumatic disorders, such as spmal cord disorders, head trauma, and cerebrovascular diseases such as stroke Penpheral neuropathies resultmg from chemotherapy or other medical therapies may also be treatable using a PR0364 or PRO 175 polypeptide herem or antagonist thereto Ischemia-reperfusion injury is another indication Endothelial cell dysfunction may be important in both the initiation of, and in regulation of the sequelae of events that occur followmg ischemia-reperfusion injury Rheumatoid arthntis is a further indication Blood vessel growth and targetmg of inflammatory cells through the vasculature is an important component in the pathogenesis of rheumatoid and sero-negative forms of arthπtis PR0364 or PR0175 polypeptide or its antagonist may also be administered prophylactically to patients with cardiac hypertrophy, to prevent the progression of the condition, and avoid sudden death, mcludmg death of asymptomatic patients Such preventative therapy is particularly waπanted in the case of patients diagnosed with massive left ventπcular cardiac hypertrophy (a maximal wall thickness of 35 mm or more m adults, or a comparable value in children), or in instances when the hemodynamic burden on the heart is particularly strong PR0364 or PRO 175 polypeptide or its antagonist may also be useful m the management of atπal fibπllation, which develops m a substantial portion of patients diagnosed with hypertrophic cardiomyopathy Further indications include angina, myocardial infarctions such as acute myocardial infarctions, and heart failure such as congestive heart failure Additional non-neoplastic conditions include psoriasis, diabetic and other prohferative retinopathies including retinopathy of prematunty, retrolental fibroplasia. neovascular glaucoma, thyroid hyperplasias (mcludmg Grave's disease), comeal and other tissue transplantation, chronic inflammation, lung inflammation, nephrotic syndrome, preeclampsia, ascites, pencardial effusion (such as that associated with peπcarditis), and pleural effusion In view of the above, the PR0364 or PRO 175 polypeptides or agonists or antagonists thereof descnbed herem, which are shown to alter or impact endothelial cell function, proliferation, and/or form, are likely to play an important role m the etiology and pathogenesis of many or all of the disorders noted above, and as such can serve as therapeutic targets to augment or inhibit these processes or for vascular-related drug targeting in these disorders. xi. Administration Protocols, Schedules, Doses, and Formulations The molecules herem and agonists and antagonists thereto are pharmaceutically useful as a prophylactic and therapeutic agent for vanous disorders and diseases as set forth above. Therapeutic compositions of the PR0364 or PR0175 polypeptides or agonists or antagonists are prepared for storage by mixing the desired molecule havmg the appropnate degree of punty with optional pharmaceutically acceptable earners, excipients, or stabilizers (Remington's Pharmaceutical Sciences. 16th edition, Osol, A. ed. (1980)), in the form of lyophihzed formulations or aqueous solutions Acceptable earners, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and mclude buffers such as phosphate, citrate, and other organic acids; antioxidants mcludmg ascorbic acid and methiomne; preservatives (such as octadecyldimethylbenzyl ammonium chloπde, hexamethomum chloπde: benzalkonium chlonde, benzethomum chlonde, phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol, resorcmol, cyclohexanol, 3-pentanol; and m-cresol), low molecular weight (less than about 10 residues) polypeptides; protems, such as serum albumm, gelatm, or immunoglobulms; hydrophilic polymers such as polyvinylpyrrolidone, ammo acids such as glycine, glutamine, asparagme, histidme, argmme, or lysme, monosacchandes, disacchandes, and other carbohydrates mcludmg glucose, mannose, or dextπns, chelatmg agents such as EDTA, sugars such as sucrose, manmtol, trehalose or sorbitol. salt-forming counter-ions such as sodium, metal complexes (e g , Zn-protem complexes); and/or non-ionic surfactants such as TWEEN™, PLURONICS™ or polyethylene glycol (PEG) Additional examples of such earners mclude ion exchangers, alumina, alummum stearate, lecithin, serum protems, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceπde mixtures of saturated vegetable fatty acids, water, salts, or electrolytes such as protamme sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloπde, zmc salts, colloidal silica, magnesium tnsi cate, polyvinyl pyπohdone, cellulose-based substances, and polyethylene glycol Carπers for topical or gel-based forms of antagonist mclude polysacchandes such as sodium carboxymethylcellulose or methylcellulose, polyvinylpyπo done, polyacrylates, polyoxyethylene- polyoxypropylene-block polymers, polyethylene glycol, and wood wax alcohols For all administrations, conventional depot forms are suitably used Such forms mclude, for example, microcapsules, nano-capsules, hposomes, plasters, inhalation forms, nose sprays, sublmgual tablets, and sustained-release preparations The PRO230, PR0216, or PRO302 polypeptides or agonists or antagonists will typically be formulated in such vehicles at a concentration of about 0 1 mg/ml to 100 mg/ml Another formulation comprises incorporating a PR0364 or PRO 175 polypeptide or antagonist thereof mto formed articles Such articles can be used in modulating endothelial cell growth and angiogenesis In addition, mmor invasion and metastasis may be modulated with these articles PR0364 or PRO 175 polypeptide or antagonist to be used for in vivo administration must be sterile This is readily accomplished by filtration through sterile filtration membranes, pπor to or following lyophihzation and reconstimtion. PR0364 or PROl 75 polypeptide ordinanly will be stored in lyophilized form or in solution if admmistered systemically If in lyophilized form. PR0364 or PRO 175 polypeptide or antagonist thereto is typically formulated in combination with other ingredients for reconstimtion with an appropnate diluent at the time for use An example of a liquid formulation of PR0364 or PRO 175 polypeptide or antagonist is a stenle, clear, colorless unpreserved solution filled m a smgle-dose vial for subcutaneous injection Preserved pharmaceutical compositions suitable for repeated use may contam, for example, dependmg mamly on the indication and type of polypeptide: a) PR0364 or PR0175 polypeptide or agonist or antagonist thereto; b) a buffer capable of maintaining the pH in a range of maximum stability of the polypeptide or other molecule m solution, preferably about 4-8; c) a detergent/surfactant pπmaπly to stabilize the polypeptide or molecule agamst agitation-induced aggregation; d) an lsotonifier; e) a preservative selected from the group of phenol, benzyl alcohol and a benzethomum hahde, e.g., chlonde; and f) water. If the detergent employed is non-ionic, it may, for example, be polysorbates (e.g., POLYSORBATE™ (TWEEN™) 20, 80, etc.) or poloxamers ( , POLOXAMER™ 188). The use of non-ionic surfactants permits the formulation to be exposed to shear surface stresses without causmg denaturation of the polypeptide. Further, such surfactant-containing formulations may be employed m aerosol devices such as those used in a pulmonary dosmg, and needleless jet mjector guns (see, e g , EP 257,956) An lsotonifier may be present to ensure lsotomcity of a liquid composition of the PR0364 or PR0175 polypeptide or antagonist thereto, and includes polyhydnc sugar alcohols, preferably tπhydπc or higher sugar alcohols, such as glycerin, erythntol, arabitol, xyhtol, sorbitol, and manmtol. These sugar alcohols can be used alone or in combmation. Alternatively, sodium chlonde or other appropnate morgamc salts may be used to render the solutions lsotonic. The buffer may, for example, be an acetate, citrate, succmate, or phosphate buffer dependmg on the pH desired. The pH of one type of liquid formulation of this mvention is buffered m the range of about 4 to 8, preferably about physiological pH. The preservatives phenol, benzyl alcohol and benzethomum hahdes, e g , chloπde, are known antimicrobial agents that may be employed Therapeutic PR0364 or PROl 75 polypeptide compositions generally are placed mto a contamer havmg a stenle access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle. The formulations are preferably admmistered as repeated intravenous (l v ), subcutaneous (s.c ), or intramuscular (l.m.) injections, or as aerosol formulations suitable for lntranasal or mtrapulmonary delivery (for mtrapulmonary delivery see, e g , EP 257,956) PR0364 or PRO 175 polypeptide can also be administered in the form ot sustained-released preparations Suitable examples of sustamed-release preparations include semipermeable matπces of solid hydrophobic polvmers containing the protein which matrices are in the form of shaped articles, e g , films or microcapsules Examples of sustained-release matrices include polyesters hvdrogels (e g , polv(2-hvdroxvethyl-methacrylate) as described bv Langer et al J Biomed Mater Res . 15 167-277 ( 1981 ) and Langer. Chem Tech , 12 98-105 (1982) or poly(vιnylalcohol)), polylactides (U S Patent No 3,773,919, EP 58 481), copolymers of L-glutamic acid and gamma ethvl-L-glutamate (Sidman et al Biopolvmers 22 547-556 (1983)), non-degradable ethvlene- vinyl acetate (Langer et al , supra), degradable lactic acid-glycolic acid copolvmers such as the Lupron Depot™ (mjectable microspheres composed of lactic acid-glycolic acid copolymer and leuprohde acetate), and poly-D-(-)- 3-hydroxvbutvπc acid (EP 133 988) While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time peπods When encapsulated proteins remam m the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37°C, resultmg m a loss of biological activity and possible changes in lmmunogenicity Rational strategies can be devised for protem stabilization depending on the mechanism involved For example if the aggregation mechanism is discovered to be intermolecular S-S bond formation through thio-disulfide mterchange, stabilization may be achieved by modifying sulfhydryl residues lyophihzing from acidic solutions controlling moisture content, usmg appropnate additives, and developmg specific polymer matπx compositions Sustamed-release PR0364 or PRO 175 polypeptide compositions also include hposomally entrapped PR0364 or PR0175 polypeptide Liposomes contammg PR0364 or PR0175 polypeptide are prepared by methods known per se DE 3.218.121, Epstein et al . Proc Natl Acad Sci USA, 82 3688-3692 (1985), Hwang et al . Proc Natl Acad Sci USA. 77 4030-4034 (1980), EP 52,322, EP 36,676, EP 88,046, EP 143,949, EP 142,641, Japanese patent application 83-118008, U S Patent Nos 4,485,045 and 4,544,545, and EP 102,324 Ordinanly the liposomes are of the small (about 200-800 Angstroms) umlamellar type in which the pid content is greater than about 30 mol % cholesterol, the selected proportion being adjusted for the optimal therapy The therapeutically effective dose of PR0364 or PR0175 polypeptide or antagonist thereto will, of course, vary depending on such factors as the pathological condition to be treated (mcludmg prevention), the method of administration the type of compound being used tor treatment anv co-therapy involved, the patient's age, weight, general medical condition, medical history, etc , and its determination is well withm the skill of a practicmg physician Accordmgly, it will be necessary for the therapist to titer the dosage and modify the route of administration as required to obtain the maximal therapeutic effect If the PR0364 or PRO 175 polypeptide has a naπow host range, for the treatment of human patients formulations compnsmg human PR0364, or human PROl 75 polypeptide, more preferably native-sequence human PR0364, or human PRO 175 polypeptide, are prefeπed The clinician will admmister PR0364 or PRO 175 polypeptide until a dosage is reached that achieves the desired effect for treatment of the condition in question For example, if the objective is the treatment of CHF the amount would be one that inhibits the progressive cardiac hypertrophy associated with this condition The progress of this therapy is easily monitored by echo cardiography Similarly, in patients with hypertrophic cardiomyopathy, PR0364 or PROl 75 polypeptide can be admmistered on an empiπcal basis With the above guidelines, the effective dose generally is within the range of from about 0 001 to about 1 0 mg/kg, more preferably about 0 01-1 mg/kg, most preferably about 0 01-0 1 mg/kg For non-oral use m treating human adult hypertension, it is advantageous to administer PR0364 or PRO 175 polypeptide in the form of an injection at about 0 01 to 50 mg, preferably about 0 05 to 20 mg, most preferably 1 to 20 mg, per kg body weight 1 to 3 times daily bv intravenous injection For oral administration a molecule based on the PR0364 or PRO 175 polypeptide is preferably administered at about 5 mg to 1 g, preferably about 10 to 100 mg. per kg body weight, 1 to 3 times daily It should be appreciated that endotoxin contamination should be kept minimally at a safe level, for example, less than 0 5 ng/mg protein Moreover for human administration, the formulations preferably meet steπ ty, pyrogemcity, general safety, and puntv as required by FDA Office and Biologies standards The dosage regimen of a pharmaceutical composition containing PR0364 or PR0175 polypeptide to be used in tissue regeneration will be determined by the attending physician considenng various factors that modify the action of the polypeptides, e , amount of tissue weight desired to be formed, the site of damage, the condition of the damaged tissue, the size of a wound, type of damaged tissue (e g , bone), the patient's age, sex, and diet, the seventy of any mfection, tune of administration, and other clinical factors The dosage may vary with the type of matπx used m the reconstimtion and with inclusion of other proteins in the pharmaceutical composition For example, the addition of other known growth factors, such as IGF-I, to the final composition may also affect the dosage Progress can be monitored by peπodic assessment of tissue/bone growth and/or repair, for example, X-rays, histomorphometnc determinations, and tetracychne labeling The route of PR0364 or PRO 175 polypeptide or antagonist or agonist administration is in accord with known methods, e g , by injection or infusion by intravenous, intramuscular, intracerebral, mtrapentoneal, lntracerobrospinal, subcutaneous, intraocular, lntraarticular, intrasynovial, mtrathecal, oral, topical, or inhalation routes, or by sustained-release systems as noted below The PR0364 or PR0175 polypeptide or antagonists thereof also are suitably admmistered by intratumoral, pentumoral, intralesional, or peπlesional routes, to exert local as well as systemic therapeutic effects The mtrapentoneal route is expected to be particularly useful, for example, m the treatment of ovaπan tumors If a peptide or small molecule is employed as an antagonist or agonist, it is preferably admmistered orally or non-orally m the form of a liquid or solid to mammals Examples of pharmacologically acceptable salts of molecules that form salts and are useful hereunder include alkali metal salts (e , sodium salt, potassium salt), alkaline earth metal salts (e g , calcium salt, magnesium salt), ammonium salts, organic base salts (e , pyπdme salt, tπethylamine salt), inorganic acid salts (e g , hydrochloπde, sulfate, nitrate), and salts of organic acid (e g , acetate, oxalate, p-toluenesulfonate) For compositions herein that are useful for bone, cartilage, tendon, or ligament regeneration, the therapeutic method mcludes admmistenng the composition topically, systemically, or locally as an implant or device When admmistered, the therapeutic composition for use is m a pyrogen-free, physiologically acceptable form Further, the composition may desirably be encapsulated or injected in a viscous form for delivery to the site of bone, cartilage, or tissue damage Topical administration may be suitable for wound healmg and tissue repair Preferably, for bone and/or cartilage formation, the composition would include a matrix capable of delivering the protem-contammg composition to the site of bone and/or cartilage damage, providing a stracmre for the developmg bone and cartilage and preferably capable of bemg resorbed into the body Such matnces may be formed of mateπals presently m use for other implanted medical applications The choice of matπx material is based on biocompatibility, biodegradabuty, mechanical properties, cosmetic appearance, and interface properties The particular application of the compositions will define the appropnate formulation Potential matnces for the compositions may be biodegradable and chemically defined calcium sulfate, tncalcium phosphate, hydroxvapatite, polylactic acid, polyglycohc acid, and polyanhydndes Other potential matenals are biodegradable and biologically well-defined, such as bone or dermal collagen Further matnces are comprised of pure proteins or extracellular matrix components Other potential matrices are nonbiodegradable and chemically defined, such as sintered hydroxyapatite bioglass. aluminates. or other ceramics Matnces may be comprised of combinations of any ot the above-mentioned types of mateπal, such as polylactic acid and hydroxyapatite or collagen and tπcalcium phosphate The bioceramics mav be altered in composition, such as in calcium-aluminate-phosphate and processing to alter pore size, particle size, particle shape, and biodegradabi ty One specific embodiment is a 50 50 (mole weight) copolymer of lactic acid and glycohc acid in the form of porous particles having diameters ranging from 150 to 800 microns In some applications, it will be useful to utilize a sequesteπng agent, such as carboxymethyl cellulose or autologous blood clot, to prevent the polypeptide compositions from disassociating from the matnx One suitable family of sequestenng agents is cellulosic mateπals such as alkylcelluloses (mcludmg hydroxyalkylcelluloses), mcludmg methylcellulose, ethylcellulose, hydoxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, and carboxymethylcellulose, one prefeπed bemg cationic salts of carboxymethylcellulose (CMC) Other prefeπed sequesteπng agents include hvaluromc acid, sodium algmate, poly(ethylene glycol) polyoxyethylene oxide, carboxyvinyl polymer, and poly( vinyl alcohol) The amount of sequesteπng agent useful herein is 0 5-20 wt%, preferably 1-10 wt%. based on total formulation weight, which represents the amount necessary to prevent desorption of the polypeptide (or its antagonist) from the polymer matπx and to provide appropnate handlmg of the composition, yet not so much that the progenitor cells are prevented from infiltrating the matnx, thereby providmg the polypeptide (or its antagonist) the opportunity to assist the osteogemc activity of the progenitor cells xn Combination Therapies The effectiveness of the PR0364 or PR0175 polypeptide or an agonist or antagonist thereof in preventmg or treating the disorder m question mav be unproved by admmistenng the active agent seπally or m combmation with another agent that is effective for those purposes, either in the same composition or as separate compositions For example, for treatment of cardiac hypertrophy, PR0364 or PRO 175 polypeptide therapy can be combined with the administration of inhibitors of known cardiac myocyte hypertrophy factors, e g , inhibitors of α-adrenergic agonists such as phenylephπne, endothelm- 1 inhibitors such as BOSENTAN™ and MOXONODIN™. inhibitors to CT-1 (US Pat No 5,679,545), inhibitors to LIF, ACE inhibitors, des-aspartate- angiotensm I inhibitors (U S Pat No 5,773,415), and angiotensm II inhibitors For treatment of cardiac hypertrophy associated with hypertension, PR0364 or PRO 175 polypeptide can be administered m combination with β-adrenergic receptor blocking agents, e , propranolol, timolol. tertalolol, carteolol, nadolol. betaxolol, penbutolol, acetobutolol, atenolol, metoprolol. or carvedilol, ACE inhibitors, e g , qumapπl, captopnl. enalapπl, ramipnl, benazepπl, fosmopnl, or hsinopπl, diuretics, e , chorothiazide, hydrochlorothiazide, hydro flumethazide, methylchlothiazide, benzthiazide, dichlorphenamide, acetazolamide, or mdapamide, and/or calcium channel blockers, e g , diltiazem, nifedipine, verapamil, or mcardipme Pharmaceutical compositions compnsmg the therapeutic agents identified herem by their genenc names are commercially available, and are to be administered following the manufacturers' instructions for dosage, administration, adverse effects, contraindications, etc See, e g , Physicians' Desk Reference (Medical Economics Data Production Co Montvale, N J , 1997), 51 th Edition Prefeπed candidates for combination therapy in the treatment of hypertrophic cardiomyopathy are β- adrenergic-blocking drags (e , propranolol, timolol, tertalolol. carteolol, nadolol. betaxolol, penbutolol, acetobutolol. atenolol. metoprolol or carvedilol) v erapamil difedipme or diltiazem Treatment ot hypertrophy associated with high blood pressure may require the use of antihypertensive drag therapy, using calcium channel blockers, e g . diltiazem. nifedipine. verapamil. or mcardipme β-adrenergic blocking agents, diuretics, e , chorothiazide. hydrochlorothiazide. hydroflumethazide, methylchlothiazide. benzthiazide, dichlorphenamide. acetazolamide. or mdapamide, and/or ACE-inhibitors. e , qumapπl, captopnl, enalapπl, ramipπl, benazepnl, fosinopπl. or hsinopπl For other indications, PR0364 or PRO 175 polypeptides or their antagonists may be combined with other agents beneficial to the treatment of the bone and/or cartilage defect, wound, or tissue in question These agents include vanous growth factors such as EGF. PDGF, TGF-α or TGF-β, IGF, FGF, and CTGF In addition, PR0364 or PROl 75 polypeptides or their antagonists used to treat cancer may be combmed with cytotoxic, chemotherapeutic, or growth-inhibitory agents as identified above Also, for cancer treatment, the PR0364 or PRO 175 polypeptide or antagonist thereof is suitably administered seπally or in combination with radiological treatments, whether involving lπadiation or administration of radioactive substances The effective amounts of the therapeutic agents admmistered m combmation with PR0364 or PRO 175 polypeptide or antagonist thereof will be at the physician's or vetermaπan's discretion Dosage administration and adjustment is done to achieve maximal management of the conditions to be treated For example, for treating hypertension, these amounts ideally take mto account use of diuretics or digitalis, and conditions such as hyper- or hypotension, renal impairment, etc The dose will additionally depend on such factors as the type of the therapeutic agent to be used and the specific patient bemg treated Typically, the amount employed will be the same dose as that used, if the given therapeutic agent is admmistered without PR0364 or PRO 175 polypeptide xni. Articles of Manufacmre An article of manufacmre such as a kit contammg PR0364 or PRO 175 polypeptide or antagonists thereof useful for the diagnosis or treatment of the disorders descnbed above compnses at least a contamer and a label Suitable containers mclude, for example, bottles, vials, syringes, and test tubes The containers may be formed from a vaπety of mateπals such as glass or plastic The contamer holds a composition that is effective for diagnosing or treating the condition and may have a sterile access port (for example, the contamer may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). The active agent in the composition is the PR0364 or PRO 175 polypeptide or an agonist or antagonist thereto The label on, or associated with, the container indicates that the composition is used for diagnosing or treating the condition of choice The article of manufacmre may further compnse a second container compnsmg a pharmaceutically- acceptable buffer, such as phosphate-buffered saline, Ringer's solution, and dextrose solution It may further include other matenals desirable from a commercial and user standpomt, including other buffers, diluents, filters, needles, synnges, and package inserts with instructions for use The article of manufacmre may also compnse a second or third container with another active agent as descnbed above C. Antibodies Some of the most promising drag candidates accordmg to the present invention are antibodies and antibody fragments that may inhibit the production or the gene product of the genes identified herem and/or reduce the activity of the gene products l Polyclonal Antibodies Methods of preparing polyclonal antibodies are known to the skilled artisan Polyclonal antibodies can be raised in a mammal, for example, by one or more injections of an immunizing agent and, if desired, an adjuvant Typically, the immunizing agent and/or adjuvant will be injected in the mammal by multiple subcutaneous or mtrapentoneal injections The immunizing agent mav include the PR0364 or PR0175 polypeptide or a fusion protein thereof It may be useful to conjugate the immunizing agent to a protein known to be lmmunogemc in the mammal being immunized Examples of such immunogenic proteins include, but are not limited to. keyhole limpet hemocyamn, serum albumin, bovine thyroglobuhn and soybean trypsin inhibitor Examples of adjuvants that may be employed include Freund's complete adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid A or synthetic trehalose dicorynomycolate) The immunization protocol may be selected by one skilled in the art without undue experimentation n Monoclonal Antibodies The anti- PR0364 or -PRO 175 antibodies may, alternatively, be monoclonal antibodies Monoclonal antibodies may be prepared usmg hybndoma methods, such as those descnbed by Kohler and Milstem, Nature, 256 495 (1975) In a hybndoma method, a mouse, hamster, or other appropriate host animal is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent Alternatively, the lymphocytes may be immunized in vitro The immunizing agent will typically include the PR0364 or PR0175 polypeptide or a fusion protem thereof Generally, either peπpheral blood lymphocytes ("PBLs") are used if cells of human ongm are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol. to form a hybndoma cell Godmg, Monoclonal Antibodies Pnnciples and Practice (New York Academic Press, 1986), pp 59-103 Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovme, and human ongm Usually, rat or mouse myeloma cell lmes are employed The hybndoma cells may be cultured m a suitable culture medium that preferably contams one or more substances that inhibit the growth or survival of the unfused, immortalized cells For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoπbosyl transferase (HGPRT or HPRT), the culture medium for the hybndomas typically will include hypoxanthine, aminoptenn, and thymidme ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells Prefeπed immortalized cell lines are those that fuse efficiently, support stable high-level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium More prefeπed immortalized cell lines are munne myeloma lines, which can be obtamed. for mstance. from the Salk Institute Cell Distnbution Center, San Diego, California and the Amencan Type Culture Collection, Manassas, Virginia Human myeloma and mouse-human heteromyeloma cell lmes also have been descnbed for the production of human monoclonal antibodies Kozbor, J Immunol . 133 3001 (1984). Brodeur et al , Monoclonal Antibodv Production Techniques and Applications (Marcel Dekker, Inc New York, 1987) pp 51-63 The culture medium in which the hybndoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against PR0364 or PRO 175 Preferably, the bmdmg specificity of monoclonal antibodies produced by the hybndoma cells is determined by lmmunoprecipitation or by an in vitro bmdmg assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA) Such techniques and assays are known in the art The bindmg affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, Anal Biochem , 107 220 (1980) After the desired hybndoma cells are identified, the clones may be subcloned by limiting dilution procedures and grown by standard methods Godmg, supra Suitable culture media for this purpose mclude, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium Alternatively, the hybndoma cells may be grown in vivo as ascites in a mammal The monoclonal antibodies secreted bv the subclones mav be isolated or punfied from the culture medium or ascites fluid by conventional immunoglobulm purification procedures such as. for example, protein A- Sepharose. hvdroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography The monoclonal antibodies may also be made bv recombinant DNA methods, such as those described in U S Patent No 4,816,567 DNA encodmg the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures ( , by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of muπne antibodies) The hybndoma cells of the invention serve as a prefeπed source of such DNA Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulm protein, to obtain the svnthesis of monoclonal antibodies in the recombinant host cells The DNA also may be modified, for example, by substituting the codmg sequence for human heavy- and light-chain constant domains in place of the homologous muπne sequences (U S Patent No 4,816,567, Moπison et al , supra) or by covalently loimng to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobu n polypeptide Such a non-immunoglobulin polypeptide can be substimted for the constant domains of an antibody of the invention, or can be substimted for the vaπable domams of one antigen-combining site of an antibody of the invention to create a chimenc bivalent antibody The antibodies may be monovalent antibodies Methods for preparing monovalent antibodies are well known in the art For example, one method involves recombinant expression of immunoglobulm light cham and modified heavy cham The heavy cham is truncated generally at any pomt m the Fc region so as to prevent heavy-chain crosslinkmg Alternatively, the relevant cysteine residues are substimted with another amino acid residue or are deleted so as to prevent crosslinkmg In vitro methods are also suitable for prepaπng monovalent antibodies Digestion of antibodies to produce fragments thereof, particularly Fab fragments, can be accomplished using routine techniques known m the art in Human and Humanized Antibodies The anti- PR0364 or -PRO 175 antibodies may further compnse humanized antibodies or human antibodies Humanized forms of non-human (e g , muπne) antibodies are chimenc immunoglobulms, immunoglobulm chams, or fragments thereof (such as Fv, Fab. Fab', F(ab or other antigen-binding subsequences of antibodies) that contain minimal sequence denved from non-human immunoglobulm Humanized antibodies include human rmmunoglobuhns (recipient antibody) in which residues from a CDR of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat, or rabbit having the desired specificity, affinity, and capacity In some mstances, Fv framework residues of the human immunoglobulm are replaced by coπespondmg non-human residues Humanized antibodies may also compnse residues that are found neither m the recipient antibody nor in the imported CDR or framework sequences In general, the humanized antibody will compnse substantially all of at least one, and typically two, vanable domams, m which all or substantially all of the CDR regions coπespond to those of a non-human immunoglobulm, and all or substantially all of the FR regions are those of a human immunoglobulm consensus sequence The humanized antibody preferably also will compnse at least a portion of an immunoglobulm constant region (Fc), typically that of a human immunoglobulin Jones et al , Nature, 321 522-525 (1986), Riechmann et al , Nature. 332 323-329 (1988), Presta, Cuπ Op Struct Biol . 2 593-596 (1992) Methods for humanizing non-human antibodies are well known m the art Generally, a humanized antibody has one or more ammo acid residues introduced into it from a source that is non-human These non-human ammo acid residues are often refeπed to as "import" residues, which are typically taken from an "import" anable domam Humanization can be essentially performed followmg the method ot Winter and co-workers (Jones et al Namre 321 522-525 ( 1986) Riechmann et al , Namre, 332 323-327 (1988) Verhoeven et al , Science, 239 1534-1536 (1988)), bv substituting rodent CDRs or CDR sequences for the coπesponding sequences of a human antibodv Accordingly, such "humanized" antibodies are chimenc antibodies (U S Patent No 4,816 567), wherem substantially less than an intact human variable domain has been substimted by the coπespondmg sequence from a non-human species In practice humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substimted bv residues from analogous sites in rodent antibodies Human antibodies can also be produced using vanous techniques known in the art. mcludmg phage display libraries Hoogenboom and Winter, J Mol Biol , 227 381 (1991), Marks et al , J Mol Biol , 222 581 (1991) The techniques of Cole et al and Boerner et al are also available for the preparation of human monoclonal antibodies Cole et al , Monoclonal Antibodies and Cancer Therapy. Alan R Liss, p 77 (1985) and Boerner et al J Immunol . 147(1) 86-95 (1991) Similarly, human antibodies can be made by introducing human immunoglobulm loci mto transgemc animals e , mice in which the endogenous immunoglobulin genes have been partially or completely inactivated Upon challenge, human antibody production is observed that closely resembles that seen in humans in all respects, mcludmg gene reaπangement, assembly, and antibodv repertoire This approach is descπbed, for example, in U S Patent Nos 5,545.807, 5,545,806, 5,569 825. 5 625,126, 5,633,425. and 5,661,016, and in the following scientific publications Marks et al Bio/Technology. 10 779- 783 (1992), Lonberg et al , Namre, 368 856-859 (1994), Mornson, Namre. 368 812-813 (1994), Fishwild et al , Namre Biotechnology. J4 845-851 (1996), Neuberger, Namre Biotechnology, J4 826 (1996), Lonberg and Huszar. Intern Rev Immunol . 13 65-93 (1995) iv Bispecific Antibodies Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have bmdmg specificities for at least two different antigens In the present case, one of the binding specificities is for the PR0364 or PR0175, the other one is for anv other antigen, and preferably for a cell-surface protein or receptor or receptor subunit Methods for making bispecific antibodies are known m the art Traditionally the recombmant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/hght-chatn parrs where the two heavy chams have different specificities Milstein and Cuello, Namre, 305 537-539 (1983) Because of the random assortment of immunoglobulin heavy and light chams, these hybπdomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the coπect bispecific structure The puπfication of the coπect molecule is usually accomplished by affinity chromatography steps Similar procedures are disclosed in WO 93/08829, published 13 May 1993, and in Traunecker et al , EMBO J . JO 3655-3659 (1991) Antibody vaπable domams with the desired bindmg specificities (antibody-antigen combmmg sites) can be fused to immunoglobulm constant- domain sequences The fusion preferably is with an immunoglobulm heavy- chain constant domain, compnsmg at least part of the hmge, CH2, and CH3 regions It is prefeπed to have the first heavy-chain constant region (CHI) contammg the site necessary for light-chain bmdmg present in at least one of the fusions DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulm light cham, are mserted mto separate expression vectors, and are co-transfected mto a suitable host organism For further details of generating bispecific antibodies, see, for example Suresh et al , Methods m Enzvmology, 121 210 (1986) v Heteroconiugate Antibodies Heteroconjugate antibodies are composed of t v o covalentlv joined antibodies Such antibodies have for example been proposed to target immune-system cells to unwanted cells (U S Patent No 4 676 980) and for treatment of HIV infection WO 91/00360, WO 92/200373, EP 03089 It is contemplated that the antibodies may be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslmking agents For example immunotoxins mav be constracted using a disulfide-exchange reaction or by forming a thioether bond Examples ot suitable reagents for this purpose include lmmothiolate and methyl-4- mercaptobutvπmidate and those disclosed, for example, in U S Patent No 4,676,980 vi Effector Function Engineeπng It may be desirable to modify the antibody of the invention with respect to effector function, so as to enhance, , the effectiveness of the antibody m treating cancer For example, cysteine resιdue(s) may be mtroduced mto the Fc region, thereby allowing interchain disulfide bond formation m this region The homodimeπc antibody thus generated may have improved lnternahzation capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC) See Caron et al , J Exp Med J76 1191-1195 (1992) and Shopes, J Immunol , J48 2918-2922 (1992) Homodimenc antibodies with enhanced anti-tumor activity may also be prepared using heterobifunctional cross-linkers as descnbed in Wolff et al Cancer Research, 53 2560-2565 (1993) Alternatively, an antibody can be engmeered that has dual Fc regions and may thereby have enhanced complement lysis and ADCC capabilities See Stevenson et al , Anti- Cancer Drug Design 3 219-230 (1989) vu Immunoconiugates The mvention also pertains to immunoconjugates compnsmg an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxm (e g , an enzymatically active toxin of bactenal, fungal, plant, or animal oπgin, or fragments thereof), or a radioactive isotope (i e , a radioconjugate) Chemotherapeutic agents useful in the generation of such immunoconjugates have been descnbed above Enzymatically active toxms and fragments thereof that can be used include diphtheπa A cham, nonbindmg active fragments of diphthena toxin, exotoxin A chain (from Pseudomonas aerugtnosa), πcm A cham, abπn A cham, modeccm A cham, alpha-sarcin. Aleurites fordu proteins, dianthin protems, Phvtolaca americana protems (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin sapaonana officmalis inhibitor, gelonm, mitogellm, restπctocin, phenomycin, enomycin, and the tπcothecenes A vanety of radionuc des are available for the production of radioconjugated antibodies Examples include Bi, I, In, Y, and Re Conjugates of the antibodv and cytotoxic agent are made usmg a vaπety of bifunctional protein-coupling agents such as N-succιmmιdyl-3-(2-pyπdyldιthιol) propionate (SPDP), lminothiolane (IT), bifunctional deπvatives of lmidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccimmidyl suberate), aldehydes (such as glutareldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamme), bis- diazomum denvatives (such as bιs-(p-dιazonιumbenzoyl)-ethvlenedιamιne), dnsocyanates (such as tolyene 2,6- dnsocyanate), and bis-active fluonne compounds (such as l,5-dιfluoro-2,4-dιnιtrobenzene) For example, a πcm lmmunotoxm can be prepared as descπbed in Vitetta et al , Science 238 1098 (1987) Carbon- 14-labeled 1- ιsothιocyanatobenzyl-3-methyldιethylene tnaminepentaacetic acid (MX-DTPA) is an exemplary chelatmg agent for conjugation of radionucleotide to the antibody See W094/11026 In another embodiment, the antibody may be conjugated to a "receptor" (such streptavidin) for utilization in mmor pretargetmg wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a cleanng agent and then administration of a "ligand" (e g avidin) that is conjugated to a cytotoxic agent (e , a radionucleotide) viii Immunohposomes The antibodies disclosed herein may also be formulated as immunohposomes Liposomes contammg the antibody are prepared by methods known in the art such as described in Epstein et al Proc Natl Acad Sci USA. 82 3688 (1985). Hwang et al Proc Natl Acad Sci USA. 77 4030 (1980), and U S Pat Nos 4,485,045 and 4 544,545 Liposomes with enhanced circulation time are disclosed in U S Patent No 5,013,556 Particularly useful liposomes can be generated by the reverse-phase evaporation method with a lipid composition compnsmg phosphatidylchohne. cholesterol, and PEG-denvatized phosphatidylethanolamine (PEG- PE) Liposomes are extraded through filters of defined pore size to yield liposomes with the desired diameter Fab' fragments of the antibody of the present invention can be conjugated to the liposomes as descπbed m Martin et al , J Biol Chem 257 286-288 (1982) via a disulfide-interchange reaction A chemotherapeutic agent (such as Doxorabicin) is optionally contained within the hposome See Gabizon et al . J National Cancer Inst 81(19) 1484 (1989) lx Pharmaceutical Compositions of Antibodies Antibodies specifically binding a PR0364 or PRO 175 polypeptide identified herein, as well as other molecules identified by the screening assays disclosed hereinbefore, can be administered for the treatment of vanous disorders as noted above and below in the form of pharmaceutical compositions If the PR0364 or PRO 175 polypeptide is mtracellular and whole antibodies are used as inhibitors, internalizing antibodies are prefeπed However, hpofections or liposomes can also be used to deliver the antibody, or an antibody fragment, into cells Where antibody fragments are used, the smallest inhibitory fragment that specifically binds to the bmdmg domain of the target protem is prefeπed For example, based upon the vaπable-region sequences of an antibody, peptide molecules can be designed that retam the ability to bmd the target protem sequence Such peptides can be synthesized chemically and/or produced by recombinant DNA technology See, e g , Marasco et al , Proc Natl Acad Sci USA, 90 7889-7893 (1993) The formulation herein may also contain more than one active compound as necessary for the particular indication bemg treated, preferably those with complementary activities that do not adversely affect each other Alternatively, or in addition, the composition may compnse an agent that enhances its function, such as, for example, a cytotoxic agent, cytokme, chemotherapeutic agent, or growth-inhibitory agent Such molecules are suitably present m combination m amounts that are effective for the purpose mtended The active ingredients may also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymenzation, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmefhacylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumm microspheres, microemulsions. nano-particles. and nanocapsules) or m macroemulsions Such techniques are disclosed in Remmgton's Pharmaceutical Sciences, supra The formulations to be used for in vivo administration must be stenle This is readily accomplished by filtration through stenle filtration membranes Sustamed-release preparations may be prepared Suitable examples of sustamed-release preparations include semipermeable matnces of solid hydrophobic polymers contammg the antibody, which matnces are in the form of shaped articles, e g , films, or microcapsules Examples of sustamed-release matnces mclude polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vιnylalcohol)), polylactides (U S Pat No 3.773.919). copolymers of L-glutamic acid and γ ethvl-L-glutamate, non-degradable ethylene-vinyl acetate degradable lactic acid-glycolic acid copolvmers such as the LUPRON DEPOT r (mjectable microspheres composed of lactic acid-glycolic acid copolymer and leuprohde acetate) and polv-D-(-)-3- hvdroxybutvπc acid While polymers such as ethvlene-vmyl acetate and lactic acid glycohc acid enable release ot molecules for over 100 davs certain hvdrogels release protems for shorter time peπods When encapsulated antibodies remain in the body for a long time thev mav denature or aggregate as a result of exposure to moisture at 37°C, resultmg in a loss of biological activity and possible changes in immunogenicity Rational strategies can be devised for stabilization depending on the mechanism involved For example if the aggregation mechanism is discovered to be lntermolecular S-S bond formation through thio-disulfide interchange, stabilization may be achieved by modifying sulfhydryl residues, lyophihzing from acidic solutions, controlling moisture content, usmg appropriate additives, and developing specific polvmer matnx compositions x Methods of Treatment using the Antibodv It is contemplated that the antibodies to PR0364 or PRO 175 polypeptide may be used to treat vanous cardiovascular endothelial, and angiogenic conditions as noted above The antibodies are admmistered to a mammal, preferably a human, in accord with known methods, such as intravenous admmistration as a bolus or by continuous infusion over a penod of time, by intramuscular, mtrapentoneal lntracerobrospmal subcutaneous lntra-aiticular, intrasynovial intrathecal, oral topical or inhalation routes Intravenous administration of the antibody is prefeπed Other therapeutic regimens may be combmed with the admmistration of the antibodies of the instant invention as noted above For example, if the antibodies are to treat cancer, the patient to be treated with such antibodies may also receive radiation therapy Alternatively, or in addition, a chemotherapeutic agent may be admmistered to the patient Preparation and dosmg schedules for such chemotherapeutic agents may be used accordmg to manufacturers' instructions or as determined empiπcally by the skilled practitioner Preparation and dosmg schedules for such chemotherapy are also descπbed m Chemotherapy Service, Ed , M C Perry (Williams & Wilkins Baltimore, MD, 1992) The chemotherapeutic agent may precede, or follow admmistration of the antibody, or may be given simultaneously therewith The antibody may be combined with an anti-oestrogen compound such as tamoxifen or EVISTA™ or an anti-progesterone such as onapπstone (see EP 616812) m dosages known tor such molecules If the antibodies are used for treatmg cancer it may be desirable also to administer antibodies against other tumor-associated antigens, such as antibodies that bind to one or more of the ErbB2, EGFR, ErbB3 ErbB4, or VEGF receptor(s) These also mclude the agents set forth above Also, the antibody is suitably admmistered senally or in combination with radiological treatments, whether involving lπadiation or admmistration of radioactive substances Alternatively, or in addition, two or more antibodies bindmg the same or two or more different antigens disclosed herein may be co-admmistered to the patient Sometimes, it may be beneficial also to admmister one or more cytokines to the patient In a prefeπed embodiment, the antibodies herein are co- admmistered with a growth- inhibitory agent For example, the growth- inhibitory agent may be admmistered first, followed by an antibody of the present invention However, simultaneous administration or administration of the antibody of the present mvention first is also contemplated Suitable dosages for the growth-inhibitorv agent are those presently used and may be lowered due to the combined action (synergy) of the growth-inhibitory agent and the antibody herem In one embodiment, vasculaπzation of tumors is attacked in combination therapy The anti- PR0364 or - PRO 175 polypeptide and another antibody ( g , anti- VEGF) are admmistered to tumor-beaπng patients at therapeuticallv effective doses as determined for example, by observing necrosis of the mmor or its metastatic foci if any This therapy is continued until such time as no further beneficial effect is observed or clinical examination shows no trace of the tumor or anv metastatic foci Then TNF is administered, alone or in combination with an auxiliary agent such as alpha- beta-, or gamma-interferon antι-HER2 antibody, heregulm anti-heregulin antibody D-factor, mterleukm- 1 (IL-1) ιnterleukιn-2 (IL-2), granulocvte-macrophage colonv stimulating factor (GM-CSF), or agents that promote microvascular coagulation in tumors, such as anti-protem C antibodv, anti-protem S antibody, or C4b binding protein (see WO 91/01753, published 21 February 1991), or heat or radiation Since the auxiliary agents will vary in their effectiveness it is desirable to compare their impact on the mmor by matnx screenmg in conventional fashion The administration of anti- PR0364 or antι-PR0175 polypeptide antibody and TNF is repeated until the desired clinical effect is achieved Alternatively, the of anti- PR0364 or antι-PR0175 polypeptide antibody is admmistered together with TNF and, optionally, auxiliary agent(s) In instances where solid tumors are found in the limbs or in other locations susceptible to isolation from the general circulation, the therapeutic agents descnbed herem are admmistered to the isolated mmor or organ In other embodiments, a FGF or PDGF antagonist, such as an anti-FGF or an anti-PDGF neutralizing antibody, is administered to the patient in conjunction with the of anti- PR0364 or antι-PR0175 polypeptide antibody Treatment with anti- PR0364 or antι-PR0175 polypeptide antibodies preferably may be suspended dunng penods of wound healing or desirable neovasculanzation For the prevention or treatment of cardiovascular, endothelial, and angiogenic disorder, the appropnate dosage of an antibody herein will depend on the type of disorder to be treated, as defined above, the seventy and course of the disease, whether the antibody is admmistered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the antibody, and the discretion of the attendmg physician The antibody is suitably admmistered to the patient at one time or over a seπes of treatments For example, dependmg on the type and seventy of the disorder, about 1 μg/kg to 50 mg/kg (e g , 0 1-20 mg/kg) of antibody is an initial candidate dosage for admmistration to the patient whether, for example, by one or more separate admmistrations, or bv continuous infusion A typical daily or weekly dosage might range from about 1 μg/kg to 100 mg/kg or more, depending on the factors mentioned above For repeated administrations over several days or longer, depending on the condition, the treatment is repeated or sustained until a desired suppression of disorder symptoms occurs However other dosage regimens may be useful The progress of this therapy is easily monitored by conventional techniques and assays, mcludmg, for example, radiographic mmor imagmg xi Articles of Manufacmre with Antibodies An article of manufacmre contammg a container with the antibody and a label is also provided Such articles are descnbed above, wherein the active agent is an antι-PR0364 or -PRO 175 antibody xii Diagnosis and Prognosis of Tumors using Antibodies If the indication for which the antibodies are used is cancer while cell- surface protems, such as growth receptors overexpressed in certain tumors, are excellent targets for drug candidates or mmor (e , cancer) treatment, the same protems along with PR0364 or PRO 175 polypeptides find additional use in the diagnosis and prognosis of tumors For example, antibodies directed agamst the PR0364 or PRO 175 polypeptides mav be used as mmor diagnostics or prognostics For example, antibodies, including antibody fragments, can be used qualitatively or quantitatively to detect the expression of genes including the gene encoding the PR0364 or PRO 175 polypeptide The antibody preferably is equipped with a detectable e g fluorescent label and binding can be monitored by light microscopy flow cvtometrv fluorimetry or other techniques known in the art Such binding assavs are performed essentially as described above In situ detection of antibodv bindmg to the marker gene products can be performed for example by lmmunofluorescence or immunoelectron microscopy For this purpose, a histological specimen is removed from the patient, and a labeled antibodv is applied to it, preferably by overlaying the antibodv on a biological sample This procedure also allows for determining the distnbution of the marker gene product in the tissue examined It will be apparent to those skilled in the art that a wide varietv of histological methods are readily available for in situ detection The following Examples are offered for illustrative purposes only, and are not mtended to limit the scope of the present invention m any way The disclosures of all patent and literature references cited in the present specification are hereby incorporated by reference in their entirety EXAMPLES Commercially available reagents refeπed to in the Examples were used accordmg to manufacturer's instructions unless otherwise indicated The source of those cells identified in the following Examples, and throughout the specification, by ATCC accession numbers is the Amencan Type Culture Collection, Manassas, VA Unless otherwise noted, the present invention uses standard procedures of recombmant DNA technology, such as those descnbed heretnabove and in the following textbooks Sambrook et al , supra, Ausubel er al , Cuπent Protocols in Molecular Biology (Green Publishing Associates and Wiley Interscience, N Y , 1989), Imus et al , PCR Protocols A Guide to Methods and Applications (Academic Press, Inc N Y , 1990), Harlow et al , Antibodies A Laboratory Manual (Cold Spring Harbor Press Cold Spring Harbor, 1988), Gait, Oligonucleotide Synthesis (IRL Press Oxford, 1984), Freshney, Animal Cell Culture. 1987, Cohgan et al , Cuπent Protocols m Immunology. 1991 EXAMPLE 1 Isolation of cDNA Clones Encoding Human PRQ364 An expressed sequence tag (EST) DNA database (LIFESEQ™, Incyte Pharmaceuticals. Palo Alto, CA) was searched and an EST (Incyte EST No 3003460) was identified that showed homology to members of the mmor necrosis factor receptor (TNFR) family of polypeptides A consensus DNA sequence was then assembled relative to the Incyte 3003460 EST and other EST sequences usmg repeated cycles of BLAST (Altshul et al , Methods m Enzvmology 266 460-480 (1996)) and "phrap" (Phil Green, University of Washmgton, Seattle, http //bozeman mbt washmgton edu/phrap docs/phrap html) This consensus sequence is herem designated "<consen01>" m Figures 3A-C The "<consen01>" consensus sequence (SEQ ID NO 4) shown m Figures 3A-C is also herein designated as "DNA44825" (see Figure 4. SEQ ID NO 4) Based upon the DNA44825 and "<consenl>" consensus sequences shown in Figures 3-4, oligonucleotides were synthesized 1) to identify by PCR a cDNA library that contained the sequence of mterest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PR0364 Forward and reverse PCR pnmers generally range from 20 to 30 nucleotides and are often designed to give a PCR product of about 100-1000 bp m length The probe sequences are typically 40-55 bp in length In some cases, additional oligonucleotides are synthesized when the consensus sequence is greater than about Tl 5kbp In order to screen sev eral libraries for a full-length clone DNA from the libraries was screened bv PCR amplification as per Ausubel et al Cuπent Protocols m Molecular Biology with the PCR primer pair A positive library was then used to isolate clones encoding the gene of interest using the probe oligonucleotide and one of the pnmer pairs Pairs of PCR primers (forward and reverse) were synthesized forward PCR pnmer (44825 fl) 5' CACAGCACGGGGCGATGGG-3' (SEQ ID NO 6) forward PCR pnmer (44825 f2) 5'-GCTCTGCGTTCTGCTCTG-3' (SEQ ID NO 11) forward PCR primer (44825 GITR f) 5 -GGCACAGCACGGGGCGATGGGCGCGTTT-3' (SEQ ID NO 5) reverse PCR primer (44825 rl) 5'-CTGGTCACTGCCACCTTCCTGCAC-3' (SEQ ID NO 12) reverse PCR pnmer (44825 r2) 5'-CGCTGACCCAGGCTGAG-3' (SEQ ID NO 8) reverse PCR pπmer (44825 GITR r) 5'-GAAGGTCCCCGAGGCACAGTCGATACA-3' (SEQ ID NO 10) Additionally, synthetic oligonucleotide hybπdization probes were constracted from the consensus DNA44825 sequence which had the following nucleotide sequences hvbπdization probe (44825 pi) 5'-GAGGAGTGCTGTTCCGAGTGGGACTGCATGTGTGTCCAGC-3' (SEQ ID NO 9) hvbndization probe (44825 GITR p) 5'-AGCCTGGGTCAGCGCCCCACCGGGGGTCCCGGGTGCGGCC-3' (SEQ ID NO 7) In order to screen several libranes for a source of a full-length clone, DNA from the libranes was screened by PCR amplification with the PCR pnmer parrs identified above A positive library was then used to isolate clones encodmg the PR0364 gene using the probe oligonucleotides and one of the PCR pnmers RNA for construction of the cDNA libranes was isolated from human bone maπow tissue The cDNA libranes used to isolate the cDNA clones were constructed by standard methods usmg commercially available reagents such as those from Invitrogen, San Diego, CA The cDNA was pnmed with oligo dT contammg a Notl site, linked with blunt to Sail hemikinased adaptors, cleaved with Notl, sized appropnately by gel electrophoresis, and cloned m a defined onentation mto a suitable cloning vector (such as pRKB or pRKD, pRK5B is a precursor of pRK5D that does not contain the Sfil site, see, Holmes et al , Science, 253 1278-1280 (1991) in the unique Xhol and Notl sites DNA sequencing of the clones isolated as descπbed above gave the full-length DNA sequence for PR0364 [herein designated as UNQ319 (DNA47365-1206)] (SEQ ID NO 1) and the denved protein sequence for PR0364 The entire nucleotide sequence of UNQ319 (DNA47365-1206) is shown in Figure 1 (SEQ ID NO 1) Clone UNQ319 (DNA47365-1206) has been deposited with ATCC and is assigned ATCC Deposit No ATCC 209436 Clone UNQ319 (DNA47365-1206) contains a single open reading frame with an apparent translational initiation site at nucleotide positions 121-123 [Kozak et al , supra] and ending at the stop codon at nucleotide positions 844-846 (Figure 1, SEQ ID NO 1) The predicted polypeptide precursor is 241 ammo acids long (Figure 2 SEQ ID NO 3) The full-length PR0364 protein (SEQ ID NO 3) shown in Figure 2 has an estimated molecular weight of about 26 000 daltons and a pi of about 6 34 A potential N-glvcosvlation site exists between amino acids 146 and 149 of the amino acid sequence shown in Figure 2 (SEQ ID NO 3) Hydropathy analysis (not shown) suggested a Type I transmembrane typology, a putative signal sequence is from amino acids 1 to 25 and a potential transmembrane domain exists betw een ammo acids 162 to 180 of the sequence shown m Figure 2 (SEQ ID NO 3) Analysis of the amino acid sequence of the full-length PR0364 polypeptide suggests that portions of it possess homology to members of the mmor necrosis factor receptor family, thereby indicating that PR0364 mav be a novel member of the mmor necrosis factor receptor family The mtracellular domain of PR0364 contams a motif (in the region of amino acids 207-214 of Figure 2 SEQ ID NO 3) similar to the minimal domain within the CD30 receptor shown to be required for TRAF2 bmdmg and which is also present within TNFR2 [Lee et al , supra. (1996)] There are three apparent extracellular cysteine-πch domains characteristic of the TNFR family [see, Naismith and Sprang, Trends Biochem Sci . 23 74-79 (1998)], of which the third CRD has 3 rather than the more typical 4 or 6 cystemes of the TNFR family As compared to the mouse GITR (descπbed below) the PR0364 ammo acid sequence has 8 cystemes in CRDl relative to 5 cystemes in CRDl of mouse GITR, and the presence of one potential N-linked glycosylation site in the ECD as compared to 4 potential N-linked glycosylation sites in mouse GITR A detailed review of the putative amino acid sequence of the full-length native PR0364 polypeptide and the nucleotide sequence that encodes it evidences sequence homology with the mouse GITR (mGITR) protem reported by Nocentmi et al , Proc Natl Acad Sci USA 94 6216-6221 (1997) It is possible, therefore, that PR0364 represents the human counterpart or ortholog to the mouse GITR protem reported by Nocentmi et al EXAMPLE 2 Isolation of Human PRO 175 Methods descπbed m Klein et al , PNAS. 93 7108-7113 (1996) were employed with the followmg modifications Yeast transformation was performed with limiting amounts of transformmg DNA in order to reduce the number of multiple transformed veast cells Instead of plasmid isolation from the yeast followed bv transformation of £ coli as descπbed in Klein et al . supra. PCR analysis was performed on single yeast colonies This was accomplished by restreaking the oπgmal sucrose positive colony onto fresh sucrose medium to punfy the positive clone A smgle puπfied colony was then used for PCR using the following primers TGTAAAACGACGGCCAGTTTCTCTCAGAGAAACAAGCAAAAC (SEQ ID NO 15) and CAGGAAACAGCTATGACCGAAGTGGACCAAAGGTCTATCGCTA (SEQ ID NO 16) The PCR pnmers are bipartite in order to amplify the insert and a small portion of the mvertase gene (allowing to determine that the insert was in frame with mvertase) and to add on universal sequencmg primer sites A library of cDNA fragments derived from human HUVEC cells fused to mvertase was transformed mto yeast and transformants were selected on SC-URA media URA and transformants were replica plated onto sucrose medium m order to identify clones secretmg mvertase Positive clones were re-tested and PCR products were sequenced The sequence of one clone, DNA1840, was determined to contain a signal peptide codmg sequence Oligonucleotide primers and probes were designed using the nucleotide sequence of DNA 1840 A full length plasmid library of cDNAs from human umbilical vem endothelial cells (HUVEC) was titered and approximately 100,000 c were plated in 192 pools of 500 cfu pool into 96-well round bottom plates The pools were grown overnight at 37°C with shaking (200rpm) PCR was performed on the individual culmres using primers specific to DNA1840 agarose gel electrophoresis was performed and positive w ells were identified bv visualization of a band ot the expected size Individual positiv e clones were obtained by colonv lift followed by hybridization with P-labeled oligonucleotide These clones were charactenzed bv PCR, restπction digest, and southern blot analyses A cDNA clone (DNA119355) was sequenced in entirety A nucleotide sequence of PR0175 is shown in Figure 5A-B (SEQ ID NO 13). Clone PRO175-1150 contains a single open reading frame with an apparent translational initiation site at nucleotide positions 21-23 [Kozak et al , supra] (Figure 5, SEQ ID NO 13) The predicted polypeptide precursor is 177 amino acids long and has a calculated molecular weight of approximately 20,308 daltons Hydropathy analysis suggests a type II transmembrane protem typology, with a putative cytoplasmic region (ammo acids 1-25) transmembrane region (amino acids 26-51), and extracellular region (amino acids 52-177) Two potential N-hnked glycosylation sites have been identified at position 129 (Asn) and position 161 (Asn) of the sequence shown in Figure 5 (SEQ ID NO 14) Clone PRO 175-1150 has been deposited with ATCC and is assigned ATCC deposit no 209466 PRO 175 polypeptide is obtained or obtainable by expressing the molecule encoded by the cDNA insert of the deposited ATCC 209466 vector Digestion of the vector with Xbal and Notl restπction enzymes will yield a 1411 bp fragment and 668 bp fragment Based on a BLAST and FastA sequence alignment analysis (usmg the ALIGN computer program) of extracellular sequence, PRO 175 shows amino acid sequence identity to several members of the TNF cytokine family, and particularly, to human Apo-2L (19 8%), Fas/Apol -ligand (19 0%), TNF-alpha (20 6%) and Lymphotoxιn-α(17 5%) Most of the ammo acid sequence identity is found in the regions coπesponding to the beta-strands in the crystal stracmre of TNF-alpha [Banner et al , Cell, 73 431-435 (1993), Eck et al . J Biol Chem , 264 17595-605 (1989), Lewit-Bentley et al , J Mol Biol . 199 389-92 (1988)] The sequence of strand C is especially conserved in all members of the family The sequence between the putative transmembrane domam and the first beta-strand of the PROl 75 polypeptide is relatively short, including 5 residues, as compared to about 30 to about 80 residues in TNF-alpha, CD95L or Apo-2 ligand EXAMPLE 3 Northern Blot Analysis of PRO 175 Expression of PRO 175 mRNA in human tissues and mmor cell lines was exammed bv Northern blot analysis (see Figure 8) Human RNA blots were hvbπdized to an approximately 700 bp-long " P-labeled DNA probe generated by digestion of the pRK5 plasmid encoding full-length PRO 175 cDNA with Xba-I. this probe coπesponds to the entire coding sequence plus some flanking 5' and 3' sequences Human fetal, adult, or cancer cell line mRNA blots (Clontech) were incubated with the DNA probe m hybπdization buffer (5X SSPE, 2X Denhardt's solution, 100 mg/mL denatured sheared salmon sperm DNA, 50% formamide, 2% SDS) for 60 hours at 42°C The blots were washed several times in 2X SSC, 0 05% SDS for 1 hour at room temperature, followed by a 30 mmute wash in 0 IX SSC, 0 1% SDS at 50°C The blots were developed after overnight exposure by phosphonmager analysis (Fuji) As shown in Figure 8 a predominant mRNA transcnpt of about 3 2 kB was detected m fetal kidney and lung, and in adult small mtestine Expression was also detected in 6 out of 8 human mmor cell lmes tested, which showed about the same 3 2 kB transcnpt, as well as weaker expression of about 1 5 and about 5 kB transcnpts The results indicate that the mRNA expression of the PRO 175 polypeptide is relatively restπcted in normal tissues, but is markedly elevated in mmor cell lines from lvmphoid as well as non-lymphoid oπgm EXAMPLE 4 Assays to Detect Fxpression of PRQ364 mRNA in Human Cells and Tissues Assays were conducted to examine expression of PR0364 mRNA in normal human tissues and in cancer cells lines Various human tissues and cancer cell lines (Clontech) were tested by Northern blot hybridization for detection of PR0364 transcπpts, but none were detected Using quantitative reverse-transcπptase PCR, PR0364 mRNA was detected in PBL, bram, bone maπow, spleen, thymus and lung, and at relatively lower levels, in kidney, heart, small intestine and liver tissues (see Figure 6). The relative mRNA expression levels were determined by quantitative PCR usmg a Taqman instrument (ABI) essentially as descπbed in Held et al Genome Res . 6_986-94 (1996) using PR0364 specific pnmers and fluorogenic probes DNA47365 tm f - CCACTGAAACCTTGGACAGA (SEQ ID NO 17) DNA47365 tm p - CCCAGTTCGGGTTTCTCACTGTGTTCC (SEQ ID NO 18) DNA47365 tm r - ACAGCGTTGTGGGTCTTGTTC (SEQ ID NO 19) The authenticity of the PCR product was confirmed by Southern blot hybπdization to the coπespondmg cDNA Expression levels were normalized relative to small intestine tissue In a separate assay, primary human T cells (isolated from donor whole blood usmg a T cell enπchment column (R & D Systems)) and monocytes/macrophages (isolated from donor whole blood by adherence to tissue culture flasks) were maintained m RPMI supplemented with 10% FBS and 2 mM glutamine The cells were then treated for 24 hours with PHA (1 microgram/ml, Sigma), antι-CD3 antibody (1 microgram/ml, Pharmingen), LPS (1 microgram/ml, Sigma), TNF-alpha (1 microgram/ml, prepared essentially as descnbed in Pennica et al , Namre, 312 724-729 (1984)), or the soluble PRO 175 ligand (5 microgram/ml) The relative mRNA expression levels were then analyzed by the Taqman procedure descnbed above The expression levels were normalized relative to buffer-treated T cells The results are shown in Figure 7 Substantial up-regulation of PR0364 mRNA was observed in isolated peripheral blood T cells after stimulation by phytohemagglutmin (PHA) or by antι-CD3 antibody High levels of expression were observed m isolated monocytes/macrophages and this expression was further mcreased by LPS (See Figure 7) EXAMPLE 5 Expression of PRO 175 m E coli The DNA sequence (Figure 5A-B, SEQ ID NO 13) encodmg an extracellular region of the PRO 175 polypeptide (ammo acids 52 to 177 of Figure 5, SEQ ID NO 14) was amplified with PCR pnmers contammg flanking Ndel and Xbal restπction sites, respectively forward 5'-GAC GAC AAG CAT ATG TTA GAG ACT GCT AAG GAG CCC TG-3' (SEQ ID NO 20), reverse 5'-TAG CAG CCG GAT CCT AGG AGA TGA ATT GGG GATT-3' (SEQ ID NO 21) The PCR was digested and cloned into the Ndel and Xbal sites of plasmid pET19B (Novagen) downstream and in frame of a Met Gly Hιs 10 sequence followed by a 12 amino acid enterokmase cleavage site (deπved from the plasmid) Met Gly His His His His His His His His His His Ser Ser Gly His He Asp Asp Asp Asp Lys His Met (SEQ ID NO 22) The resulting plasmid was used to transform E coli strain JM 109 (ATCC 53323) using the methods described in Sambrook et al , supra Transfor mants were identified by PCR Plasmid DNA was isolated and confirmed by restriction analysis and DNA sequencing Selected clones were grown overnight in liquid culmre medium LB supplemented with antibiotics The overnight culmre was subsequently used to inoculate a larger scale culmre The cells were grown to a desired optical density, dunng which the expression promoter is turned on After cultuπng the cells for several more hours, the cells were harvested by centrifugation The cell pellet obtained by the centrifugation was solubi zed using a microfluidizer in a buffer contammg 0 1M Tns, 0 2M NaCl, 50 mM EDTA, pH 8 0 The solubihzed PRO 175 protein was punfied using Nickel-sepharose affinity chromatography The PRO 175 protein was analyzed by SDS-PAGE followed by Western Blot with nickel-conjugated horseradish peroxidase followed by ECL detection (Boehπnger Mannheim) Three predominant protein bands were detected, which coπesponded in size to monomenc, homodimeπc, and homotπmenc forms of the protein (Figure 9) It is believed based on this result that m its native form, m the absence of SDS denaturation, the soluble PRO 175 protein is capable of forming homotπmers EXAMPLE 6 Binding Specificity of PRQ175for the PRQ364 Receptor Assays were conducted to determine whether the PRO 175 polypeptide (descnbed in Example 2,3 and 5 above) interacts and specifically binds with PR0364, which is believed to be a human ortholog of the munne GITR (mGITR) polypeptide descπbed in Nocentmi et al , Proc Natl Acad Sci , 94 6216-6221 ( 1997) To test for bmdmg, a soluble immunoglobulin fusion protein (lmmunoadhesin) which included a PR0364 extracellular domam (see amino acids 1-161 of Figure 2, SEQ ID NO 3) was expressed m msect cells The PR0364 ECD was expressed as a C-terminus IgG-Fc tagged form in msect cells usmg Baculovirus A soluble PRO 175 polypeptide was prepared by expressing an ECD as descπbed above m Example 5 The soluble PRO 175 ECD molecule was abeled with 125 I, for testmg its ability to interact with the PR0364 lmmunoadhesin For comparison, lmmunoadhesin constructs were also made of the following TNF receptor family members CD95, DR4, DR5, TNFR1. TNFR2, and Apo-3 CD95. DR4, DR5, TNFR1. TNFR2, and Apo-3 immunoadhesins were prepared by fusing each receptor's ECD to the hmge and Fc portion of human IgG, as descπbed previously for TNFR1 [Ashkenazi et al , Proc Natl Acad Sci . 88 10535-10539 (1991)] The respective TNF receptor family members are descnbed (and relevant references cited) in the Background of the Invention section 125 For the co-precipitation assay, each lmmunoadhesin (5 microgram) was incubated with I-labeled soluble PR0175 polypeptide (1 microgram) for 1 hour at 24°C, followed by protem A-sepharose for 30 mmutes on ice The reaction mixtures were spun down and washed several times in PBS. boiled in SDS-PAGE buffer contammg 20 mM dithiothreitol and then resolved by SDS-PAGE and autoradiography The results are shown in Figure 9 The position of the molecular weight markers (kDa) are indicated m the figure The PR0364-IgG bound to the radioiodinated soluble PRO 175 polypeptide However, the PR0364- IgG did not bmd to the lmmunoadhesin constructs of CD95, DR4, DR5, TNFR1, TNFR2, or Apo-3 In another assay, human 293 cells were transiently transfected with full-length PRO 175 and the ability of receptor lmmunoadhesin constructs for PR0364. TNFRl, HVEM. and DcRl to bind to those transfected cells was determined by FACS analysis The 293 cells were maintained in high glucose DMEM media supplemented with 10% fetal bovine serum (FBS). 2mM glutamine. 100 microgram/ml penicillin, and 100 microgram/ml streptomycin The transfected cells ( 1 x 10 ) were incubated for 60 minutes at 4°C in 200 microliters 2% FBS/PBS with 1 microgram of the respective receptor or ligand lmmunoadhesin. The cells were then washed with 2% FBS/PBS, stained with R-phycoerythπn-conjugated goat anti-human antibody (Jackson Immunoresearch, West Grove, PA) Next, the cells were analyzed by FACS. To test the binding of the respective lmmunoadhesins to the transiently transfected cells, an expression vector (pRK5-CD4, Smith et al., Science, 328.1704- 1707 ( 1987)) for CD4 was co-transfected with PRO 175 expression vector (see above). FITC- conjugated antι-CD4 (Pharmingen. San Diego, CA) was then used to identify and gate the transfected cell population in the FACS analysis As shown m Figure 1 1A, the PR0364-IgG bound specifically to the surface of cells transfected with the expression plasmid encoding the full length PRO 175 No such binding was observed for the TNFRl. HVEM or DcRl immunoadhesms. The PR0364-IgG did not bind to the cells transfected with a control plasmid (data not shown). The results demonstrate a specific bindmg mteraction of the PRO 175 polypeptide with PR0364 and that the PROl 75 polypeptide does not interact with any of the other TNF receptor family members tested. The PRO 175 polypeptide was identified in a human umbilical vein endothelial cell (HUVEC) library, and the PROl 75 polypeptide transcnpts are readily detectable in HUVEC by RT-PCR (data not shown). A FACS analysis assay was conducted to examine whether specific bmdmg of PR0364-IgG could be demonstrated with HUVEC by FACS analysis. HUVEC were purchased from Cell Systems (Krrkland, WA) and grown m a 50:50 mix of Ham's F12 and Low Glucose DMEM media containing 10% fetal bovme serum. 2 mM L-glutamme, 10 mM Hepes, and 10 ng/ml basic FGF. Cells were FACS sorted with PBS. PR0364-IgG, TNFRl-IgG or Fas-IgG as a primary antibody and goat anti-human F(ab')2 conjugated to phycoerythπn (CalTag, Burhngame. CA). It was found that PR0364-IgG specifically bound to HUVEC (See Figure 11B). Neither the Fas-IgG nor the TNFRl-IgG exhibited specific binding to the endothelial cells. EXAMPLE 7 Chromosomal Mapping Chromosomal localization of the human PRO 175 gene was examined by radiation hybπd (RH) panel analysis. RH mappmg was performed by PCR using a mouse-human cell radiation hybnd panel (Research Genetics) and pnmers based on the coding region of the PR0175 cDNA [Gelb et al., Hum. Genet., 98: 141 (1996)]. Analysis of the PCR data usmg the Stanford Human Genome Center Database indicated that PR0175 is linked to the STS marker D1S2790 and to Genethon marker AFMb352xe9, and maps to the human chromosome lq23. Notably, CD95L also maps to chromosome lq23 [Takahashi et al.. Int. Immunol., 6: 1567-1574 (1994), whereas OX40 ligand maps to chromosome lq25 [Baum et al., EMBO J . J3.3992-4001 (1994)] Accordmgly, these TNF family members may have ansen by duplication and divergence of a common ancestral gene. EXAMPLE 8 Induction of c-tos in Endothelial Cells This assay was performed to determine whether PR0364 (human GITR) showed the ability to induce c-fos in endothelial cells Human venous umbilical vein endothelial cells (HUVEC, Cell Systems) in growth media (50% Ham's F12 w/o GHT low glucose, and 50% DMEM without glycine with NaHCO,, 1% glutamine, 10 mM HEPES, 10% FBS, 10 ng/ml bFGF) were plated on 96-well microtiter plates at a cell density of lxlO 4 cells/well The day after plating, the cells were starved by removing the growth media and addmg 100 μl/well serum- free media (growth media without FBS or bFGF) After 24 hrs, the serum-free media was removed The cells were treated with 100 μl/well test samples and controls (positive control growth media, negative control 10 mM HEPES, 140 mM NaCl, 4% (w/v) mannitol, pH 6 8) The cells were incubated for 30 minutes at 37°C, in 5% C0 2 The samples were removed, and the first part of the bDNA kit protocol (Chiron Diagnostics, cat #6005-037) is followed, where each capitalized reagent/buffer listed below is available from the Bπefly, the amounts of the TM Lysis Buffer and Probes needed for the tests were calculated based on information provided by the manufacturer The appropnate amounts of thawed Probes were added to the TM Lysis Buffer The Capture Hybndization Buffer was warmed to room temperature The bDNA strips were set up in the metal stπp holders, and 100 μl of Capture Hybπdization Buffer were added to each b-DNA well needed, followed by mcubation for at least 30 mmutes The test plates with the cells were removed from the incubator, and the media were gently removed usmg the vacuum manifold 100 μl of Lysis Hybπdization Buffer with Probes were quickly pipetted mto each well of the microtiter plates The plates were then incubated at 55 °C for 15 mmutes Upon removal from the incubator, the plates were placed on the vortex mixer with the microtiter adapter head and vortex on the #2 settmg for one mmute 80 μl of the lysate was removed and added to the bDNA wells contammg the Capture Hybπdization Buffer, and pipetted up and down to mix The plates were incubated at 53 °C for at least 16 hours On the next day, the second part of the bDNA kit protocol was followed Specifically, the plates were removed from the incubator and placed on the bench to cool for 10 mmutes The volumes of additions needed were calculated based upon information provided by the manufacturer An Amplifier Workmg Solution was prepared by makmg a 1 100 dilution of the Amplifier Concentrate (20 fm μl) in AL Hybridization Buffer The hybndization mixmre was removed from the plates and washed twice with Wash A 50 μl of Amplifier Workmg Solution were added to each well and the wells were incubated at 53 °C for 30 mmutes The plates were then removed from the incubator and allowed to cool for 10 minutes The Label Probe Working Solution was prepared by making a 1 100 dilution of Label Concentrate (40 pmoles/μl) m AL Hybπdization Buffer After the 10-mιnute cool-down period, the amplifier hybπdization mixture was removed and the plates were washed twice with Wash A 50 μl of Label Probe Working Solution were added to each well and the wells were incubated at 53°C for 15 mmutes The Substrate Solution was prepared by making a 1 100 dilution of Substrate Enhancer m Substrate Buffer The plates were allowed to cool for 10 mmutes, the label hybπdization mixmre was removed, and the plates were washed twice with Wash A and three times with Wash D 50 μl of the Substrate Solution with Enhancer were added to each well The plates were mcubated for 30 minutes at 37 °C and RLU was read m an appropnate lummometer The replicates ere averaged and the coefficient of v nation was determined The measure of activity of the told increase over the negative control (HEPES buffer described abov e) value was indicated by chemilummescence units (RLU) Samples that show an at least two-fold value over the negati e control value were considered positive PR0364 assay results 1 Negative control = 2 57 RLU Positive control = 29 57 RLU PR0364 at 0 01% = 8 60 RLU PR0364 at 0 1% = 9 66 RLU PR0364 at 1 % = 3 44 RLU 2 Negative control = 3 19 RLU Positive control = 18 22 RLU PR0364 at 0 01% = 3 51 RLU PR0364 at 0 1% = 4 54 RLU PR0364 at 1 % = 6 98 RLU As shown above PR0364 assayed positive twice, indicating its ability to induce c-fos expression m endothelial cells EXAMPLE 9 This assay was performed to determine whether PRO 175 (hGLITTER) showed the ability to mduce c-fos m peπcytes On Day 1, 4 T-25 tissue culmre flasks of bovme pencytes (VEC Technologies) m growth media were received All but 5 ml media was removed, and the flasks were placed in an mcubator at 37°C m 5%C0 2 On Day 2, the peπcytes were trypsmized. spun down, resuspended m growth media (low glucose DMEM with 20% FBS, IX penicillin and streptomycin, and IX ftingizone) and plated onto 4 96-well microtiter plates On Day 7, the media was removed, and the peπcytes were treated with lOOμl of test samples and controls (assay diluent DMEM + 5% FBS, positive control DMEM+5%serum +/- PDGF@50 ng/ml, negative control protem 32) The cells were incubated for 30 minutes at 37°C in 5%C0 2 The samples were removed and the first part of the bDNA Kit (Chiron) protocol was followed Probes for c-fos were added to the Lysis Buffer included m the bDNA Kit After the 30 mmute incubation, the media was aspirated from the cells and 100 μl of the Lysis Buffer contammg the c-fos probes was added to each well The plates were then incubated for 15 mmutes at 55°C Duπng this time, 100 μl of the Capture Hybndization Buffer was added to the bDNA Plate included in the kit At the end of the 15 mmutes, the cells are removed from the mcubator, and vortexed on a microtiter plate shaker for 1 mmute 85 μl of the cell lysate was removed and added to the 100 μl of Capture Hybndization Buffer in the bDNA Plate The plates were then incubated at 53°C for at least 16 hours The next day, the second part of the bDNA Kit protocol was followed All the reagents were removed from the kit and allowed to come to room temperature The plates were removed from the incubator and placed on the bench to cool for 10 mmutes The Amplifier was diluted to 1 100 in Amplifier/Label Probe Diluent After 10 mmutes. the hybndization mixmre was aspirated from the plates and the wells were washed twice with Wash Buffer A 50 μl of diluted amplifier was added to each of the wells, and the plates were incubated for 30 mmutes at 53°C The plates were then removed from the incubator and allowed to cool for 10 minutes The Label Probe was diluted 1 100 in Amplifier/Label Probe Diluent After 10 mmutes the amplifier was aspirated off. and the plates were again washed twice with Wash Buffer A 50 μl of the diluted Label Probe was added to each of the wells and the plates were incubated for 15 minutes at 53°C The plates were then removed from the mcubator. and allowed to cool for 10 mmutes At this point the substrate solution was prepared bv adding 3 μl of Substrate Enhancer to each ml of Substrate needed for the assay The label probe mixmre was then aspirated from the wells and the plates are washed twice with Wash Buffer A and three times with Wash Buffer B 50 μl of substrate solution was added to each well, and the plates were incubated at 37°C for 30 minutes The plates were then read for chemilummescence using a luminometer The replicates were averaged and the standard deviation coefficient of vanation was determined The measure of activity of the fold increase over negative control (Protein 32) value was indicated by chemilummescence units (RLU) Samples that show at least two fold value over the negative control value were considered a positive The results from these analyses are shown in Figure 12 As shown in Figure 12. PRO 175 assayed positive for induction of c-fos expression in bovme pencytes Deposit of Matenal The followmg mateπals have been deposited with the Amencan Type Culmre Collection, 10801 University Blvd , Manassas, Virginia USA (ATCC) Matenal ATCC Pep No Deposit Date DNA47365-1206 ATCC 209436 November 7, 1997 DNA19355-1150 ATCC 209466 November 7, 1997 This deposit was made under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and the Regulations thereunder (Budapest Treaty) This assures maintenance of a viable culmre of the deposit for 30 years from the date of deposit The deposit will be made available by ATCC under the terms of the Budapest Treaty, and subject to an agreement between Genentech, Inc and ATCC, which assures permanent and unrestncted availability of the progeny of the culmre of the deposit to the public upon issuance of the pertinent U S patent or upon laving open to the public of any U S or foreign patent application, whichever comes first, and assures availability of the progeny to one determined by the U S Commissioner of Patents and Trademarks to be entitled thereto accordmg to 35 USC Section 122 and the Commissioner's rales pursuant thereto (mcludmg 37 CFR Section 1 14 with particular reference to 886 OG 638) The assignee of the present application has agreed that if a culmre of the mateπals on deposit should die or be lost or destroyed when cultivated under suitable conditions, the matenals will be promptly replaced on notification with another of the same Availability of the deposited material is not to be construed as a license to practice the mvention m contravention of the nghts granted under the authonty of any government in accordance with its patent laws The foregomg wntten specification is considered to be sufficient to enable one skilled m the art to practice the invention The present invention is not to be limited in scope by the construct(s) deposited, smce the deposited embodιment(s) is/are intended as single ιllustratιon(s) of certain aspects of the invention and any constracts that are functionally equivalent are within the scope of this invention The deposit of mateπal(s) herein does not constitute an admission that the wntten descπption herein contamed is inadequate to enable the practice of any aspect of the invention, including the best mode thereof, nor is it to be construed as limiting the scope of the claims to the specific illustrations that it represents. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims.

Claims: WHAT IS CLAIMED IS 1 A composition comprising a PR0364 polypeptide in admixture with a pharmaceutically acceptable earner 2 A composition comprising a PRO 175 polypeptide in admixture with a pharmaceutically acceptable caπier 3 The composition of claim 1 comprising a therapeutically effective amount of the polypeptide 4 The composition of claim 2 comprising a therapeutically effective amount of the polypeptide 5 A composition compnsmg a PR0364 or PRO 175 polypeptide in admixture with a pharmaceutically acceptable earner and a cardiovascular, endothelial, or angiogenic agent or an angiostatic agent. 6 The composition of claim 5 wherein the polypeptide and agent are present m therapeutically effective amounts. 7 A method for prepanng a composition for the treatment of a cardiovascular, endothelial. and angiogenic disorder compnsmg admixing a therapeutically effective amount of PR0364 or PRO 175 polypeptide with a pharmaceutically acceptable earner. 8 A pharmaceutical product compnsmg: (a) a composition compnsmg a therapeutically effective amount of PR0364 or PRO 175 polypeptide m admixture with a pharmaceutically acceptable caπier, (b) a contamer contammg said composition; and (c) a label affixed to said container, or a package insert included in said pharmaceutical product referπng to the use of said PR0364 or PR0175 polypeptide in the treatment of a cardiovascular, endothelial. and angiogenic disorder 9 A process for diagnosing a disease or a susceptibility to a disease related to a mutation in a nucleic acid sequence encodmg PR0364 or PRO 175 polypeptide compnsmg- (a) isolating a nucleic acid sequence encoding PR0364 or PR0175 polypeptide from a sample denved from a host; and (b) determining a mutation in the nucleic acid sequence encodmg the PR0364 or PRO 175 polypeptide. 10 A method of diagnosing cardiovascular, endothelial, and angiogenic disorders in a mammal compnsmg detectmg the level of expression of a gene encoding a PR0364 or PRO 175 polypeptide (a) in a test sample of tissue cells obtamed from the mammal, and (b) m a control sample of known normal tissue cells of the same cell type, wherem a higher or lower expression level in the test sample indicates the presence of a cardiovascular, endothelial. and angiogenic dysfunction in the mammal from which the test tissue cells were obtamed 11 A method for treating a cardiovascular, endothelial, and angiogenic disorder in a mammal compnsmg admmistenng to the mammal an effective amount of a PR0364 or PRO 175 polypeptide 12 The method of claim 1 1 wherem the cardiovascular endothelial and angiogenic disorder is cardiac hypertrophy, trauma, or cancer 13 The method of claim 12 wherein said mammal is human 14 The method of claim 12 wherein said cardiac hypertrophy is characterized by the presence of an elevated level of PGF 2α 15 The method of claim 12 wherein said cardiac hypertrophy has been induced by myocardial infarction 16 The method of claim 15 wherein the administration of said PR0364 or PRO 175 polypeptide is initiated withm 48 hours followmg myocardial mfarction 17 The method of claim 12 wherein the cardiovascular, endothelial, and angiogenic disorder is cardiac hypertrophy and said PR0364 or PR0175 polypeptide is admmistered together with a cardiovascular, endothelial. or angiogenic agent 18 The method of claim 17 wherein said cardiovascular, endothelial, or angiogenic agent is selected from the group consisting of an antihypertensive drag, an ACE-inhibitor, an endothelm receptor antagonist, and a thrombolytic agent 19 The method of claim 12 wherem the cardiovascular, endothelial, and angiogenic disorder is a cancer and the PR0364 or PRO 175 polypeptide is admmistered m combination with a chemotherapeutic agent, a growth inhibitory agent, or a cytotoxic agent 20 A process for identifying agonists to PR0364 or PRO 175 polypeptide compnsmg (a) contacting cells and a compound to be screened under conditions suitable for the stimulation of cell proliferation by PR0364 or PRO 175 polypeptide, and (b) measurmg the proliferation of the cells to determine if the compound is an effective agonist 21 An agonist to PR0364 or PRO 175 polypeptide identified by the process of claim 20 22 A method for identifymg a compound that inhibits the expression or activity of a PR0364 or PRO 175 polypeptide, compnsmg contactmg a candidate compound with a PR0364 or PROl 75 polypeptide under conditions and for a tune sufficient to allow the compound and polypeptide to interact 23 The process of claim 22 comprising the steps of (a) contacting cells and a compound to be screened in the presence of a PR0364 or PRO 175 polypeptide under conditions suitable for the stimulation of cell proliferation by a PR0364 or PRO 175 polypeptide, and (b) measuπng the proliferation of the cells to determine if the compound is an effective antagonist 24 A compound that inhibits the expression or activity of a PR0364 or PRO 175 polypeptide 25 compound identified by the process of claim 20 26 A method for treating a cardiovascular, endothelial, and angiogenic disorder in a mammal compnsmg administering to the mammal an effective amount of an antagonist to a PR0364 or PRO 175 polypeptide 27 The method of claim 26 wherein the cardiovascular, endothelial. and angiogenic disorder is cardiac hypertrophy trauma, a cancer, or age-related macular degeneration 28 The method of claim 26 wherem the mammal is human 29 The method of claim 26 wherein an effective amount of a cardiovascular, endothelial, or angiogenic agent or angiostatic agent is administered in conjunction with the antagonist 30 A method for determining the presence of a PR0364 or PRO 175 polypeptide compnsmg exposing a cell suspected of contammg the PR0364 or PRO 175 polypeptide to an anti- PR0364 or -PRO 175 antibody and determining binding of said antibody to said cell 31 A method of diagnosmg cardiovascular, endothelial, and angiogenic disorders in a mammal compnsmg (a) contactmg an anti- PR0364 or -PRO 175 antibody with a test sample of tissue cells obtamed from the mammal, and (b) detectmg the formation of a complex between the anti- PR0364 or -PR0175 antibody and the PR0364 or PR0175 polypeptide m the test sample 32 A cancer diagnostic kit compnsmg an anti- PR0364 or -PRO 175 antibody and a earner in suitable packagmg 33 The kit of claim 32 further comprising instructions for using said antibody to detect the PR0364 or PRO 175 polypeptide 34. An article of manufacmre, compnsmg a contamer; a label on the container; and a composition compnsmg an anti- PR0364 or -PRO 175 antibody contained withm the contamer. wherem the label on the container indicates that the composition can be used for treating cardiovascular, endothelial, and angiogenic disorders. 35. A method foi inhibiting angiogenesis induced by PR0364 or PR0175 polypeptide in a mammal compnsmg administering to the mammal a therapeutically effective amount of an antibody that binds a PR0364 or PRO 175 polypeptide 36 The method of claim 35 wherem the mammal is a human 37 The method of claim 35 wherem the mammal has a mmor or a retinal disorder

Inventors: GERRITSEN MARY E, WILLIAMS P MICKEY, GERRITSEN, MARY, E., WILLIAMS, P., MICKEY
Applicants: GENENTECH INC, GENENTECH, INC.
Application year: 2000
Main classification: A61K38
IPC codes: A61K38, A61K39, A61K45, A61P1, A61P3, A61P7, A61P9, A61P11, A61P13, A61P15, A61P17, A61P19, A61P21, A61P25, A61P27, A61P29, A61P35, A61P41, A61P43, C07K14, C12N15, C12Q1, G01N33